Document:

Exhibit

SEPARATION AGREEMENT AND GENERAL RELEASE
Jimmie Walker, Jr., of XXXXXXXXXXXXXX, Atlanta, GA 30342 (“Employee” or “you”), and Agilysys NV, LLC, (“the Company” or “Agilysys”) a Delaware limited liability company located at 1000 Windward Concourse, Suite 250, Alpharetta, Georgia 30005, in exchange for their mutual covenants and obligations set forth herein, hereby agree as follows:

1.Employee’s Right to Review this Agreement and Consult a Lawyer.  You have the right to and are advised to review this Separation Agreement and General Release (“Agreement”) and to consult a lawyer of your own choice before signing it.  You have twenty-one (21) calendar days from October 16, 2017 (“Tender Date”) to consider this Agreement before signing it.  Any change to this Agreement after the Tender Date shall not restart or extend the consideration period.  You can sign this Agreement sooner than that, but if you do that, you are agreeing to give up your right to think about this Agreement for a full twenty-one (21) calendar days.
If you signed this Agreement, it is only because you read and understood all of it, and because you have already consulted a lawyer if you wanted to.  Employee is entering into this Agreement voluntarily and without any coercion from anyone and hereby certifies that: (a) Employee carefully read this Agreement; (b) Employee fully understood it; (c) it is written in a manner that is understandable to Employee; (d) Employee is entering into it freely, knowingly and voluntarily; and (e) that no one pressured Employee into signing this Agreement.

2.    Separation.  As of October 16, 2017 (“Date of Separation”), Employee’s employment with the Company shall cease. 
3.    Severance Pay.  The Company will pay Employee severance pay in the amount of $200,000, payable pro rata on the Company’s regular paydays during the nine (9) months beginning with the first Company first pay date that is within ten (10) business days after you sign and return this Agreement, minus appropriate withholdings under federal, state, city, or other applicable laws and appropriate deductions (“Severance Pay”), which sum is payment in lieu of (and not in addition to) any severance or other separation payment of any kind to which you would otherwise be entitled.  Employee further agrees and acknowledges that the Severance Pay constitutes good, valuable and adequate consideration for his/her covenants and obligations set forth herein, it being an amount over and above any entitlements, payments or otherwise that Employee has or may have had by reason of Employee’s separation from employment with the Company.
4.    Benefit Continuation.  Benefits terminate for medical/dental/vision coverage on your Date of Separation.  Our records indicate you have Family medical/dental/vision coverage and your coverage will terminate on the Date of Separation.
If you timely and properly elect health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), the Company will reimbursement you for the monthly COBRA premium paid by you for yourself and your dependents. Such reimbursement shall be paid to you no later than the 15th day of the month immediately following the month in which you timely remit the premium payment. You shall be eligible to receive such reimbursement until the earliest of: (A) the nine-month anniversary of the Date of Separation; (B) the date you are no longer eligible to receive COBRA continuation coverage; and (C) the date on which you become eligible to receive substantially similar coverage from another employer or other source. 
You will receive a letter from Discovery Benefits explaining your rights under COBRA.  You will have sixty (60) days from the date of the COBRA letter to respond.  If you elect coverage, it will be retroactive to the date benefits terminate so no lapse in coverage will occur.  You may continue COBRA coverage for up to eighteen (18) months or longer as set forth by COBRA, provided that any expense incurred after the date in which you are no longer entitled to reimbursement as provided above shall be at your own expense.    
You also understand that if your spouse, dependents or you elect to continue health insurance coverage under COBRA or any comparable state law, that coverage will continue for as long as your spouse, dependents or you, as applicable, remain eligible for continuation coverage under the law, but only if your spouse, dependents or you, as the case may be, makes the required premium payments.
5.    Paid Time-Off (PTO).  Any unused earned PTO time will be paid to you within thirty (30) days after your Date of Separation, unless state law requires a different payment date.  Any PTO time taken prior to earning it will be deducted from your lump sum Severance Pay, unless state law requires a different method for Company to receive reimbursement of advanced PTO.
6.    Employee Assistance Program.  Agilysys will continue to offer you and your family members the ability to utilize our Employee Assistance Program through the end of your Severance Pay.  The EAP can help with a variety of issues including: coping with change, marital/relationship problems, anger management, alcohol/drug dependencies, anxiety or depression, and many others.  Furthermore, this service is confidential.  The EAP toll-free number is 1-877-259-3785.  
7.    Disability and Life Insurance.  Your disability insurance benefits will end on your Date of Separation.  Your group term life insurance benefits will end on the last day of the month following your Date of Separation.  You are eligible to convert your basic term life insurance and/or eligible to convert or port your supplemental and/or dependent life insurance to a non-group policy within thirty (30) days from your last day of coverage.  Non-group rates are based on your age at the time of conversion/portability.  Contact your Human Resources representative to convert/port your group life policy.  Terms of such policies are set forth by those policies.
8.    Profit Sharing/401(k) Plan.  MassMutual Retirement Services will automatically send you a letter explaining your options.  You are entitled to 100% of your pre-tax and post-tax contributions and any rollover monies from a previous employer.  You are also eligible for your vested portion of the company match and profit sharing.   
If you have an outstanding loan balance from your 401(k) account on your Date of Separation, you have the option to repay the outstanding principal.  If you do not repay the outstanding loan balance within sixty (60) days from your Date of Separation, the loan will be defaulted and considered a partial cash distribution.  The unpaid loan balance will be reported as taxable income and may be subject to a 10% penalty.
You may contact MassMutual Retirement Services anytime by using FLASH, MassMutual’s automated phone information service at 1-800-74-FLASH (35274), or The Journey, MassMutual’s interactive web site, at www.massmutual.com/retire.  Terms of such policies are set forth by those policies.
9.    Flexible Spending Accounts (FSA).  If you are currently participating, your eligibility under the plan ceases as of your Date of Separation.  You may claim eligible expenses through March 31st of the calendar year following the Date of Separation (i.e., any claims for eligible expenses incurred during your eligibility period in 2017 can be submitted until March 31, 2018). If you are a participant in the medical FSA you will be offered COBRA, whereas you may continue to fund your account on an after-tax basis through the remainder of the calendar year. Terms of such policies are set forth by those policies.
10.    Expense Reports.  You must submit all final expense reports within one (1) month of your Date of Separation in order to be reimbursed.
11.    Return of Company Property.      Please be advised that none of your Severance Pay will be paid until all Company property in your possession (including your keys, identification badge, computer, etc.) is returned to the Company.  This applies to your Company-provided computer systems, and includes (but is not limited to) all hardware, data, software, pass codes, and login credentials; provided, that you may retain the laptop computer and iPad that was assigned to you by the Company as of the Separation Date.  The information contained on the computer and iPad is the property of Company and must be returned or permanently deleted.  Note that removing any data and software, any detected alteration of the system software, data, or other files, as well as equipment or resources disruption or destruction, tampering, obstructing, or attempting to modify the operation or performance of any piece of computer hardware or software is unlawful and may subject you to legal action.  In addition to the return of all of the Company’s property, no copy of the Company’s information may be retained by Employee in a digital or electronic format, regardless of whether such information qualifies as “Confidential Information” (as defined herein).  To the extent that Employee has any such Company information on his or her personal electronic devices (desktop computer, laptop computer, cell phone, iPad, thumb drive, etc.), servers, or on any cloud computing service, the information must be permanently deleted.  
12.    Confidential Information.  You agree that you shall not, directly or indirectly, use any Confidential Information (as defined herein) on your own behalf or on behalf of any individual or entity, or reveal, divulge, or disclose any Confidential Information to any individual or entity outside of the Company.  This obligation shall remain in effect for as long as the information or materials in question retain their status as Confidential Information.  You further agree that you shall fully cooperate with the Company in maintaining the Confidential Information to the extent permitted by law. The parties acknowledge and agree that this Agreement is not intended to, and does not, alter either the Company’s rights or your obligations under any state or federal statutory or common law regarding trade secrets and unfair trade practices.  Anything herein to the contrary notwithstanding, you shall not be restricted from disclosing information that is required to be disclosed by law, court order or other valid and appropriate legal process; provided, however, that in the event such disclosure is required by law, Employee shall provide the Company with prompt notice of such requirement so that the Company may seek an appropriate protective order prior to any such required disclosure by you.
a.    “Confidential Information” means any and all data and information relating to the Company, its activities, business, or clients that (i) was disclosed to you or of which you became aware as a consequence of your employment with the Company; (ii) has value to the Company; and (iii) is not generally known outside of the Company.  “Confidential Information” shall include, but is not limited to the following types of information regarding, related to, or concerning the Company: trade secrets (as defined by applicable law); financial plans and data; management planning information; business plans; operational methods; market studies; marketing plans or strategies; pricing information; sales information; product development techniques or plans; customer and prospective customer lists; customer files, data and financial information; details of customer and prospective customer contracts; current and prospective customer requirements; identifying and other information pertaining to business referral sources; past, current and planned research and development; information regarding potential or pending legal or litigation matters; computer aided systems, software, strategies and programs; schematics; bills of materials; costs of materials; software source codes; software binary codes; mechanical drawings; written/verbal specifications; business acquisition plans; management organization and related information (including, without limitation, data and other information concerning the compensation and benefits paid to officers, directors, employees and management); personnel and compensation policies; new personnel acquisition plans; and other similar information.  “Confidential Information” also includes combinations of information or materials which individually may be generally known outside of the Company, but for which the nature, method, or procedure for combining such information or materials is not generally known outside of the Company.  In addition to data and information relating to the Company, “Confidential Information” also includes any and all data and information relating to or concerning a third party that otherwise meets the definition set forth above, that was provided or made available to the Company by such third party, and that the Company has a duty or obligation to keep confidential.  This definition shall not limit any definition of “confidential information” or any equivalent term under state or federal law.  “Confidential Information” shall not include information that has become generally available to the public by the act of one who has the right to disclose such information without violating any right or privilege of the Company.
b.    You acknowledge that all Confidential Information is the exclusive property of the Company or its customers or suppliers, respectively.  You recognize and agree that any material violation of this Paragraph is likely to result in immediate and irreparable harm to the Company for which money damages are likely to be inadequate.  Accordingly, you consent to injunctive and other appropriate equitable relief upon the institution of proceedings by the Company in order to protect the Company’s rights under this Paragraph.  Such relief shall be in addition to any other relief to which the Company may be entitled at law or in equity.
Nothing in this Agreement, however, shall be construed to prohibit Employee from making a good-faith report of any violation of the law to any governmental authority or to participate in any governmental investigation or proceeding. Notwithstanding anything to the contrary contained herein, no provision of this Agreement shall be interpreted so as to impede Employee (or any other individual) from reporting possible violations of federal law or regulation to any governmental agency or entity, including but not limited to the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General, or making other disclosures under the whistleblower provisions of federal law or regulation. Employee does not need the prior authorization of the Company to make any such reports or disclosures and Employee shall not be required to notify the Company that such reports or disclosures have been made. Similarly, nothing in this Agreement is intended to conflict with 18 U.S.C. § 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by 18 U.S.C. § 1833(b). Accordingly, the parties to this Agreement have the right to disclose in confidence trade secrets to federal, state, and local government officials, or to an attorney, for the sole purpose of reporting or investigating a suspected violation of law. The parties also have the right to disclose trade secrets in a document filed in a lawsuit or other proceeding, but only if the filing is made under seal and protected from public disclosure. By way of reference, 18 U.S.C. §1833(b) provides: “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that—(A) is made—(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.” Nothing in this Agreement or any Company policy is intended to conflict with this statutory protection, and no Company director, officer, or member of management has the authority to impose any rule to the contrary.
13.    Confidentiality of the Agreement.  You hereby represent and warrant that you have not and agree that you will not disclose the existence of the Agreement or the terms or provisions of the Agreement, in whole or in part, to any other person or entity except your spouse, attorney, accountant and/or tax or financial consultant.  You understand and agree that, before you disclose information about this Agreement to any such person or entity identified in this Paragraph, you must instruct that person or entity that he, she, or it must maintain the strict confidentiality of such information, and you agree to be liable for any breach by any such person. Anything herein to the contrary notwithstanding, Employee shall not be restricted from disclosing information regarding the Agreement that is required to be disclosed by law, court order or other valid and appropriate legal process; provided, however, that in the event such disclosure is required by law, Employee shall provide the Company with prompt notice of such requirement so that the Company may seek an appropriate protective order prior to any such required disclosure by Employee.
14.    Restrictive Covenants.  In consideration for the Severance Pay, for a period of nine (9) months after the Date of Separation, Employee agrees that, within the Territory, Employee will not for any reason whatsoever, directly or indirectly, on Employee’s behalf or for or on behalf of any other person, firm, corporation, or entity:
		
	a.
	for any of the Competing Entities, undertake to perform duties and responsibilities substantially similar to those Employee conducted, offered or provided for the Company during the last twelve (12) months of Employee’s employment with the Company; 

		
	b.
	on behalf of any Competing Business, solicit or attempt to solicit any business from any customer of the Company with whom Employee had Material Contact during Employee's employment with the Company, for purposes of providing products or services that are competitive with those offered by the Company.

“Business of the Company” means the business of developing, selling, implementing, enhancing, customizing and/or supporting point of sale (POS), property management (PMS), inventory and procurement, payment gateway and related mobile and wireless solutions for the hospitality or gaming industries and any other products, technologies and/or solutions that the Company develops for sale or sells during the period of Employee’s employment with the Company.
“Competing Business” means any business organization of whatever form engaged, either directly or indirectly, in any business or enterprise which is the same as, or substantially the same as, the Business of the Company. 
“Competing Entities” mean the entities described in the written notice from the Company to you dated October 16, 2017.
“Material Contact” means the contact between Employee and each customer:  (a) with whom or which Employee dealt on behalf of the Company; (b) whose dealings with the Company were coordinated or supervised by Employee; (c) about whom Employee obtained confidential information in the ordinary course of business as a result of Employee’s employment; or (d) who receives products or services authorized by the Company, the sale or provision of which results or resulted in compensation, commissions, or earnings for Employee within two years prior to the date of Employee’s termination.
“Territory” means the geographic regions for which, or in which, Employee had executive, managerial, supervisory, sales, marketing, and/or other responsibilities at the time of the termination of Employee’s employment with the Company.
15.    Release.  Employee does hereby, on Employee’s own behalf and on behalf of Employee’s heirs, agents, successors, and representatives, forever release and discharge Agilysys NV, LLC and all of its past, present and future parents, subsidiaries, sister companies, affiliates, and related entities, and all of their respective officers, directors, owners, managers, employees, shareholders, agents, successors, assigns, attorneys, insurers, employee benefit plans, employee benefit plan administrators, and other representatives, from all claims of any kind that arose at any time before Employee signed this Agreement.  By signing this Agreement, Employee is agreeing to waive and give up forever Employee’s ability to bring any type of claim against Agilysys, and all of the other persons and entities who Employee is releasing, based on events that happened before Employee signed of this Agreement.  Employee understands and agrees that this release includes all claims arising under any federal, state, or local statutes and laws, including but not limited to the National Labor Relations Act, as amended (29 U.S.C. § 141 et seq. and 29 U.S.C. §151 et seq.); Title VII of the Civil Rights Act of 1964, and the Civil Rights Act of 1991 (42 U.S.C. § 2000e et seq.); Sections 1981 through 1988 of Title 42 of the United States Code; the Employee Retirement Income Security Act of 1974, as amended (29 U.S.C. § 1001 et seq.); the Immigration Reform and Control Act of 1986 (8 U.S.C. § 1101 et seq.); the Americans with Disabilities Act of 1990 (42 U.S.C. § 12101 et seq.); the Age Discrimination in Employment Act of 1967, as amended by the Older Workers Benefit Protection Act (29 U.S.C. § 621 et seq.); the Family and Medical Leave Act (29 U.S.C. § 2601 et seq.); the Worker Adjustment and Retraining Notification Act of 1988 (29 U.S.C. § 2101 et seq.); the Sarbanes-Oxley Act (18 U.S.C. § 1514A et seq.); and any statutory or common law claims for discrimination, workplace harassment,  retaliation, or wrongful termination; and any common law claims, including but not limited to any and all possible contractual or tort claims, arising out of Employee’s employment at or separation of employment with Agilysys.  Other than as protected by law, Employee agrees never to file, solicit, assist, cooperate in, participate in or encourage any lawsuits against Agilysys (or any of the other persons and entities who Employee is releasing) that are based upon any claim that Employee is releasing.
This release does not affect Employee’s entitlement to receive any vested benefit that Employee may have under any Company employee benefit plan, including pension and 401(k) plans, other than claims under the Agilysys, Inc. Annual Incentive Plan, which are intended to and are hereby released hereunder.  This release also does not apply to any future claims or to any claims that, by law, cannot be released.  Nothing in this release prevents either Employee or the Company from filing an action to enforce the provisions of this Agreement.
16.    Non-Recruitment and Non-Hire of Employees.  You agree that for 12 months after the Date of Separation, you shall not, directly or indirectly, whether on your own behalf or on behalf of another individual or entity, solicit or induce or attempt to solicit or induce any employee of the Company to terminate his/her employment relationship with the Company or to enter into employment with you or any other individual or entity.  You further agree that for 12 months after the Date of Separation, you shall not, directly or indirectly, employ or retain, have any other individual or entity employ or retain, or otherwise participate in the employment or retention of any person employed or retained by the Company.
17.    Affirmations.  Employee affirms that Employee is not a party to, and that Employee has not filed or caused to be filed, any claim, complaint, charge or action against Company in any forum or form.  Employee further affirms that Employee has no known workplace injuries or occupational diseases and has been provided and/or has not been denied any leave requested under the Family and Medical Leave Act and/or any other federal, state or local leave law.  Employee further affirms that Employee has not complained of and is not aware of any fraudulent activity or any act(s) which would form the basis of a claim of fraudulent or illegal activity by Company.  Employee warrants and represents that Employee has been advised to consult with an attorney before executing this Agreement. 
18.    Waiver of Unknown Claims.  Employee hereby knowingly and voluntarily waives all claims set forth in Paragraph 15, including unknown claims.  It is the intention of Employee, by executing this Agreement, that the same shall be effective as a bar as to each and every claim, demand and cause of action hereinabove specified and to the extent permitted by law, including unknown claims, resulting from any act or omission by or on the part of the Company, committed or omitted prior to the date Employee executes this Agreement.  In furtherance of this intention, Employee hereby expressly waives any and all rights or benefits conferred by any federal, state or local statute regarding release of unknown or unsuspected claims.
19.    Government Agency Proceedings.  Nothing in this Agreement shall be construed to prevent Employee from filing charges or complaints with government agencies or impair the power of those agencies to accept or investigate any such charges or complaints.  In addition, nothing in this Agreement shall be construed to prevent Employee from participating in proceedings before government agencies or in investigations conducted by those agencies.  However, Employee forever waives any right that Employee might have otherwise had to recover any individual remedy that a government agency might try to obtain on Employee’s behalf (to the extent that this is permissible under law).
20.    Individual Proceedings Only.  Employee agrees that any lawsuit or claim relating to this Agreement or to Employee’s former employment with Agilysys (to the extent not released under this Agreement) may only be brought in Employee’s individual capacity, and not as part of any class, collective, or other representative action.  Employee waives his/her right to be a representative or member of any purported class or collective action against Agilysys or against any of the other persons or entities who Employee is releasing in this Agreement.
21.    Receipt of Wages and Other Benefits.  By signing this Agreement, Employee acknowledges that Employee has been paid in full for all of the hours that Employee has worked or any work Employee has provided for Agilysys, and has received all wages (including overtime), wage statements, meal and rest breaks, leaves of absence, expense reimbursements, and other rights and benefits to which Employee may be entitled based on any hours Employee has worked for Agilysys under any state, federal, or local law (including but not limited to the federal Fair Labor Standards Act, 29 U.S.C. § 201 et seq., the Family and Medical Leave Act, 29 U.S.C. § 2601 et seq., and the Uniformed Services Employment and Reemployment Rights Act, 38 U.S.C. § 4301 et seq.).  
22.    Employee has not Sold or Assigned any Claims.  Employee represents and warrants that he/she is the sole legal and equitable owner of all of the rights, claims, and causes of action that Employee is releasing in this Agreement.  Employee has not assigned, sold, transferred, encumbered any of these rights, claims, and causes of action to anyone else.  Employee understands that Company is relying on Employee’s representations in making its own decision to enter into this Agreement.  
23.    Revocation Period under the Age Discrimination in Employment Act.  You have the right to revoke your release of claims under the federal Age Discrimination in Employment Act of 1967 (the “ADEA”), as amended by the Older Workers Benefit Protection Act (29 U.S.C. § 621 et seq.).  You understand that if you want to exercise this right, you must do so no later than seven (7) calendar days after you have signed this Agreement, and must prepare a written document that says, in effect, “I revoke my release of claims under the ADEA,” and such document must be received by Theresa Putnal, Senior Director, Human Resources at 1000 Windward Concourse, Suite 250, Alpharetta, GA  30005 no later than seven (7) calendar days after the date you signed this Agreement.  You understand that your release of claims under the ADEA will not become effective and none of the consideration described above will be paid to you until after the expiration of the seven-day revocation period.  You also understand that if you revoke your release of claims under the ADEA, then you will not receive the Severance Pay described herein.  Once you sign this Agreement, you do not have the right to revoke any other part of your release other than your release of claims under the federal Age Discrimination in Employment Act.  In the event that you revoke your release of claims under the federal Age Discrimination in Employment Act of 1967 (the “ADEA”), you will receive $50.00 minus all applicable withholdings in lieu of the payments set forth in Paragraph 3.
24.    No Admission of Wrongdoing.  Employee understands that neither Company nor Employee is admitting any wrongdoing by signing this Agreement, and that no one should interpret this Agreement as an admission by either Company or Employee that either of party did anything wrong or illegal.
25.    Agreement to Cooperate.   If a federal, state, or local administrative agency is required to approve this Agreement before it can be effective, you agree to cooperate and perform any act necessary or requested to bring about that approval.  On reasonable notice and at reasonable times, Employee will cooperate with Company and its counsel in connection with any investigation, administrative or regulatory proceeding or litigation relating to any matter in which Employee was involved or of which Employee has knowledge as a result of Employee’s employment with Company.
26.    Entire Agreement.  The text of this Agreement contains the entire understanding and the entire contract between Company and Employee with respect to employment, termination of employment, or employee benefits.  There are no other agreements, contracts, or promises between the parties relating to employment, termination of employment, or employee benefits, other than those set forth in this Agreement.  This Agreement supersedes all prior agreements, contracts, understandings, and promises between us relating to employment, termination of employment, or employee benefits, whether express or implied.  This Agreement shall not be amended or modified in any manner except upon written agreement by the parties.  However, Employee and Company agree that notwithstanding this Paragraph, any non-competition, non-disclosure, confidentiality or other agreements that Employee has previously made with Company or any of its past or present parent companies, subsidiaries, affiliates and parent company affiliates and subsidiaries, will continue to be in full force and effect.
27.    Severability.  Except for Paragraph 15, Company and Employee intend for all of the provisions of this Agreement to be severable.  If any part of this Agreement, other than Paragraph 15, is found to be unlawful or unenforceable, Company and Employee want every other part of this Agreement to remain fully valid and enforceable to the maximum extent permitted by law.  
28.    Headings.  Employee understands that the headings in this Agreement exist only for the sake of convenience.  The headings do not constitute part of Employee’s Agreement with Company.
29.    Governing Law.  This Agreement shall be governed and interpreted pursuant to the laws of the State of Georgia.
30.    Attorneys Fees.  In the event either of the parties initiates litigation asserting a breach of any provision of this Agreement, the parties agree that the prevailing party in such litigation shall be entitled to an award of her or its reasonable attorney's fees and costs, in addition to any damages awarded by the court.
31.    Notice.  All notices and other communications required or permitted to be given hereunder or by reason of this Agreement shall be in writing and shall be deemed to have been properly given (i) when delivered in person to the party to whom such notice is directed; (ii) three days after being deposited in the United States mail, return receipt requested, postage prepaid, addressed, if to the Company, to the address shown at the beginning of this Agreement or, if to you, to your address indicated in the Company’s records, or such other address as a party may designate by notice in accordance with this Section; or (iii) upon receipt when delivered by courier or overnight delivery services to the address specified in (ii) above. 
32.    Forfeiture of Payments.  Employee acknowledges that if Employee breaches, in any material respect, the terms or conditions contained in this Agreement, the Company will no longer be required to make or continue any payments described herein, to the extent permitted by applicable law.  In addition, unless prohibited by law, other than the payments made in the event Employee revokes the ADEA waiver pursuant to Paragraph 23, Employee will return to Company all payments made to Employee prior to exercising any of his or her legal rights against Company.
IN WITNESS WHEREOF, Employee and the Company agree as set forth above:

UNDERSTOOD, AGREED TO, AND ACCEPTED BY EMPLOYEE:

__/s/Jimmie Walker, Jr.__________________________            12-11-17        
Employee Signature    Date      

AGREED TO AND ACCEPTED BY:
AGILYSYS NV, LLC

BY:     /s/ Kyle C. Badger            
        

TITLE:    /s/ SVP, General Counsel        

DATE:      12-12-17            

1EX-4.1

 Exhibit 4.1 

Execution Version 
  

 
  

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 

$1,500,000,000 9.000% SENIOR NOTES DUE 2025 
  

 
 INDENTURE

 DATED AS OF December 18, 2017 
  

 
 THE BANK OF NEW
YORK MELLON, 
 AS TRUSTEE, REGISTRAR AND PAYING AGENT 
  

 
  

 TABLE OF CONTENTS 
  

							
	 	  	 	  	Page	 
	
	ARTICLE 1	 
	
	DEFINITIONS AND INCORPORATION BY REFERENCE	 
			
	Section 1.1	  	 Definitions
	  	 	1	 
	Section 1.2	  	 Other Definitions
	  	 	22	 
	Section 1.3	  	 [Reserved]
	  	 	23	 
	Section 1.4	  	 Rules of Construction
	  	 	23	 
	
	ARTICLE 2	 
	
	THE SECURITIES	 
			
	Section 2.1	  	 Form and Dating
	  	 	24	 
	Section 2.2	  	 Execution and Authentication
	  	 	25	 
	Section 2.3	  	 Registrar and Paying Agent
	  	 	25	 
	Section 2.4	  	 Paying Agent to Hold Money in Trust
	  	 	26	 
	Section 2.5	  	 Noteholder Lists
	  	 	26	 
	Section 2.6	  	 Transfer and Exchange
	  	 	26	 
	Section 2.7	  	 Replacement Notes
	  	 	27	 
	Section 2.8	  	 Outstanding Notes
	  	 	27	 
	Section 2.9	  	 Treasury Notes
	  	 	28	 
	Section 2.10	  	 Temporary Notes
	  	 	28	 
	Section 2.11	  	 Cancellation
	  	 	28	 
	Section 2.12	  	 Legend; Additional Transfer and Exchange Requirements
	  	 	28	 
	Section 2.13	  	 CUSIP, Common Code and ISIN Numbers
	  	 	30	 
	
	ARTICLE 3	 
	
	REDEMPTION AND PURCHASES	 
			
	Section 3.1	  	 Right to Redeem
	  	 	30	 
	Section 3.2	  	 Selection of Notes to Be Redeemed
	  	 	30	 
	Section 3.3	  	 Notice of Redemption
	  	 	31	 
	Section 3.4	  	 Effect of Notice of Redemption
	  	 	32	 
	Section 3.5	  	 Deposit of Redemption Price
	  	 	32	 
	Section 3.6	  	 Notes Redeemed in Part
	  	 	32	 
	Section 3.7	  	 Optional Redemption
	  	 	32	 
	Section 3.8	  	 Purchase of Notes at Option of the Holder Upon Change of Control
	  	 	33	 
	Section 3.9	  	 Effect of Change of Control Purchase Notice
	  	 	35	 
	Section 3.10	  	 Deposit of Change of Control Purchase Price
	  	 	35	 
	Section 3.11	  	 Notes Purchased in Part
	  	 	36	 
	Section 3.12	  	 Compliance with Securities Laws upon Purchase of Notes
	  	 	36	 
	Section 3.13	  	 Repayment to the Company
	  	 	36	 
	Section 3.14	  	 Offer to Purchase by Application of Excess Proceeds
	  	 	36	 
	
	ARTICLE 4	 
	
	COVENANTS	 
			
	Section 4.1	  	 Payment of Notes
	  	 	38	 

  
 -i- 

							
	 	  	 	  	Page	 
	Section 4.2	  	 Maintenance of Office or Agency
	  	 	38	 
	Section 4.3	  	 Reports
	  	 	38	 
	Section 4.4	  	 Compliance Certificates
	  	 	39	 
	Section 4.5	  	 Further Instruments and Acts
	  	 	40	 
	Section 4.6	  	 Maintenance of Corporate Existence
	  	 	40	 
	Section 4.7	  	 Changes in Covenants When Notes Rated Investment Grade
	  	 	40	 
	Section 4.8	  	 Restricted Payments
	  	 	40	 
	Section 4.9	  	 Incurrence of Indebtedness and Issuance of Preferred Stock
	  	 	43	 
	Section 4.10	  	 [Reserved]
	  	 	46	 
	Section 4.11	  	 Liens
	  	 	46	 
	Section 4.12	  	 Dividend and Other Payment Restrictions Affecting Restricted Subsidiaries
	  	 	46	 
	Section 4.13	  	 Transactions with Affiliates
	  	 	48	 
	Section 4.14	  	 Asset Sales
	  	 	49	 
	Section 4.15	  	 Additional Note Guarantees
	  	 	51	 
	Section 4.16	  	 Designation of Restricted and Unrestricted Subsidiaries
	  	 	51	 
	Section 4.17	  	 Business Activities
	  	 	52	 
	Section 4.18	  	 [Reserved]
	  	 	52	 
	Section 4.19	  	 Stay, Extension and Usury Laws
	  	 	52	 
	Section 4.20	  	 Notice of Default
	  	 	52	 
	Section 4.21	  	 Payment of Additional Amounts
	  	 	52	 
	
	ARTICLE 5	 
	
	MERGER, CONSOLIDATION OR SALE OF ASSETS	 
			
	Section 5.1	  	 Merger, Consolidation or Sale of Assets
	  	 	54	 
	Section 5.2	  	 Successor Substituted
	  	 	56	 
	
	ARTICLE 6	 
	
	DEFAULT AND REMEDIES	 
			
	Section 6.1	  	 Events of Default
	  	 	56	 
	Section 6.2	  	 Acceleration
	  	 	57	 
	Section 6.3	  	 Other Remedies
	  	 	58	 
	Section 6.4	  	 Waiver of Defaults and Events of Default
	  	 	58	 
	Section 6.5	  	 Control by Majority
	  	 	58	 
	Section 6.6	  	 Limitations on Suits
	  	 	58	 
	Section 6.7	  	 Rights of Holders to Receive Payment
	  	 	59	 
	Section 6.8	  	 Collection Suit by Trustee
	  	 	59	 
	Section 6.9	  	 Trustee May File Proofs of Claim
	  	 	59	 
	Section 6.10	  	 Priorities
	  	 	59	 
	Section 6.11	  	 Undertaking for Costs
	  	 	59	 
	
	ARTICLE 7	 
	
	TRUSTEE	 
			
	Section 7.1	  	 Duties of Trustee
	  	 	60	 
	Section 7.2	  	 Rights of Trustee
	  	 	60	 
	Section 7.3	  	 Individual Rights of Trustee
	  	 	61	 
	Section 7.4	  	 Trustee’s Disclaimer
	  	 	62	 
	Section 7.5	  	 Notice of Default or Events of Default
	  	 	62	 
	Section 7.6	  	 [Reserved]
	  	 	62	 
	Section 7.7	  	 Compensation and Indemnity
	  	 	62	 
	Section 7.8	  	 Replacement of Trustee
	  	 	62	 

  
 -ii- 

							
	 	  	 	  	Page	 
	Section 7.9	  	 Successor Trustee by Merger, Etc.
	  	 	63	 
	Section 7.10	  	 Eligibility; Disqualification
	  	 	63	 
	Section 7.11	  	 Preferential Collection of Claims Against the Company
	  	 	63	 
	
	ARTICLE 8	 
	
	 DEFEASANCE; SATISFACTION AND

DISCHARGE OF INDENTURE
	  
  

			
	Section 8.1	  	 Satisfaction and Discharge of Indenture
	  	 	64	 
	Section 8.2	  	 Legal Defeasance
	  	 	65	 
	Section 8.3	  	 Covenant Defeasance
	  	 	66	 
	Section 8.4	  	 Application of Trust Money
	  	 	67	 
	Section 8.5	  	 Repayment to the Company
	  	 	67	 
	Section 8.6	  	 Reinstatement
	  	 	67	 
	
	ARTICLE 9	 
	
	AMENDMENTS, SUPPLEMENTS AND WAIVERS	 
			
	Section 9.1	  	 Without Consent of Holders
	  	 	67	 
	Section 9.2	  	 With Consent of Holders
	  	 	68	 
	Section 9.3	  	 Notice of Amendment, Supplement or Waiver
	  	 	69	 
	Section 9.4	  	 Revocation and Effect of Consents
	  	 	69	 
	Section 9.5	  	 Notation on or Exchange of Notes
	  	 	69	 
	Section 9.6	  	 Trustee to Sign Amendments, Etc.
	  	 	69	 
	Section 9.7	  	 Effect of Supplemental Indentures
	  	 	69	 
	
	ARTICLE 10	 
	
	NOTE GUARANTEES	 
			
	Section 10.1	  	 Note Guarantees
	  	 	69	 
	Section 10.2	  	 Execution and Delivery of Note Guarantees
	  	 	71	 
	Section 10.3	  	 Limitation on Note Guarantor Liability
	  	 	71	 
	Section 10.4	  	 Merger and Consolidation of Note Guarantors
	  	 	71	 
	Section 10.5	  	 Release
	  	 	72	 
	
	ARTICLE 11	 
	
	MISCELLANEOUS	 
			
	Section 11.1	  	 Certain Trust Indenture Act Sections
	  	 	72	 
	Section 11.2	  	 Notices
	  	 	72	 
	Section 11.3	  	 Communications by Holders With Other Holders
	  	 	73	 
	Section 11.4	  	 Certificate and Opinion of Counsel as to Conditions Precedent
	  	 	73	 
	Section 11.5	  	 Record Date for Vote or Consent of Holders
	  	 	74	 
	Section 11.6	  	 Rules by Trustee, Paying Agent and Registrar
	  	 	74	 
	Section 11.7	  	 Legal Holidays
	  	 	74	 
	Section 11.8	  	 Governing Law; Submission to Jurisdiction; Waiver of Jury Trial
	  	 	74	 
	Section 11.9	  	 No Adverse Interpretation of Other Agreements
	  	 	75	 
	Section 11.10	  	 No Recourse Against Others
	  	 	75	 
	Section 11.11	  	 Successors
	  	 	75	 
	Section 11.12	  	 Multiple Counterparts
	  	 	75	 
	Section 11.13	  	 Separability
	  	 	75	 

  
 -iii- 

							
	 	  	 	  	Page	 
	Section 11.14	  	 Table of Contents, Headings, etc.
	  	 	75	 
	Section 11.15	  	 Calculations in Respect of the Notes
	  	 	75	 
	Section 11.16	  	 Agent for Service and Waiver of Immunities
	  	 	75	 
	Section 11.17	  	 Judgment Currency
	  	 	76	 
	Section 11.18	  	 Foreign Currency Equivalent
	  	 	76	 
	Section 11.19	  	 Usury Savings Clause
	  	 	76	 
	Section 11.20	  	 Interest Act (Canada)
	  	 	76	 
	Section 11.21	  	 Tax Matters
	  	 	77	 

 EXHIBITS 
  

					
	EXHIBIT A	  	-	  	FORM OF NOTE
	EXHIBIT B	  	-	  	FORM OF GUARANTEE
	EXHIBIT C	  	-	  	FORM OF CERTIFICATE FROM ACQUIRING INSTITUTIONAL ACCREDITED INVESTOR
	EXHIBIT D	  	-	  	FORM OF CANADIAN NOTE GUARANTEE

  
 -iv- 

 THIS INDENTURE dated as of December 18, 2017 is among Valeant Pharmaceuticals International,
Inc., a corporation continued under the British Columbia Business Corporations Act (the “Company”), the Note Guarantors party hereto and The Bank of New York Mellon (“BNY Mellon”), a New York banking corporation,
not in its individual capacity but solely as Trustee, Registrar, and Paying Agent (the “Trustee”). 
 In consideration of
the premises and the purchase of the Notes by the Holders thereof, all parties agree as follows for the benefit of the other and for the equal and ratable benefit of the registered Holders of the Company’s Notes. 

ARTICLE 1 

DEFINITIONS AND INCORPORATION BY REFERENCE 

Section 1.1    Definitions. 

“144A Global Note” means a Global Note substantially in the form of Exhibit A hereto bearing the Global Note
Legend and the Private Placement Legend and deposited with or on behalf of, and registered in the name of, the Depositary or its nominee that will initially be issued in a denomination equal to the principal amount of the Notes sold in reliance on
Rule 144A. 
 “Acquired Debt” means, with respect to any specified Person: 

(1)    Indebtedness of any other Person existing at the time such other Person is merged with or into or
became a Subsidiary of such specified Person and which is not satisfied in full at such time, whether or not such Indebtedness is incurred in connection with, or in contemplation of, such other Person merging with or into, or becoming a Subsidiary
of, such specified Person; and 
 (2)    Indebtedness secured by a Lien encumbering any asset acquired by
such specified Person. 
 “Additional Notes” means the additional principal amount of Notes (other than the Initial Notes)
that may be issued from time to time under this Indenture in accordance with Section 2.1(c) of this Indenture as part of the same series of Notes issued on the date hereof other than Notes issued in exchange for, or replacement of outstanding
Notes. 
 “Affiliate” of any specified Person means any other Person directly or indirectly controlling or controlled by or
under direct or indirect common control with such specified Person. For purposes of this definition, “control,” as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction
of the management or policies of such Person, whether through the ownership of voting securities, by agreement or otherwise. For purposes of this definition, the terms “controlling”, “controlled by” and “under common control
with” have correlative meanings. 
 “Agent” means any Registrar or Paying Agent. 

“Applicable Premium” means, with respect to the Notes, as determined by the Company, the greater of 

(1)    1.0% of the then outstanding principal amount of such Notes and 

(2)    (a) the present value of all remaining required interest and principal payments due on such Notes
and all premium payments relating to such Notes assuming a redemption date of December 15, 2021, computed using a discount rate equal to the Treasury Rate plus 50 basis points, minus 

(b)    the then outstanding principal amount of such Note, minus 

(c)    accrued interest paid on the date of redemption. 

 “Applicable Procedures” means, with respect to any transfer or exchange of
beneficial ownership interests in the Global Notes, the rules and procedures of the Depositary, Euroclear and Clearstream, in each case to the extent applicable, to such transfer or exchange. 

“Asset Sale” means: 

(1)    the sale, lease, conveyance or other disposition of any assets, property or rights outside of the
ordinary course of business; provided that the sale, conveyance or other disposition of all or substantially all of the assets of the Company and its Restricted Subsidiaries taken as a whole will be governed by Section 3.8 and/or
Section 5.1 hereof and not by the provisions of Section 4.14; and 
 (2)    the issuance of
Equity Interests by any of the Company’s Restricted Subsidiaries or the sale of Equity Interests in any of its Restricted Subsidiaries, in each case other than directors’ qualifying shares. 

Notwithstanding the preceding, none of the following items will be deemed to be an Asset Sale: 

(1)    any single transaction or series of related transactions that involves assets having a Fair Market
Value of less than $100.0 million; 
 (2)    a transfer of assets between or among the Company and
its Restricted Subsidiaries; 
 (3)    an issuance of Equity Interests by a Restricted Subsidiary of the
Company to the Company or to another Restricted Subsidiary of the Company; 
 (4)    any sale of
receivables in connection with a Qualified Securitization Transaction; 
 (5)    the sale or other
disposition of cash or Cash Equivalents; 
 (6)    a Restricted Payment or Permitted Investment that is
permitted by Section 4.8 hereof; 
 (7)    the license or sublicense of intellectual property or
other general intangibles and licenses, leases or subleases of other property which do not materially interfere with the business of the Company and its Restricted Subsidiaries, taken as a whole, determined in good faith by the Company; 

(8)    the sale, exchange or other disposition of obsolete, worn out, uneconomical or surplus assets,
including any such intellectual property; 
 (9)    the sale, lease, conveyance or other disposition to
the extent required by, or made pursuant to, customary buy/sell arrangements between joint venture parties set forth in joint venture arrangements and similar binding agreements; 

(10)    foreclosures on, or condemnation of, assets and the surrender or waiver of contract rights or the
settlement, release or surrender of contract, tort or other claims; and 
 (11)    sales, transfers or
other dispositions of assets for consideration at least equal to the Fair Market Value of the assets sold or disposed of, but only if the consideration received consists of property or assets (other than cash, except to the extent used as a bona
fide means of equalizing the value of the property or assets involved in the swap transaction; provided, however, that cash does not exceed 10% of the sum of the amount of the cash and the Fair Market Value of the assets received or
given) of a nature or type that are used in a business having property or assets of a nature or type or engaged in a Permitted Business (or Capital Stock of a Person whose assets consist of assets of the type described in this clause (11)).

  
 -2- 

 “Attributable Debt” in respect of a sale and leaseback transaction means, at the
time of determination, the present value of the obligation of the lessee for net rental payments during the remaining term of the lease included in such sale and leaseback transaction including any period for which such lease has been extended or
may, at the option of the lessor, be extended. Such present value shall be calculated using a discount rate equal to the rate of interest implicit in such transaction, determined in accordance with GAAP. 

“Bankruptcy Law” means any of Title 11 of the United States Code, the BIA, the CCAA, the WURA and the CBCA, and any other
applicable insolvency, corporate arrangement or restructuring or other similar law of any jurisdiction including any law of any jurisdiction permitting a debtor to obtain a stay or a compromise of the claims of its creditors against it. 

“Beneficial Owner” has the meaning assigned to such term in Rule 13d-3 and Rule 13d-5 under the Exchange Act, except that in calculating the beneficial ownership of any particular “person” (as that term is used in Section 13(d)(3) of the Exchange Act), such
“person” will be deemed to have beneficial ownership of all securities that such “person” has the right to acquire by conversion or exercise of other securities, whether such right is currently exercisable or is exercisable only
after the passage of time. The terms “Beneficially Owns” and “Beneficially Owned” have corresponding meanings. 

“BIA” means the Bankruptcy and Insolvency Act (Canada). 

“Board of Directors” means: 

(1)    with respect to a company or corporation, the board of directors of the company or corporation or
any committee thereof duly authorized to act on behalf of such board; 
 (2)    with respect to a
partnership, the Board of Directors of the general partner of the partnership or any committee thereof duly authorized to act on behalf of such board; and 

(3)    with respect to any other Person, the board or committee of such Person serving a similar function.

 “Business Day” means each day that is not a Legal Holiday. 

“Canadian Note Guarantee” means each Guarantee of the obligations with respect to the Notes issued by each Canadian Note
Guarantor pursuant to the terms of this Indenture and substantially in the form of Exhibit D. 
 “Canadian
Note Guarantor” means each Note Guarantor that is organized under the laws of Canada or any province or territory thereof. 

“Capital Lease Obligations” means, at the time any determination is to be made, the amount of the liability in respect of a
capital lease that would at that time be required to be capitalized on a balance sheet in accordance with GAAP. 
 “Capital Markets
Indebtedness” means any Indebtedness consisting of bonds, debentures, notes or other similar debt securities issued in (a) a public offering registered under the Securities Act, (b) a private placement to institutional investors
that is resold in accordance with Rule 144A or Regulation S under the Securities Act, whether or not it includes registration rights entitling the holders of such debt securities to registration thereof with the SEC or (c) a private
placement to institutional investors. For the avoidance of doubt, the term “Capital Markets Indebtedness” does not include any Indebtedness under the Credit Agreement, Indebtedness incurred in connection with a sale and leaseback
transaction, Indebtedness incurred in the ordinary course of business of the Company, Capital Lease Obligations or recourse transfer of any financial asset or any other type of Indebtedness incurred in a manner not customarily viewed as a
“securities offering.” 

  
 -3- 

 “Capital Stock” means: 

(1)    in the case of a corporation, corporate stock; 

(2)    in the case of an association or business entity, any and all shares, interests, participations,
rights or other equivalents (however designated) of corporate stock; 
 (3)    in the case of a
partnership or limited liability company, partnership or membership interests (whether general or limited); and 

(4)    any other interest or participation (including, without limitation, quotas) that confers on a Person
the right to receive a share of the profits and losses of, or distributions of assets of, the issuing Person. 
 “Cash
Equivalents” means: 
 (1)    securities issued or directly and fully guaranteed or insured by
the U.S. government or any agency or instrumentality thereof (provided, that the full faith and credit of the U.S. is pledged in support thereof) having repricings or maturities of not more than one year from the date of acquisition; 

(2)    certificates of deposit and time deposits with maturities of one year or less from the date of
acquisition, bankers’ acceptances with maturities not exceeding one year and overnight bank deposits, in each case, with any U.S. commercial bank having capital and surplus in excess of $500.0 million; 

(3)    repurchase obligations with a term of not more than 14 days for underlying securities of the types
described in clauses (1) and (2) above entered into with any financial institution meeting the qualifications specified in clause (2) above; 

(4)    commercial paper having a rating of at least “P-2”
or better from Moody’s or at least “A-2” or better from S&P, or carrying an equivalent rating by an internationally recognized rating agency and, in each case, maturing within one year after
the date of acquisition; 
 (5)    auction-rate, corporate and municipal securities, in each case
(x) having either short-term debt ratings of at least “P-2” or better from Moody’s or at least “A-2” or better from S&P or long-term
senior debt ratings of “A2” or better from Moody’s or at least “A” or better from S&P, or carrying an equivalent rating by an internationally recognized rating agency, (y) having repricings or maturities of not more
than one year from the date of acquisition and (z) which are classifiable as cash and cash equivalents under GAAP; 

(6)    money market funds at least 95% of the assets of which constitute Cash Equivalents of the kinds
described in clauses (1) through (5) of this definition; or 
 (7)    in the case of the Company or
any Foreign Subsidiary: 
 (a)    direct obligations of the sovereign nation, or any agency thereof, in
which the Company or such Foreign Subsidiary is organized or is conducting business or in obligations fully and unconditionally guaranteed by such sovereign nation, or any agency thereof; provided, that such obligations have repricings or
maturities of not more than one year from the date of acquisition and are used by the Company or such Foreign Subsidiary in accordance with normal investment practices for cash management in investments of the type analogous to clauses (1)
through (5) above; or 
 (b)    investments of the type and maturity described in clauses (1)
through (5) above of foreign obligors, which investments or obligors have ratings described in such clauses or equivalent ratings from internationally recognized rating agencies; provided, that such investments are used by the Company or such
Foreign Subsidiary in accordance with normal investment practices for cash management in investments of the type analogous to clauses (1) through (5) above. 

  
 -4- 

 “CBCA” means the Canada Business Corporations Act. 

“CCAA” means the Companies’ Creditors Arrangement Act (Canada). 

“Change of Control” means the occurrence of any of the following: 

(1)    any “person” (as that term is used in Section 13(d)(3) of the Exchange Act) becomes
the Beneficial Owner, other than by way of merger or consolidation of the Company, of shares of the Company’s Voting Stock representing 50% or more of the total voting power of all of the Company’s outstanding Voting Stock; 

(2)    the Company consolidates with, or merges with or into, another Person, or the Company, directly or
indirectly, sells, assigns, conveys, transfers, leases or otherwise disposes of all or substantially all of the properties or assets of the Company and its Restricted Subsidiaries, taken as a whole (other than by way of merger or consolidation), in
one or a series of related transactions, or any Person consolidates with, or merges with or into, the Company, in any such event other than pursuant to a transaction in which the Persons that Beneficially Owned the shares of the Company’s
Voting Stock immediately prior to such transaction Beneficially Own at least a majority of the total voting power of all outstanding Voting Stock (other than Disqualified Stock) of the surviving or transferee Person; or 

(3)    the holders of the Company’s Capital Stock approve any plan or proposal for the liquidation or
dissolution of the Company (whether or not otherwise in compliance with this Indenture). 
 Notwithstanding the foregoing, a transaction
will not be deemed to involve a Change of Control if (1) the Company becomes a direct or indirect wholly-owned Subsidiary of a holding company and (2) (a) the direct or indirect holders of the Voting Stock of the ultimate parent
holding company immediately following that transaction are substantially the same as the holders of the Company’s Voting Stock immediately prior to that transaction or (b) no “person” (as that term is used in
Section 13(d)(3) of the Exchange Act) becomes the Beneficial Owner of 50% or more of the total voting power of the Voting Stock of such ultimate parent holding company. 

“Clearstream” means Clearstream Banking, société anonyme, Luxembourg. 

“Company” means the party named as such in the first paragraph of this Indenture until a successor replaces it pursuant to
the applicable provisions of this Indenture, and thereafter “Company” shall mean such successor Company. 
 “Consolidated
Cash Flow” means, with respect to any specified Person for any period, the Consolidated Net Income of such Person for such period plus (without duplication): 

(1)    provision for taxes based on income or profits of such Person and its Restricted Subsidiaries for
such period, to the extent that such provision for taxes was deducted in computing such Consolidated Net Income; plus 

(2)    Fixed Charges of such Person and its Restricted Subsidiaries for such period, to the extent that any
such expense was deducted in computing such Consolidated Net Income; plus 
 (3)    any
restructuring charges or expenses (which, for the avoidance of doubt, shall include retention, severance, systems establishment costs, excess pension charges, contract termination costs and costs to consolidate facilities and relocate employees), to
the extent that any such charge or expense was deducted in computing such Consolidated Net Income; plus 

  
 -5- 

 (4)    fees and expenses in connection with any proposed or
actual issuance of any Indebtedness or Equity Interests, or any proposed or actual acquisitions, Investments, Asset Sales or divestitures permitted to be incurred under this Indenture; plus 

(5)    depreciation, amortization (including amortization of intangibles but excluding amortization of
prepaid cash expenses that were paid in a prior period), and other non-cash charges or expenses (including impairment charges and other write-offs of intangible assets and goodwill, but excluding amortization
of a prepaid cash expense that was paid in a prior period to the extent added back in such prior period) of such Person and its Restricted Subsidiaries for such period to the extent that such depreciation, amortization and other non-cash charges or expenses were deducted in computing such Consolidated Net Income; provided that if any such non-cash charge or expense (or any portion thereof)
represents an accrual or reserve for any potential cash items in any future period, (i) the Company may elect not to add back such non-cash charge in the then-current period and instead add back such
amount to a following period, and (ii) to the extent the Company elects to add back such non-cash charge, the cash payment in respect thereof in such future period shall be subtracted from Consolidated
Cash Flow to the same extent in such future period; plus 
 (6)    any expense or charge for
extraordinary, unusual or non-recurring expenses or charges (including costs of, and payments of, litigation expenses, actual or prospective legal settlements, fines, judgments or orders); minus 

(7)    non-cash items increasing such Consolidated Net Income for
such period, other than the accrual of revenue in the ordinary course of business, in each case, on a consolidated basis and determined in accordance with GAAP. 

“Consolidated Net Income” means, with respect to any specified Person for any period, the aggregate of the Net Income of such
Person and its Restricted Subsidiaries for such period, on a consolidated basis, determined in accordance with GAAP; provided that: 

(1)    the Net Income (but not loss) of any Person that is not a Restricted Subsidiary or that is accounted
for by the equity method of accounting will be included only to the extent of the amount of dividends or distributions paid in cash to the specified Person or a Restricted Subsidiary of the Person; 

(2)    solely for purposes of Section 4.8 hereof, the Net Income of any Restricted Subsidiary (other
than any Note Guarantor) will be excluded to the extent that the declaration or payment of dividends or similar distributions by that Restricted Subsidiary of that Net Income is not at the date of determination permitted without any prior
governmental approval (that has not been obtained or cannot be obtained other than pursuant to customary filings) or, directly or indirectly, by operation of the terms of its charter or any agreement, instrument, judgment, decree, order, statute,
rule or governmental regulation applicable to that Restricted Subsidiary or its stockholders; 

(3)    the cumulative effect of a change in accounting principles will be excluded; 

(4)    any unrealized net gain or loss resulting in such period from Hedging Obligations or other
derivative instruments will be excluded; 
 (5)    any expense or charge attributable to the disposition
of discontinued operations will be excluded; 
 (6)    non-cash
goodwill or asset impairment charge and any non-cash compensation expense recorded from grants of stock, stock appreciation or similar rights, stock options, restricted stock or other rights to officers,
directors, employees or consultants of such Person or any of its Restricted Subsidiaries will be excluded; 

  
 -6- 

 (7)    any amortization expense incurred during such period
with respect to products acquired by the Company or any of its Subsidiaries that are used or useful in a Permitted Business will be excluded; 

(8)    any gain or loss, together with any related provision for taxes on such gain or loss, realized in
connection with: (a) any Asset Sale; or (b) the disposition of any securities by such Person or any of its Restricted Subsidiaries or the extinguishment of any Indebtedness of such Person or any of its Restricted Subsidiaries will be
excluded; 
 (9)    any extraordinary, nonrecurring or unusual gain or loss, together with any related
provision for taxes on such extraordinary, nonrecurring or unusual gain or loss will be excluded; 

(10)    any (i) non-cash compensation charge or expense
arising from any grant of stock, stock options or other equity based awards and any non-cash deemed finance charges in respect of any pension liabilities or other provisions or on the re-valuation of any benefit plan obligation and (ii) income (loss) attributable to deferred compensation plans or trusts, will be excluded; 

(11)    any purchase accounting effects including adjustments to inventory, property and equipment,
software and other intangible assets and deferred revenue in component amounts required or permitted by GAAP and related authoritative pronouncements (including the effects of such adjustments pushed down to the Restricted Subsidiaries), as a result
of any consummated acquisition, or the amortization or write-off of any amounts thereof (including any write-off of in process research and development) will be
excluded; and 
 (12)    to the extent covered by insurance and actually reimbursed, or, so long as the
Company has made a determination that there exists reasonable evidence that such amount will in fact be reimbursed by the insurer and only to the extent that such amount is (a) not denied by the applicable carrier in writing within 90 days
and (b) in fact reimbursed within 365 days of the date of such evidence (with a deduction for any amount so added back to the extent not so reimbursed within 365 days), expenses with respect to liability or casualty events or business
interruption; provided that (x) if net income is increased as a result of any amounts received from an insurer in respect of such a liability, casualty event or business interruption and the right to be so reimbursed was used in a prior
period to increase Consolidated Net Income pursuant to this clause (12), such amounts received shall be excluded from Consolidated Net Income and (y) to the extent the actual reimbursement received is less than the expected reimbursement
amount excluded in a prior period pursuant to this clause (12), Consolidated Net Income shall be reduced by the difference in the period in which such lower actual reimbursement amounts are received or in which a final judgment of a court of
competent jurisdiction is made that the Company is entitled to no reimbursement. 
 “Consolidated Total Assets” means, as
of any date of determination, the total assets shown on the consolidated quarterly or annual balance sheet of the Company and its Restricted Subsidiaries as of the most recent date for which such a quarterly or annual balance sheet is available,
determined on a consolidated basis in accordance with GAAP (and in the case of any determination relating to any incurrence of Indebtedness or Investment, on a pro forma basis). In addition, “Consolidated Total Assets” will be calculated
in a manner consistent with the definition of “Fixed Charge Coverage Ratio” to give effect to transactions that occurred after the date of the most recent quarterly or annual balance sheet date. 

“Corporate Trust Office” means the designated office of the Trustee at which at any particular time its corporate trust
business shall be administered which office at the date of the execution of this Indenture is located at 101 Barclay Street, Floor 7E, New York, New York 10286, Attention: Corporate Trust Administration or at any other time at such other
address as the Trustee may designate from time to time by notice to the Company. 
 “Credit Agreement” means the Third
Amended and Restated Credit and Guaranty Agreement, dated as of February 13, 2012, as in effect on the Issue Date (as it may be amended, restated, replaced, supplemented or otherwise modified from time to time), among the Company, certain
subsidiaries of the Company, as guarantors, the lenders party thereto from time to time, Goldman Sachs Lending Partners LLC, J.P. Morgan Securities LLC and Morgan Stanley Senior Funding, Inc., as joint lead arrangers and joint bookrunners, JPMorgan
Chase Bank, N.A. 

  
 -7- 

 
and Morgan Stanley Senior Funding, Inc., as co-syndication agents, JPMorgan Chase Bank, N.A., as issuing bank, Barclays Bank PLC (as successor to Goldman
Sachs Lending Partners LLC), as administrative agent and collateral agent, as amended, supplemented, restated and otherwise modified, together with the related documents thereto (including any guarantees and security documents), and in each case as
amended, extended, renewed, restated, supplemented or otherwise modified (in whole or in part, and without limitation as to amount, terms, conditions, covenants and other provisions) from time to time, and any agreement or instrument (and related
documents) governing Indebtedness incurred to refinance or replace, in whole or in part, the borrowings and commitments then outstanding or permitted to be outstanding under such facilities or a successor facility, whether by the same or any other
bank, institutional lender, purchaser, investor, trustee or agent or group thereof. 
 “Credit Facilities” means the
facilities under the Credit Agreement and one or more other debt facilities, credit agreements, commercial paper facilities, indentures or other agreements in each case with banks, institutional lenders, purchasers, investors, trustees or agents
providing for revolving credit loans, term loans, receivables financing (including through the sale of receivables to such lenders or to special purpose entities formed to borrow from such lenders against such receivables), letters of credit or
other extensions of credit or other Indebtedness, in each case including any notes, mortgages, guarantees, collateral documents, instruments and agreements executed in connection therewith, and in each case as amended, extended, renewed, restated,
supplemented or otherwise modified (in whole or in part, and without limitation as to amount, terms, conditions, covenants and other provisions) from time to time, and any agreement or instrument (and related documents) governing Indebtedness
incurred to refinance or replace, in whole or in part, the borrowings and commitments then outstanding or permitted to be outstanding under such facilities or a successor facility, whether by the same or any other bank, institutional lender,
purchaser, investor, trustee or agent or group thereof. 
 “Custodian” means any receiver, trustee, assignee, liquidator,
sequestrator, receiver-manager, custodian, administrative receiver, administrator or similar official under any Bankruptcy Law. 

“Default” means any event that is, or with the passage of time or the giving of notice or both would be, an Event of Default.

 “Definitive Notes” means Notes that are in substantially the form attached hereto as Exhibit A
and that do not include the information to which footnotes 1, 5, 6 and 8 thereof apply. 
 “Depositary” means with respect
to the Notes issuable or issued in whole or in part in global form, DTC, including any and all successors thereto appointed as depositary hereunder and having become such pursuant to the applicable provisions of this Indenture. 

“Designated Noncash Consideration” means noncash consideration received by the Company or one of its Restricted Subsidiaries
in connection with an Asset Sale that is designated by the Company as Designated Noncash Consideration, less the amount of cash or Cash Equivalents received in connection with a subsequent sale of such Designated Noncash Consideration, which cash
and Cash Equivalents shall be considered Net Proceeds received as of such date and shall be applied pursuant to Section 4.14. 

“Disqualified Stock” means any Capital Stock that, by its terms (or by the terms of any security into which it is
convertible, or for which it is exchangeable, in each case at the option of the holder thereof), or upon the happening of any event, matures or is mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, or redeemable at the
option of the holder thereof, in whole or in part, on or prior to the date that is 91 days after the date on which the Notes mature. Notwithstanding the preceding sentence, any Capital Stock that would constitute Disqualified Stock solely because
the holders of the Capital Stock have the right to require the Company to repurchase such Capital Stock upon the occurrence of a change of control or an asset sale will not constitute Disqualified Stock if the terms of such Capital Stock provide
that the Company may not repurchase or redeem any such Capital Stock pursuant to such provisions unless such repurchase or redemption complies with Section 4.8 hereof. 

  
 -8- 

 “Dollar Equivalent” of any amount means, at the time of determination thereof,

 (1)    if such amount is expressed in U.S. dollars, such amount, or 

(2)    if such amount is expressed in any other currency, the equivalent of such amount in U.S. dollars
determined by using the rate of exchange quoted by Barclays Capital Inc. in New York, New York at 11:00 a.m. (New York City time) on the date of determination (or, if such date is not a Business Day, the last Business Day prior thereto) to prime
banks in New York for the spot purchase in the New York currency exchange market of such amount of U.S. dollars with such currency. 

“Domestic Subsidiary” means any Restricted Subsidiary that was formed under the laws of the United States or any state
thereof or the District of Columbia. 
 “DTC” means The Depository Trust Company. 

“Equity Interests” means Capital Stock and all warrants, options or other rights to acquire Capital Stock (but excluding any
debt security that is convertible into, or exchangeable for, Capital Stock). 
 “Equity Offering” means a public or private
offering of Equity Interests (other than Disqualified Stock). 
 “Euroclear” means Euroclear Bank S.A./N.V. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder,
as in effect from time to time. 
 “Existing Indebtedness” means Indebtedness of the Company and its Restricted
Subsidiaries (other than Indebtedness incurred under Section 4.9(b)(i) or (xx) hereof) in existence on the date of this Indenture, until such amounts are repaid. 

“Existing Secured Notes” means the Company’s outstanding 6.50% Senior Secured Notes due 2022, 7.00% Senior Secured Notes
due 2024 and 5.500% Senior Secured Notes due 2025. 
 “Fair Market Value” means the price that could be negotiated in an arm’s-length transaction, for cash, between a willing seller and a willing and able buyer, neither of whom is under undue pressure or compulsion to complete the transaction, determined in good faith by
(i) a responsible financial or accounting officer of the Company with respect to valuations not in excess of $750.0 million and (ii) the Board of Directors of the Company with respect to valuations equal to or in excess of
$750.0 million, as applicable. 
 “Fall Away Event” means such time as the Notes shall have an Investment Grade Rating
and the Company shall have delivered to the Trustee an Officers’ Certificate certifying that the foregoing condition has been satisfied. 

“Final Maturity Date” means December 15, 2025. 

“Fixed Charge Coverage Ratio” means, with respect to any specified Person for any period, the ratio of the Consolidated Cash
Flow of such Person for such period to the Fixed Charges of such Person for such period. In the event that the specified Person or any of its Restricted Subsidiaries incurs, assumes, Guarantees, repays, repurchases or redeems any Indebtedness (other
than ordinary working capital borrowings) or issues, repurchases or redeems preferred stock subsequent to the commencement of the period for which the Fixed Charge Coverage Ratio is being calculated and on or prior to the date on which the event for
which the calculation of the Fixed Charge Coverage Ratio is made (the “Calculation Date”), then the Fixed Charge Coverage Ratio will be calculated giving pro forma effect to such incurrence, assumption, Guarantee, repayment,
repurchase or redemption of Indebtedness, or such issuance, repurchase or redemption of preferred stock, and the use of the proceeds therefrom as if the same had occurred at the beginning of the applicable four-quarter reference period. 

  
 -9- 

 To the extent the Company elects pursuant to an Officers’ Certificate delivered to the
Trustee to treat all or any portion of the commitment under any Indebtedness as being incurred prior to the actual incurrence thereof pursuant to Section 4.9(e) hereof, the Company shall deem all or such portion of such commitment of such
Indebtedness, as applicable, as having been incurred and to be outstanding for purposes of calculating the Fixed Charge Coverage Ratio for any period in which the Company makes any such election and for any subsequent period until such commitments
or such Indebtedness, as applicable, are no longer outstanding. 
 In addition, for purposes of calculating the Fixed Charge Coverage Ratio:

 (1)    acquisitions that have been made by the specified Person or any of its Restricted Subsidiaries,
including through consolidations or mergers and including any related financing transactions, during the four-quarter reference period or subsequent to such reference period and on or prior to the Calculation Date will be given pro forma effect as
if they had occurred on the first day of the four-quarter reference period and Consolidated Cash Flow for such reference period will be calculated (x) on a pro forma basis in accordance with Regulation
S-X promulgated by the SEC and, in addition, (y) to give effect to any Pro Forma Cost Savings; 

(2)    the Consolidated Cash Flow attributable to discontinued operations, as determined in accordance with
GAAP, and operations or businesses disposed of prior to the Calculation Date, will be excluded; and 

(3)    the Fixed Charges attributable to discontinued operations, as determined in accordance with GAAP,
and operations or businesses disposed of prior to the Calculation Date, will be excluded, but only to the extent that the obligations giving rise to such Fixed Charges will not be obligations of the specified Person or any of its Restricted
Subsidiaries following the Calculation Date. 
 “Fixed Charges” means, with respect to any specified Person for any period,
the sum, without duplication, of: 
 (1)    the consolidated interest expense of such Person and its
Restricted Subsidiaries for such period, whether paid or accrued, including, without limitation, amortization of debt issuance costs and original issue discount, non-cash interest payments, the interest
component of any deferred payment obligations, the interest component of all payments associated with Capital Lease Obligations, imputed interest with respect to Attributable Debt, commissions, discounts and other fees and charges incurred in
respect of letter of credit or bankers’ acceptance financings, and net of the effect of all payments made or received pursuant to Interest Rate Hedging Obligations; plus 

(2)    the consolidated interest of such Person and its Restricted Subsidiaries that was capitalized during
such period; plus 
 (3)    any interest expense on Indebtedness of another Person that is
Guaranteed by such Person or one of its Restricted Subsidiaries or secured by a Lien on assets of such Person or one of its Restricted Subsidiaries; plus 

(4)    all dividends, whether paid or accrued and whether or not in cash, on any Disqualified Stock or any
series of preferred stock of such Person or any of its Restricted Subsidiaries, other than dividends on Equity Interests payable solely in Equity Interests of the Company (other than Disqualified Stock) or to the Company or a Restricted Subsidiary
of the Company, in each case, on a consolidated basis and determined in accordance with GAAP; minus 

(5)    the consolidated interest income of such Person and its Restricted Subsidiaries for such period;
minus 
 (6)    amortization of deferred financing fees, debt issuance costs, commissions, fees
and expenses and expensing of any financing fees. 

  
 -10- 

 “Foreign Subsidiary” means a Restricted Subsidiary that is not organized or
existing under the laws of the United States of America or any state or territory thereof or the District of Columbia or is a Restricted Subsidiary of such Foreign Subsidiary. 

“GAAP” means generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting
Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other entity as have been approved by a significant segment
of the accounting profession, as in effect on January 30, 2015. 
 “Global Note Legend” means the legend set forth in
Exhibit A hereof, as applicable, which is required to be placed on all Global Notes issued under this Indenture. 

“Global Notes” means a Global Note substantially in the form of Exhibit A hereto bearing the Global Note Legend and
the Private Placement Legend deposited with or on behalf of, and registered in the name of, the Depositary or its nominee that will initially be issued in a denomination equal to the principal amount of the Notes sold in reliance on Rule 144A. 

“Government Securities” means, as applicable, (i) direct non-callable
obligations of, or guaranteed by, the United States of America for the timely payment of which guarantee or obligations the full faith and credit of the U.S. is pledged and (ii) direct non-callable
obligations of, or guaranteed by, a member state of the European Union for the timely payment of which guarantee or obligations the full faith and credit of the government of such member state is pledged. 

“Guarantee” means a guarantee other than by endorsement of negotiable instruments for collection in the ordinary course of
business, direct or indirect, in any manner including, without limitation, by way of a pledge of assets or through letters of credit or reimbursement agreements in respect thereof, of all or any part of any Indebtedness. 

“Hedging Obligations” means, with respect to any specified Person: 

(1)    Interest Rate Hedging Obligations; and 

(2)    the obligations of such Person under agreements or arrangements designed to protect such Person
against fluctuations in currency exchange rates. 
 “Holder” or “Noteholder” means the Person in whose
name a Note is registered on the Registrar’s books. 
 “Indebtedness” means, with respect to any specified Person, any
indebtedness of such Person, whether or not contingent (without duplication): 
 (1)    in respect of
borrowed money; 
 (2)    evidenced by bonds, notes, debentures or similar instruments or letters of
credit (or reimbursement agreements in respect thereof); 
 (3)    in respect of banker’s
acceptances; 
 (4)    representing Capital Lease Obligations or Attributable Debt in respect of sale and
leaseback transactions; 
 (5)    representing the balance deferred and unpaid of the purchase price of
any property, which balance is (a) due more than twelve months from the date of incurrence of the obligation in respect thereof or (b) evidenced by a note or similar written instrument, and except any such balance that constitutes an
accrued expense or trade payable; or 

  
 -11- 

 (6)    representing net payment obligations under any Hedging
Obligations, 
 if and to the extent any of the preceding items (other than letters of credit, Attributable Debt and Hedging Obligations) would appear as a
liability upon a balance sheet of the specified Person prepared in accordance with GAAP. In addition, the term “Indebtedness” includes (x) all Indebtedness of others secured by a Lien on any asset of the specified Person (whether or
not such Indebtedness is assumed by the specified Person), the amount of such obligation being deemed to be the lesser of the Fair Market Value of such asset and the amount of the obligation so secured and (y) to the extent not otherwise
included, the Guarantee by the specified Person of any Indebtedness of any other Person. 
 Notwithstanding the foregoing, in connection
with the purchase by a Person or any of its Restricted Subsidiaries of any business, the term “Indebtedness” will exclude indemnification or post-closing payment adjustments or earn-out or similar
obligations to which the seller may become entitled to the extent such payment is determined by a final closing balance sheet, working capital calculation or other similar method or such payment depends on the performance of such business after the
closing; provided, however, that, at the time of closing, the amount of any such payment is not determinable or is of a contingent nature and, to the extent such payment thereafter becomes fixed and finally determined, the amount is
paid within 60 days thereafter. 
 The amount of any Indebtedness outstanding as of any date will be: 

(1)    the accreted value of the Indebtedness, in the case of any Indebtedness issued with original issue
discount; and 
 (2)    the principal amount of the Indebtedness, together with any interest on the
Indebtedness that is more than 30 days past due, in the case of any other Indebtedness. 
 “Indenture” means this Indenture
as amended or supplemented from time to time pursuant to the terms of this Indenture. 
 “Initial Notes” means the
$1,500,000,000 aggregate principal amount of Notes issued on the date hereof. 
 “Interest Rate Hedging Obligations” means,
with respect to any specified Person, the obligations of such Person under: 
 (1)    interest rate swap
agreements, interest rate cap agreements and interest rate collar agreements; and 
 (2)    other
agreements or arrangements designed to protect such Person against fluctuations in interest rates. 
 “Investment Grade Rating
“means a rating of Baa3 or better by Moody’s or BBB- or better by S&P (or its equivalent under any successor rating categories of Moody’s or S&P) (or, in each case, if such Rating
Agency ceases to rate the Notes for reasons outside of the control of the Company, the equivalent investment grade credit rating from any Rating Agency selected by the Company as a replacement Rating Agency). 

“Investments” means, with respect to any Person, all direct or indirect investments by such Person in other Persons
(including Affiliates) in the forms of loans (including Guarantees or other obligations), advances or capital contributions (excluding commission, travel and similar advances to officers and employees made in the ordinary course of business),
purchases or other acquisitions for consideration of Indebtedness, Equity Interests or other securities, together with all items that are or would be classified as investments on a balance sheet prepared in accordance with GAAP. If (i) the
Company or any Restricted Subsidiary of the Company sells or otherwise disposes of any Equity Interests of any direct or indirect Restricted Subsidiary of the Company such that, after giving effect to any such sale or disposition, such Person is no
longer a Restricted Subsidiary of the Company or (ii) a Restricted Subsidiary of the Company is redesignated as an Unrestricted Subsidiary, the Company will be deemed to have made an Investment on the date of any such sale, disposition or
redesignation equal to the Fair Market Value of the Company’s Investments in such Subsidiary that were not sold or disposed of in an amount determined as provided in Section 4.8(c) hereof. For the avoidance of doubt, acquisitions of or
licenses for products or assets used or useful in a Permitted Business do not constitute Investments. 

  
 -12- 

 “Issue Date” means December 18, 2017, the date of the initial issuance of
the Notes under this Indenture. 
 “Lien” means, with respect to any asset, any mortgage, lien, pledge, charge (fixed
and/or floating), security interest or encumbrance of any kind in respect of such asset, whether or not filed, recorded or otherwise perfected under applicable law, including any conditional sale or other title retention agreement, any lease in the
nature thereof, any option or other agreement to sell or give a security interest in and any filing of or agreement to give any financing statement under the UCC or Personal Property Security Act (Ontario) (or equivalent statutes) of any
jurisdiction. 
 “Moody’s” means Moody’s Investors Service, Inc., or any successor to the rating agency business
thereof. 
 “Net Income” means, with respect to any specified Person, the net income (loss) of such Person, determined in
accordance with GAAP and before any reduction in respect of preferred stock dividends. 
 “Net Proceeds” means the
aggregate cash proceeds received by the Company or any of its Restricted Subsidiaries in respect of any Asset Sale (including, without limitation, any cash received upon the sale or other disposition of any
non-cash consideration received in any Asset Sale), net of the direct costs relating to such Asset Sale, including, without limitation, legal, accounting and investment banking fees, and sales commissions, and
any relocation expenses incurred as a result of the Asset Sale, taxes paid or payable as a result of the Asset Sale, in each case, after taking into account any available tax credits or deductions and any tax sharing arrangements, and amounts
required to be applied to the repayment of Indebtedness, other than Indebtedness under the Credit Agreement, secured by a Lien on the asset or assets that were the subject of such Asset Sale and any reserve for adjustment in respect of the sale
price of such asset or assets established in accordance with GAAP. 
 “Non-Recourse
Debt” means Indebtedness: 
 (1)    as to which none of the Company or any of its Restricted
Subsidiaries (a) provides credit support of any kind (including any undertaking, agreement or instrument that would constitute Indebtedness), (b) is directly or indirectly liable as a guarantor or otherwise, or (c) constitutes the lender;

 (2)    no default with respect to which (including any rights that the holders of the Indebtedness may
have to take enforcement action against an Unrestricted Subsidiary) would permit upon notice, lapse of time or both any holder of any other Indebtedness (other than the Notes) of the Company or any of its Restricted Subsidiaries to declare a default
on such other Indebtedness or cause the payment of the Indebtedness to be accelerated or payable prior to its Stated Maturity; and 

(3)    as to which the lenders have been notified in writing that they will not have any recourse to the
stock or assets of the Company or any of its Restricted Subsidiaries. 
 “Non-U.S.
Person” means a Person who is not a U.S. Person. 
 “Note Guarantee” means each Guarantee of the obligations with
respect to the Notes issued by a Subsidiary of the Company pursuant to the terms of this Indenture. 
 “Note Guarantor”
means each Subsidiary of the Company that becomes a guarantor of the Notes pursuant to the terms of this Indenture. 

“Notes” means any of the Company’s 9.000% Senior Notes due 2025 (individually, a “Note”), as
amended or supplemented from time to time, that are issued under this Indenture. 

  
 -13- 

 “Obligations” means any principal, interest, penalties, fees, indemnifications,
reimbursements, damages and other liabilities payable under the documentation governing any Indebtedness. 
 “Offering
Memorandum” means the Offering Memorandum dated December 4, 2017, with respect to the Notes. 
 “Officer”
means the Chairman of the Board, the Chief Executive Officer, the President, any Vice President, the Chief Financial Officer, the Controller, Treasurer, the Secretary or any Assistant Controller, Assistant Treasurer or Assistant Secretary of the
Company. 
 “Officers’ Certificate” means a certificate signed by two Officers; provided, however, that
for purposes of Section 4.4 hereof, “Officers’ Certificate” means a certificate signed by the principal executive officer, principal financial officer or principal accounting officer of the Company and by one other Officer. 

“Opinion of Counsel” means a written opinion from legal counsel reasonably acceptable to the Trustee. The counsel may be an
employee of or counsel to the Company. 
 “Participant” means, a member of, or participant or account holder in, DTC,
Euroclear and/or Clearstream. 
 “Permitted Asset Swap” means the substantially concurrent purchase and sale or exchange of
assets used or useful in a Permitted Business or a combination of such assets and cash or Cash Equivalents between the Company or any of its Restricted Subsidiaries and another Person; provided that any cash or Cash Equivalents received must
be applied in accordance with Section 4.14 of this Indenture. 
 “Permitted Business” means any business conducted by
the Company and its Restricted Subsidiaries on the Issue Date and any business that is in the judgment of the Company reasonably related, ancillary or complementary to the business of the Company and its Restricted Subsidiaries on the Issue Date or
a natural extension thereof. 
 “Permitted Investments” means: 

(1)    any Investment in the Company or in a Restricted Subsidiary of the Company; 

(2)    any Investment in cash and Cash Equivalents; 

(3)    any Investment by the Company or any Subsidiary of the Company in a Person, if as a result of such
Investment: 
 (a)    such Person becomes a Restricted Subsidiary of the Company; or 

(b)    such Person is merged or consolidated with or into, or transfers or conveys substantially all of its
assets to, or is liquidated into, the Company or a Restricted Subsidiary of the Company; 
 and, in each case, any Investment held by such
Person; provided that such Investment was not acquired by such Person in contemplation of such acquisition, merger, consolidation, transfer, conveyance or liquidation; 

(4)    any Investment made as a result of the receipt of non-cash
consideration from an Asset Sale that was made pursuant to and in compliance with Section 4.14 hereof; 

(5)    any Investments made solely in exchange for the issuance of Equity Interests (other than
Disqualified Stock) of the Company; 

  
 -14- 

 (6)    (i) any Investments received in compromise of
obligations owed to the Company or any of its Restricted Subsidiaries created in the ordinary course of business, including pursuant to any plan of reorganization or similar arrangement upon the bankruptcy or insolvency of any trade creditor or
customer or in satisfaction of judgments and (ii) Investments by the Company or any of its Restricted Subsidiaries in a Securitization Special Purpose Entity or any Investment by a Securitization Special Purpose Entity in any other Person, in
each case, in connection with a Qualified Securitization Transaction; 
 (7)    receivables owing to the
Company or any Restricted Subsidiary of the Company if created or acquired in the ordinary course of business and payable or dischargeable in accordance with customary trade terms (which trade terms may include such concessionary trade terms as the
Company or any such Restricted Subsidiary deems reasonable under the circumstances), and other Investments to the extent such Investments consist of prepaid expenses, negotiable instruments held for collection and lease, utility and workers’
compensation, performance and other similar deposits made in the ordinary course of business by the Company or any Restricted Subsidiary; 

(8)    Investments represented by Hedging Obligations; 

(9)    Investments in existence on the date of this Indenture and any extension, modification or renewal of
any such Investments, but only to the extent such extension, modification or renewal does not involve additional advances, contributions or other Investments of cash or other assets or other increases thereof (other than as a result of the accrual
or accretion of interest or original issue discount or the issuance of pay-in-kind securities, in each case, pursuant to the terms of such Investment as in effect on the
date of this Indenture); 
 (10)    payroll, travel and similar advances to cover matters that are
expected at the time of such advances ultimately to be treated as expenses for accounting purposes and that are made in the ordinary course of business; 

(11)    loans and advances to officers, directors and employees in the ordinary course of business in the
aggregate amount outstanding at any one time not to exceed $25.0 million; 
 (12)    Investments in
a Permitted Joint Venture or Unrestricted Subsidiary, when taken together with all other Investments made pursuant to this clause (12) that are at the time outstanding, not to exceed the greater of (x) $675.0 million and (y) 2.5%
of Consolidated Total Assets; and 
 (13)    other Investments in any Person having an aggregate Fair
Market Value (measured on the date each such Investment was made and without giving effect to subsequent changes in value), when taken together with all other Investments made pursuant to this clause (13) that are at the time outstanding, not
to exceed the greater of (x) $2.0 billion and (y) 7.5% of Consolidated Total Assets. 
 “Permitted Joint
Venture” means any joint venture (which may be in the form of a limited liability company, partnership, corporation or other entity) in which the Company or any of its Restricted Subsidiaries is a joint venturer; provided,
however, that the joint venture is engaged solely in a Permitted Business. 
 “Permitted Liens” means: 

(1)    Liens securing Indebtedness and other Obligations under Credit Facilities that were permitted by the
terms of this Indenture to be incurred under Section 4.9(b)(i) or (xx) hereof; 
 (2)    Liens
in favor of the Company or any Note Guarantor; 
 (3)    Liens on property of a Person existing at the
time such Person is merged with or into or consolidated with or is acquired by the Company or any Subsidiary of the Company; provided, that such Liens were not incurred in contemplation of such merger, consolidation or acquisition and do not
extend to any assets other than those of the Person merged into, consolidated with or acquired by the Company or the Subsidiary; 

  
 -15- 

 (4)    Liens on property existing at the time of acquisition
of the property by the Company or any Subsidiary of the Company, provided, that such Liens were not incurred in contemplation of such acquisition; 

(5)    Liens to secure the performance of statutory obligations, surety or appeal bonds, performance bonds
or other obligations of a like nature incurred in the ordinary course of business; 
 (6)    Liens to
secure Indebtedness (including Capital Lease Obligations) permitted by Section 4.9(b)(iv) or Section 4.9(b)(v) hereof, covering only the assets acquired with such Indebtedness (and improvements or accessions thereto); 

(7)    Liens existing on the date of this Indenture and Liens securing the Existing Secured Notes; 

(8)    Liens for taxes, assessments or governmental charges or claims that are not yet delinquent or that
are being contested in good faith by appropriate proceedings promptly instituted and diligently concluded, provided, that any reserve or other appropriate provision as is required in conformity with GAAP has been made therefor; 

(9)    (i) Liens securing Hedging Obligations and (ii) Liens existing under or by reason of
Indebtedness or other contractual requirements of a Securitization Special Purpose Entity or any Standard Securitization Undertaking, in each case in respect of this subclause (ii) in connection with a Qualified Securitization Transaction; 

(10)    Liens arising by reason of deposits necessary to obtain standby letters of credit in the ordinary
course of business; 
 (11)    Liens to secure any Permitted Refinancing Indebtedness permitted to be
incurred under this Indenture; provided, however, that: 
 (a)    the new Lien shall be
limited to all or part of the same property and assets that secured or, under the written agreements pursuant to which the original Lien arose, could secure the original Lien (plus improvements and accessions to, such property or proceeds or
distributions thereof); and 
 (b)    the Indebtedness secured by the new Lien is not increased to any
amount greater than the sum of (x) the outstanding principal amount or, if greater, committed amount, of the Permitted Refinancing Indebtedness and (y) an amount necessary to pay any fees and expenses, including premiums, related to such
refinancing, refunding, extension, renewal or replacement; 
 (12)    Liens of the Company or any
Restricted Subsidiary of the Company with respect to obligations that do not exceed the greater of (x) $275.0 million and (y) 1.0% of Consolidated Total Assets at any one time outstanding; 

(13)    survey title exceptions, title defects, encumbrances, easements, reservations of, or rights of
others for, rights of way, sewers, electric lines, telegraph or telephone lines and other similar purposes or zoning or other restrictions as to the use of real property not materially interfering with the business of the Company and its Restricted
Subsidiaries taken as a whole; 
 (14)    Liens arising by operation of law in favor of landlords,
mechanics, carriers, warehousemen, materialmen, laborers, employees, suppliers or the like, incurred in the ordinary course of business for sums which are not yet delinquent or are being contested in good faith by negotiations or by appropriate
proceedings which suspend the collection thereof; 

  
 -16- 

 (15)    Liens arising out of judgments, decrees, orders or
awards in respect of which the Company or a Restricted Subsidiary of the Company shall in good faith be prosecuting an appeal or proceedings for review which appeal or proceedings shall not have been finally terminated, or if the period within which
such appeal or proceedings may be initiated shall not have expired; 
 (16)    Liens securing the Notes
issued on the Issue Date and the Note Guarantees with respect thereto; 
 (17)    Liens securing one or
more local working capital facilities of Foreign Subsidiaries, so long as such Liens do not extend to the assets of any Person other than such foreign Restricted Subsidiaries; 

(18)    Liens on assets of Foreign Subsidiaries securing Indebtedness incurred by Foreign Subsidiaries
pursuant to Section 4.9(b)(xiii) hereof; 
 (19)    Liens imposed pursuant to licenses, sublicenses,
leases and subleases which do not materially interfere with the ordinary conduct of the business of the Company and its Restricted Subsidiaries taken as a whole; 

(20)    Liens incurred to secure cash management services in the ordinary course of business; 

(21)    customary restrictions on, or options, contracts or other agreements for, transfers of assets
contained in agreements related to any sale of assets pending such sale; provided that such restrictions apply only to the assets to be sold and such sale is otherwise permitted by this Indenture; 

(22)    Liens securing obligations to the Trustee arising under this Indenture and similar Liens in favor
of trustees, agents and representatives arising under instruments governing Indebtedness permitted to be incurred under this Indenture; 

(23)    Liens on trusts, cash or Cash Equivalents or other funds in connection with the defeasance (whether
by covenant or legal defeasance), discharge or redemption of Indebtedness, pending consummation of a strategic transaction, or similar obligations; provided that such defeasance, discharge or redemption is otherwise permitted by this
Indenture; and 
 (24)    Liens to secure any Indebtedness permitted to be incurred pursuant to
Section 4.9, provided that, in the case of this clause (24), at the time of its incurrence and after giving pro forma effect thereto, the Secured Leverage Ratio would be no greater than 3.50 to 1.0. 

In the event that a Permitted Lien meets the criteria of more than one of the types of Permitted Liens (at the time of incurrence or at a
later date), the Company in its sole discretion may divide, classify or from time to time reclassify all or any portion of such Permitted Lien in any manner that complies with this definition and such Permitted Lien shall be treated as having been
made pursuant only to the clause or clauses of the definition of “Permitted Lien” to which such Permitted Lien has been classified or reclassified. 

“Permitted Refinancing Indebtedness” means any Indebtedness of the Company or any of its Restricted Subsidiaries issued in
exchange for, or the net proceeds of which are used to extend, refinance, renew, replace, defease or refund other Indebtedness of the Company or any of its Restricted Subsidiaries (other than intercompany Indebtedness); provided, that: 

(1)    the principal amount (or accreted value, if applicable) of such Permitted Refinancing Indebtedness
does not exceed the principal amount (or accreted value, if applicable) of the Indebtedness extended, refinanced, renewed, replaced, defeased or refunded (plus all accrued interest on the Indebtedness and the amount of all expenses and premiums
incurred in connection therewith); 

  
 -17- 

 (2)    such Permitted Refinancing Indebtedness has a final
maturity date later than the final maturity date of, and has a Weighted Average Life to Maturity equal to or greater than the Weighted Average Life to Maturity of, the Indebtedness being extended, refinanced, renewed, replaced, defeased or refunded;

 (3)    if the Indebtedness being extended, refinanced, renewed, replaced, defeased or refunded is
contractually subordinated in right of payment to the Notes, such Permitted Refinancing Indebtedness has a final maturity date later than the final maturity date of, and is subordinated in right of payment to, the Notes on terms at least as
favorable to the Holders of Notes as those contained in the documentation governing the Indebtedness being extended, refinanced, renewed, replaced, defeased or refunded; and 

(4)    if the Indebtedness being refinanced is Indebtedness of the Company or a Note Guarantor, such
Permitted Refinancing Indebtedness is also Indebtedness of the Company or a Note Guarantor. 
 “Person” means any
individual, corporation, partnership, joint venture, association, joint-stock company, trust, unincorporated organization, limited liability company or government or other entity. 

“Principal” or “principal” of a debt security, including the Notes, means the principal of the security
plus, when appropriate, the premium, if any, on the security. 
 “Pro Forma Cost Savings” means, without duplication, with
respect to any period, the reductions in costs and other operating improvements or operating synergies with respect to an acquisition that are reasonably identifiable, factually supportable, reasonably attributable to the action specified and
reasonably anticipated to result from such actions; provided that the relevant actions have been taken or initiated and the benefits resulting therefrom are anticipated to be realized within 18 months of the date of such acquisition
(including, for the avoidance of doubt, actions that will be taken or initiated so long as the benefits resulting therefrom are anticipated to be realized within 18 months of the date of such acquisition), as if all such reductions in costs and
other operating improvements or operating synergies had been effected as of the beginning of such period, decreased by any recurring incremental expenses incurred or to be incurred during such four-quarter period in order to achieve such reduction
in costs. Pro Forma Cost Savings described in the preceding sentence shall be calculated in good faith by a responsible financial or accounting officer of the Company and shall be accompanied by a certificate delivered to the Trustee from the
Company’s chief financial officer that generally outlines the specific actions taken or expected to be taken and the net cost reductions and other operating improvements or operating synergies achieved or expected to be achieved from each such
action and certifies that such cost reductions and other operating improvements or synergies meet the criteria set forth in the preceding sentence. 

“Qualified Securitization Transaction” means any transaction or series of transactions that may be entered into by the
Company or any of its Restricted Subsidiaries pursuant to which the Company or such Restricted Subsidiary may sell, convey, grant a security interest in or otherwise transfer to a Securitization Special Purpose Entity, and such Securitization
Special Purpose Entity may sell, convey, grant a security interest in or otherwise transfer to any other Person, any Securitization Program Assets (whether now existing or arising in the future). 

“Rating Agency” means (1) each of Moody’s and S&P and (2) if Moody’s or S&P ceases to rate the
Notes for reasons outside of the control of the Company, a nationally recognized statistical rating organization under the Exchange Act selected by the Company as a replacement agency for Moody’s or S&P, as the case may be. 

“Redemption Date” or “redemption date” means the date specified for redemption of the Notes in accordance
with the terms thereof and this Indenture. 
 “Regulation S” means Regulation S under the Securities Act or any
successor to such regulation. 
 “Regulation S-X” means Regulation S-X under the Securities Act or any successor to such regulation. 

  
 -18- 

 “Regulation S Global Note” means a Global Note substantially in the form of
Exhibit A hereto bearing the Global Note Legend and the Private Placement Legend and deposited with or on behalf of, and registered in the name of, the Depositary or its nominee that will initially be issued in a denomination equal to
the principal amount of the Notes sold in reliance on Regulation S. 
 “Restricted Global Note” means a permanent
Global Note that is substantially in the form of Exhibit A attached hereto that bears the Global Note Legend and that has the “Schedule of Exchanges of Interests in the Global Note” attached thereto, and that is deposited with
or on behalf of and registered in the name of the Depositary or a nominee of the Depositary, representing Notes that bear the Legend. 

“Restricted Investment” means an Investment other than a Permitted Investment. 

“Restricted Note” means a Note required to bear the restricted legend set forth in the form of Notes set forth in
Exhibit A of this Indenture. 
 “Restricted Subsidiary” of a Person means any Subsidiary of the referent Person
that is not an Unrestricted Subsidiary. For the avoidance of doubt, Valeant shall at all times be considered a Restricted Subsidiary of the Company. 

“Rule 144” means Rule 144 promulgated under the Securities Act or any successor to such rule. 

“Rule 144A” means Rule 144A promulgated under the Securities Act or any successor to such rule. 

“Rule 903” means Rule 903 promulgated under the Securities Act. 

“Rule 904” means Rule 904 promulgated under the Securities Act. 

“S&P” means Standard & Poor’s Ratings Group, Inc., or any successor to the rating agency business thereof.

 “SEC” means the U.S. Securities and Exchange Commission. 

“Secured Leverage Ratio” means the ratio of (i) the Total Consolidated Indebtedness of the Company and its Restricted
Subsidiaries that is secured by a Lien on assets of the Company and its Restricted Subsidiaries, after giving effect to all incurrences and repayments of Indebtedness on the relevant transaction date (net of unrestricted cash and Cash Equivalents of
the Company and its Restricted Subsidiaries as of such date), provided that in the event the Company proposes to incur Indebtedness pursuant to clauses (i) and (xx) of Section 4.9(b) hereof on the same day, Indebtedness incurred
under clause (i) on that date shall not be included in the calculation of the Secured Leverage Ratio for purposes of the calculation to be made pursuant to such clause (xx) on such date or clause (xxiv) of the definition of
“Permitted Liens” on such date (but shall, for the avoidance of doubt, be included in any and all subsequent calculations of the Secured Leverage Ratio to the extent then outstanding and secured) to (ii) Consolidated Cash Flow of the
Company for the most recent four consecutive full fiscal quarters for which financial statements are available ending on or prior to the transaction date. In addition, the “Secured Leverage Ratio” will be calculated in a manner consistent
with the definition of “Fixed Charge Coverage Ratio” to give effect to transactions that would require pro forma adjustments to such ratio. 

To the extent the Company elects pursuant to an Officers’ Certificate delivered to the Trustee to treat all or any portion of the
commitment under any Indebtedness as being incurred prior to the actual incurrence thereof pursuant to Section 4.9(e) hereof, the Company shall deem all or such portion of such commitment of such Indebtedness, as applicable, as having been
incurred and to be outstanding for purposes of calculating the Secured Leverage Ratio for any period in which the Company makes any such election and for any subsequent period until such commitments or such Indebtedness, as applicable, are no longer
outstanding. 
 “Securities Act” means the U.S. Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder, as in effect from time to time. 

  
 -19- 

 “Securitization Program Assets” means (i) all receivables customarily
transferred in connection with asset securitization transactions by the Company or any of its Restricted Subsidiaries pursuant to documents relating to any Qualified Securitization Transaction, (ii) all rights arising under the documentation
governing or related to receivables (including rights in respect of Liens securing such receivables and other credit support in respect of such receivables), any proceeds of such receivables and any lockboxes or accounts in which such proceeds are
deposited, spread accounts and other similar accounts (and any amounts on deposit therein) established in connection with a Qualified Securitization Transaction, any warranty, indemnity, dilution and other intercompany claim arising out of the
documents relating to such Qualified Securitization Transaction and other assets which are customarily transferred or in respect of which security interests are customarily granted in connection with asset securitizations involving accounts
receivable and (iii) all collections (including recoveries) and other proceeds of the assets described in the foregoing clauses (i) and (ii). 

“Securitization Special Purpose Entity” means a Person (including, without limitation, a Restricted Subsidiary) created in
connection with the transactions contemplated by a Qualified Securitization Transaction, which Person engages in no activities and holds no assets other than those incidental to such Qualified Securitization Transaction. 

“Significant Subsidiary” means any Subsidiary that would be a “significant subsidiary” as defined in
Article 1, Rule 1-02 of Regulation S-X, promulgated by the SEC, as such regulation is in effect on the date hereof. 

“Standard Securitization Undertakings” means all representations, warranties, covenants, indemnities, performance guarantees
and servicing obligations entered into by the Company or any Subsidiary (other than a Securitization Special Purpose Entity) which are customary in connection with any Qualified Securitization Transaction. 

“Stated Maturity” means, with respect to any installment of interest or principal on any series of Indebtedness, the date on
which the payment of interest or principal was scheduled to be paid in the original documentation governing such Indebtedness, and will not include any contingent obligations to repay, redeem or repurchase any such interest or principal prior to the
date originally scheduled for the payment thereof. 
 “Subsidiary” means, with respect to any specified Person: 

(1)    any corporation, association or other business entity of which more than 50% of the total voting
power of shares of Capital Stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees of the corporation, association or other business entity is at the time owned or controlled,
directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person (or a combination thereof); and 

(2)    any partnership (a) the sole general partner or the managing general partner of which is such
Person or a Subsidiary of such Person or (b) the only general partners of which are that Person or one or more Subsidiaries of that Person (or any combination thereof). 

“TIA” means the Trust Indenture Act of 1939, as amended, and the rules and regulations thereunder as in effect on the date of
this Indenture, except to the extent any amendment to the Trust Indenture Act expressly provides for application of the Trust Indenture Act as in effect on another date. 

“Total Consolidated Indebtedness” means Indebtedness consisting of Indebtedness for borrowed money, Capital Lease
Obligations, letters of credit (only to the extent of any unreimbursed drawings thereunder), debt obligations evidenced by promissory notes and similar instruments and Guarantees in respect of any of the foregoing. 

“Total Leverage Ratio” means the ratio of (i) Total Consolidated Indebtedness of the Company and its Restricted
Subsidiaries, after giving effect to all incurrences and repayments of Indebtedness on the transaction date (net of unrestricted cash and Cash Equivalents of the Company and its Restricted Subsidiaries as of such date), to (ii) Consolidated
Cash Flow of the Company and its Restricted Subsidiaries for the most recent four consecutive full fiscal quarters for which financial statements are available ending on or prior to the transaction date. In addition, the “Total Leverage
Ratio” will be calculated in a manner consistent with the definition of “Fixed Charge Coverage Ratio” to give effect to transactions that would require pro forma adjustments to such ratio. 

  
 -20- 

 To the extent the Company elects pursuant to an Officers’ Certificate delivered to the
Trustee to treat all or any portion of the commitment under any Indebtedness as being incurred prior to the actual incurrence thereof pursuant to Section 4.9(e) hereof, the Company shall deem all or such portion of such commitment of such
Indebtedness, as applicable, as having been incurred and to be outstanding for purposes of calculating the Total Leverage Ratio for any period in which the Company makes any such election and for any subsequent period until such commitments or such
Indebtedness, as applicable, are no longer outstanding. 
 “Treasury Rate” means with respect to the Notes, the rate per
annum equal to the yield to maturity at the time of computation of U.S. Treasury securities with a constant maturity most nearly equal to the period from such date of redemption to December 15, 2021, provided, however, that if the
period from such date of redemption to December 15, 2021 is not equal to the constant maturity of a U.S. Treasury security for which a weekly average yield is given, the Treasury Rate shall be obtained by linear interpolation (calculated to the
nearest one-twelfth of a year) from the weekly average yields of U.S. Treasury securities for which such yields are given, except that if the period from such date of redemption to December 15, 2021 is
less than one year, the weekly average yield on actually traded U.S. Treasury securities adjusted to a constant maturity of one year shall be used. The Company shall obtain the Treasury Rate. 

“Trustee” means The Bank of New York Mellon, a New York banking corporation, until a successor replaces it in accordance with
the provisions of this Indenture, and thereafter means the successor. 
 “Trust Officer” shall mean, when used with respect
to the Trustee, any officer within the corporate trust department of the Trustee, including any vice president, assistant secretary, associate, secretary, trust officer or any other officer of the Trustee who customarily performs functions similar
to those performed by the Persons who at the time shall be such officers, respectively, or to whom any corporate trust matter is referred because of such person’s knowledge of and familiarity with the particular subject and who shall have
direct responsibility for the administration of this Indenture. 
 “UCC” or “Uniform Commercial Code”
means the Uniform Commercial Code as the same may be in effect from time to time in the State of New York or the Uniform Commercial Code (or similar code or statute) of another jurisdiction. 

“Unrestricted Subsidiary” means any Subsidiary (other than Valeant) of the Company that is designated by the Board of
Directors of the Company as an Unrestricted Subsidiary pursuant to a resolution of the Board of Directors of the Company, but only to the extent that such Subsidiary: 

(1)    has no Indebtedness other than Non-Recourse Debt; 

(2)    is not party to any agreement, contract, arrangement or understanding with the Company or any
Restricted Subsidiary of the Company unless the terms of any such agreement, contract, arrangement or understanding are not materially less favorable to the Company or such Restricted Subsidiary, in each case, taken as a whole, than those that might
be obtained at the time from Persons who are not Affiliates of the Company; 
 (3)    is a Person with
respect to which neither the Company nor any of its Restricted Subsidiaries has any direct or indirect obligation (a) to subscribe for additional Equity Interests or (b) to maintain or preserve such Person’s financial condition or to
cause such Person to achieve any specified levels of operating results; and 
 (4)    has not Guaranteed
or otherwise directly or indirectly provided credit support for any Indebtedness of the Company or any of its Restricted Subsidiaries. 

  
 -21- 

 Any designation of a Subsidiary of the Company as an Unrestricted Subsidiary will be evidenced to
the Trustee by filing with the Trustee a certified copy of the resolution of the Board of Directors of the Company giving effect to such designation and an Officers’ Certificate certifying that such designation complied with the preceding
conditions and was permitted by Section 4.8 hereof. If, at any time, any Unrestricted Subsidiary would fail to meet the preceding requirements as an Unrestricted Subsidiary, it will thereafter cease to be an Unrestricted Subsidiary for purposes
of this Indenture and any Indebtedness of such Subsidiary will be deemed to be incurred by a Restricted Subsidiary of the Company as of such date, and, if such Indebtedness is not permitted to be incurred as of such date under Section 4.9
hereof, the Company will be in default of such covenant. The Board of Directors of the Company may at any time designate any Unrestricted Subsidiary to be a Restricted Subsidiary; provided that such designation will be deemed to be an
incurrence of Indebtedness and, if applicable, related Liens by a Restricted Subsidiary of the Company of any outstanding Indebtedness and, if applicable, related Liens of such Unrestricted Subsidiary and such designation will only be permitted if
(1) such Indebtedness and, if applicable, related Liens are permitted under Section 4.9 hereof and, if applicable, Section 4.11 hereof (other than clause (3) under the definition of “Permitted Liens”), calculated, if
applicable, on a pro forma basis as if such designation had occurred at the beginning of the four-quarter reference period; and (2) no Default or Event of Default would be in existence following such designation. 

“Valeant” means Valeant Pharmaceuticals International, a Delaware corporation, and its successors. 

“Vice President” when used with respect to the Company or the Trustee, means any vice president, whether or not designated by
a number or a word or words added before or after the title “vice president.” 
 “Voting Stock” of any Person as
of any date means the Capital Stock of such Person that is at the time entitled to vote in the election of the Board of Directors of such Person. 

“Weighted Average Life to Maturity” means, when applied to any Indebtedness at any date, the number of years obtained by
dividing: 
 (1)    the sum of the products obtained by multiplying (a) the amount of each then
remaining installment, sinking fund, serial maturity or other required payments of principal, including payment at final maturity, in respect of the Indebtedness, by (b) the number of years (calculated to the nearest one-twelfth) that will elapse between such date and the making of such payment; by 

(2)    the then outstanding principal amount of such Indebtedness. 

“WURA” means the Winding-Up and Restructuring Act (Canada). 

Section 1.2    Other Definitions. 

 

			
	 TERM
	  	 DEFINED IN
SECTION

	 “Acceptable Commitment”
	  	4.14(b)
	 “Additional Amounts”
	  	4.21(a)
	 “Affiliate Transaction”
	  	4.13(a)
	 “Agent Members”
	  	2.1(b)
	 “Agreed Guarantee Principles”
	  	4.15
	 “Asset Sale Offer”
	  	4.14(c)/3.14
	 “Authorized Agent”
	  	11.16
	 “Benefited Party”
	  	10.1(b)
	 “Change in Tax Law”
	  	3.7(e)
	 “Change of Control Offer”
	  	3.8(b)
	 “Change of Control Purchase Date”
	  	3.8(b)
	 “Change of Control Purchase Notice”
	  	3.8(c)
	 “Change of Control Purchase Price”
	  	3.8(a)

  
 -22- 

			
	 TERM
	  	 DEFINED IN
SECTION

	 “Company Notice”
	  	3.8(b)
	 “Company Order”
	  	2.2
	 “Covenant Defeasance”
	  	8.3
	 “Event of Default”
	  	6.1
	 “Excess Proceeds”
	  	4.14(c)
	 “FATCA”
	  	4.21(b)(vii)
	 “incur”
	  	4.9(a)
	 “Judgment Currency”
	  	11.17
	 “Legal Defeasance”
	  	8.2
	 “Legal Holiday”
	  	11.7
	 “Legend”
	  	2.12(a)
	 “Notice of Default”
	  	6.1
	 “Offer Amount”
	  	3.14
	 “Offer Period”
	  	3.14
	 “Paying Agent”
	  	2.3
	 “Payment Default”
	  	6.1(e)
	 “Payor”
	  	4.21(a)
	 “Permitted Debt”
	  	4.9(b)
	 “Purchase Date”
	  	3.14
	 “Registrar”
	  	2.3
	 “Regulation 803 Reimbursement”
	  	4.21(d)
	 “Relevant Taxing Jurisdiction”
	  	4.21(a)
	 “Restricted Payments”
	  	4.8(a)
	 “Tax”
	  	4.21(a)

 Section 1.3    [Reserved]. 

Section 1.4    Rules of Construction. Unless the context otherwise requires: 

(A)    a term has the meaning assigned to it; 

(B)    an accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP;

 (C)    words in the singular include the plural, and words in the plural include the singular; 

(D)    provisions apply to successive events and transactions; 

(E)    the term “merger” includes a statutory share exchange and the term “merged” has
a correlative meaning; 
 (F)    the masculine gender includes the feminine and the neuter; 

(G)    references to agreements and other instruments include subsequent amendments thereto; 

(H)    “herein,” “hereof” and other words of similar import refer to this Indenture as
a whole and not to any particular Article, Section or other subdivision; 
 (I)    references to ratings
by Moody’s or S&P shall include any successor equivalent ratings if either Moody’s or S&P changes its ratings scale subsequent to the date of this Indenture; 

  
 -23- 

 (J)    except as otherwise provided for herein, the Notes
will be treated as a single class for all purposes under this Indenture, including, without limitation, waivers, amendments, redemptions and offers to purchase; and 

(K)    a reference to a statute includes all regulations made pursuant to such statute and, unless
otherwise specified, the provisions of any statute or regulation which amends, revises, restates, supplements or supersedes any such statute or any such regulation. 

ARTICLE 2 

THE SECURITIES 
 
Section 2.1    Form and Dating. The Notes and the Trustee’s certificate of authentication with respect thereto shall be substantially in the form set forth in Exhibit A, which are
incorporated in and made part of this Indenture. The Notes may have notations, legends or endorsements required by law, stock exchange rule or usage. The Company shall provide any such notations, legends or endorsements to the Trustee in writing.
The Notes shall be in a minimum denomination of $2,000 and integral multiples of $1,000 in excess thereof. Each Note shall be dated the date of its authentication. The Notes are being offered and sold by the Company in transactions exempt from, or
not subject to, the registration requirements of the Securities Act. 
 (a)    Restricted Global
Notes. All of the Notes are initially being offered and sold to (i) qualified institutional buyers as defined in Rule 144A in reliance on Rule 144A under the Securities Act or (ii) outside the United States to persons other than U.S.
persons in reliance upon Regulation S under the Securities Act, and shall be issued initially in the form of one or more 144A Global Notes and Regulation S Global Notes, respectively, which shall be deposited on behalf of the purchasers of the Notes
represented thereby with the Trustee, as custodian for the depositary, DTC, and registered in the name of its nominee, Cede & Co., duly executed by the Company and authenticated by the Trustee as hereinafter provided. The aggregate
principal amount of the Restricted Global Notes may from time to time be increased or decreased by adjustments made on the records of the Notes Custodian as hereinafter provided, subject in each case to compliance with the Applicable Procedures.

 (b)    Form of Notes. Notes issued in global form shall be substantially in the form of
Exhibit A (including the Global Note Legend thereon and the “Schedule of Exchanges of Interests in the Global Note” attached thereto). Definitive Notes shall be substantially in the form of
Exhibit A attached hereto (but without the Global Note Legend thereon and without the “Schedule of Exchanges of Interests in the Global Note” attached thereto). Each Global Note shall represent such of the
outstanding Notes as shall be specified therein and each shall provide that it shall represent the aggregate principal amount of outstanding Notes from time to time endorsed thereon and that the aggregate principal amount of outstanding Notes
represented thereby may from time to time be reduced or increased, as appropriate, to reflect exchanges and redemptions. Any endorsement of a Global Note to reflect the amount of any increase or decrease in the aggregate principal amount of
outstanding Notes represented thereby shall be made by the Trustee or the Notes Custodian, at the direction of the Trustee, in accordance with instructions given by the Holder thereof as required by Section 2.12 hereof and shall be made on the
records of the Trustee and the Depositary. 
 Members of, or participants in, the Depositary (“Agent
Members”) shall have no rights under this Indenture with respect to any Global Note held on their behalf by the Depositary or under the Global Note, and the Depositary (including, for this purpose, its nominee) may be treated by the
Company, the Trustee and any agent of the Company or the Trustee as the absolute owner and Holder of such Global Note for all purposes whatsoever. Notwithstanding the foregoing, nothing herein shall (A) prevent the Company, the Trustee or any
agent of the Company or the Trustee from giving effect to any written certification, proxy or other authorization furnished by the Depositary or (B) impair, as between the Depositary and its Agent Members, the operation of customary practices
governing the exercise of the rights of a Holder of any Note. 

  
 -24- 

 (c)    Additional Notes. Subject to compliance with
the provisions of Sections 4.9 and 4.11 hereof, the Company may issue Additional Notes in an unlimited amount under this Indenture. 

(d)    Regulation S Global Notes. Global Notes offered and sold in reliance on Regulation S shall
initially be represented by one or more Regulation S Global Notes, substantially in the form of Exhibit A with such applicable legends as are provided in Exhibit A. The Regulation S Global Notes
will be deposited, upon issuance, on behalf of the purchasers of the Notes represented thereby with the Trustee, as custodian for the Depositary and registered in the name of the Depositary or the nominee of the Depositary, duly executed by the
Company and authenticated by the Trustee as hereinafter provided. 
 The aggregate principal amount of the Regulation S
Global Notes may from time to time be increased or decreased by adjustments made on the records of the Trustee and the Depositary or its nominee, as the case may be, in connection with transfers of interest as hereinafter provided. 

(e)    Book Entry Provisions. The Company shall execute and the Trustee shall, in accordance with
this Section 2.1(e), authenticate and deliver initially one or more Global Notes that (i) shall be registered in the name of the applicable Depositary or its nominee, (ii) shall be delivered by the Trustee to the applicable Depositary
or pursuant to the applicable Depositary’s instructions and (iii) shall bear legends substantially in the form of the first paragraph of Exhibit A attached hereto. 

Section 2.2    Execution and Authentication. An Officer of the Company shall sign
the Notes for the Company by manual or facsimile signature. Typographic and other minor errors or defects in any such facsimile signature shall not affect the validity or enforceability of any Note which has been authenticated and delivered by the
Trustee. 
 If an Officer whose signature is on a Note no longer holds that office at the time the Trustee authenticates the Note, the Note
shall be valid nevertheless. 
 A Note shall not be valid until an authorized signatory of the Trustee manually signs the certificate of
authentication on the Note. The signature shall be conclusive evidence that the Note has been authenticated under this Indenture. 
 The
Trustee shall authenticate and make available for delivery the Notes for original issue in an initial aggregate principal amount of $1,500,000,000 and Additional Notes as contemplated by Section 2.1(c) hereof, upon receipt of a written order of
the Company signed by an Officer of the Company (a “Company Order”). The Company Order shall specify the amount of Notes to be authenticated and shall provide that all such Notes will be represented by a Restricted Global Note and
the date on which such issue of Notes is to be authenticated. The aggregate principal amount of Notes outstanding at any time may not exceed the applicable amounts in the foregoing sentence, except as provided in Sections 2.1(c), 2.1(d) and 2.7
hereof. 
 The Trustee shall act as the initial authenticating agent. Thereafter, the Trustee may appoint an authenticating agent acceptable
to the Company to authenticate Notes. An authenticating agent may authenticate Notes whenever the Trustee may do so. Each reference in this Indenture to authentication by the Trustee includes authentication by such agent. An authenticating agent
shall have the same rights as an Agent to deal with the Company or an Affiliate of the Company. 
 The Notes shall be issuable only in
registered form without coupons and only in minimum denominations of $2,000 principal amount and integral multiples of $1,000 in excess thereof. 

Section 2.3    Registrar and Paying Agent. The Company shall maintain one or more
offices or agencies where Notes may be presented for registration of transfer or for exchange (each, a “Registrar”), one or more offices or agencies where Notes may be presented for payment (each, a “Paying Agent”)
and one or more offices or agencies where notices and demands to or upon the Company in respect of the Notes and this Indenture may be served. The Company will at all times maintain a Paying Agent, Registrar and an office or agency where notices and
demands to or upon the Company in respect of the Notes and this Indenture may be served in the Borough of Manhattan in the City of New York. 

  
 -25- 

 The Company shall enter into an appropriate agency agreement with any Agent not a party to this
Indenture. The agreement shall implement the provisions of this Indenture that relate to such Agent. The Company shall notify the Trustee of the name and address of any Agent not a party to this Indenture. If the Company fails to maintain a
Registrar, Paying Agent or agent for service of notices and demands in any place required by this Indenture, or fail to give the foregoing notice, the Trustee shall act as such. The Company or any Affiliate of the Company may act as Paying Agent
(except for the purposes of Section 4.1 and Article 8). 
 The Company hereby initially designates the Trustee as Paying Agent,
Registrar and Notes Custodian, and the office or agency of the Trustee in the Borough of Manhattan, The City of New York (which shall initially be the office located at 101 Barclay Street, New York, NY 10286) as one such office or agency of the
Company for each of the aforesaid purposes. 
 The Company may change the Paying Agents or Registrar in its sole discretion without prior
notice to the Holders. 
 Section 2.4    Paying Agent to Hold Money in Trust.
Prior to 11:00 a.m., New York City time, on each due date of the principal of or interest on any Notes, the Company shall deposit with a Paying Agent a sum sufficient to pay such principal or interest, if any, so becoming due. A Paying Agent shall
hold in trust for the benefit of Noteholders or the Trustee all money held by the Paying Agent for the payment of principal of or interest on the Notes, and shall notify the Trustee of any default by the Company (or any other obligor on the Notes)
in making any such payment. If the Company or an Affiliate of the Company acts as Paying Agent, the Company or such Affiliate shall, before 11:00 a.m., New York City time, on each due date of the principal of or interest on any Notes, segregate the
money and hold it as a separate trust fund. The Company at any time may require a Paying Agent to pay all money held by it to the Trustee, and the Trustee may at any time during the continuance of any Default, upon written request to a Paying Agent,
require such Paying Agent to pay forthwith to the Trustee all sums so held in trust by such Paying Agent. Upon doing so, the Paying Agent (other than the Company) shall have no further liability for the money. For the avoidance of doubt, in no event
shall any Paying Agent (unless the Company or an Affiliate of the Company is acting as Paying Agent) be required to advance funds for any payment on the Notes hereunder or to make any such payment until the Paying Agent has actually received such
funds from the Company. 
 Section 2.5    Noteholder Lists. The Trustee shall
preserve in as current a form as is reasonably practicable the most recent list available to it of the names and addresses of Noteholders. If the Trustee is not the Registrar, the Company shall furnish to the Trustee on or before each interest
payment date, and at such other times as the Trustee may request in writing, a list in such form and as of such date as the Trustee may reasonably require of the names and addresses of Noteholders. 

Section 2.6    Transfer and Exchange. 

(a)    Subject to compliance with any applicable additional requirements contained in Section 2.12 hereof, when a
Note is presented to a Registrar with a request to register a transfer thereof or to exchange such Note for an equal principal amount of Notes of other authorized denominations, the Registrar shall register the transfer or make the exchange as
requested; provided, however, that every Note presented or surrendered for registration of transfer or exchange shall be duly endorsed or accompanied by an assignment form and, if applicable, a transfer certificate in the form(s)
included in Exhibit A and Exhibit C, as applicable, and in form satisfactory to the Registrar, duly executed by the Holder thereof or its attorney duly authorized in writing. To permit registration
of transfers and exchanges, upon surrender of any Note for registration of transfer or exchange at an office or agency maintained pursuant to Section 2.3 hereof, the Company shall execute and the Trustee shall authenticate Notes of a like
aggregate principal amount at the Registrar’s request. Any exchange or transfer shall be without charge, except that the Company or the Registrar may require payment of a sum sufficient to cover any tax or other governmental charge that may be
imposed in relation thereto, and provided, that this sentence shall not apply to any exchange pursuant to Section 2.10, 2.12(a), 3.6, 3.11 or 9.5 hereof. 

  
 -26- 

 Neither the Company, any Registrar nor the Trustee shall be required to exchange or register a
transfer of any Notes or portions thereof in respect of which a Change of Control Purchase Notice or a notice in connection with an Asset Sale Offer has been delivered and not withdrawn by the Holder thereof (except, in the case of the purchase of a
Note in part, the portion thereof not to be purchased). 
 All Notes issued upon any transfer or exchange of Notes shall be valid
obligations of the Company, evidencing the same debt and entitled to the same benefits under this Indenture, as the Notes surrendered upon such transfer or exchange. 

(b)    Any Registrar appointed pursuant to Section 2.3 hereof shall provide to the Trustee such information as the
Trustee may reasonably require in connection with the delivery by such Registrar of Notes upon transfer or exchange of Notes. 

(c)    Each Holder of a Note agrees to indemnify the Company and the Trustee against any liability that may result from
the transfer, exchange or assignment of such Holder’s Note in violation of any provision of this Indenture and/or applicable United States federal, state, Canadian federal, provincial or territorial securities law. 

Section 2.7    Replacement Notes. If any mutilated Note is surrendered to the
Company, a Registrar or the Trustee, or the Company, a Registrar and the Trustee receive evidence to their satisfaction of the destruction, loss or theft of any Note, and there is delivered to the Company, the applicable Registrar and the Trustee
such security or indemnity as will be required by them to save each of them harmless, then, in the absence of notice to the Company, such Registrar or the Trustee that such Note has been acquired by a bona fide purchaser, the Company shall execute,
and upon its written request the Trustee shall authenticate and deliver, in exchange for any such mutilated Note or in lieu of any such destroyed, lost or stolen Note, a new Note of like tenor and principal amount, bearing a number not
contemporaneously outstanding. 
 In case any such mutilated, destroyed, lost or stolen Note has become or is about to become due and
payable, or is about to be purchased by the Company pursuant to Article 3, the Company in its discretion may, instead of issuing a new Note, pay or purchase such Note, as the case may be. 

Upon the issuance of any new Notes under this Section 2.7, the Company may require the payment of a sum sufficient to cover any tax or
other governmental charge that may be imposed in relation thereto and any other reasonable expenses (including the reasonable fees and expenses of the Trustee or the Registrar) in connection therewith. 

Every new Note issued pursuant to this Section 2.7 in lieu of any mutilated, destroyed, lost or stolen Note shall constitute an original
additional contractual obligation of the Company, whether or not the mutilated, destroyed, lost or stolen Note shall be at any time enforceable by anyone, and shall be entitled to all benefits of this Indenture equally and proportionately with any
and all other Notes duly issued hereunder. 
 The provisions of this Section 2.7 are (to the extent lawful) exclusive and shall
preclude (to the extent lawful) all other rights and remedies with respect to the replacement or payment of mutilated, destroyed, lost or stolen Notes. 

Section 2.8    Outstanding Notes. Notes outstanding at any time are all Notes
authenticated by the Trustee, except for those canceled by it, those delivered to it for cancellation or surrendered for transfer or exchange and those described in this Section 2.8 as not outstanding. 

If a Note is replaced pursuant to Section 2.7 hereof, it ceases to be outstanding unless the Company receives proof satisfactory to it
that the replaced Note is held by a bona fide purchaser. 
 If a Paying Agent (other than the Company or an Affiliate of the Company) holds
on a Redemption Date, Change of Control Purchase Date or the Final Maturity Date money sufficient to pay the principal of (including premium, if any) and interest on Notes (or portions thereof) payable on that date, then on and after such Redemption
Date, Change of Control Purchase Date or the Final Maturity Date, as the case may be, such Notes (or portions thereof, as the case may be) shall cease to be outstanding and interest on them shall cease to accrue. 

  
 -27- 

 Subject to the restrictions contained in Section 2.9 hereof, a Note does not cease to be
outstanding because the Company or an Affiliate of the Company holds the Note. 

Section 2.9    Treasury Notes. In determining whether the Holders of the required
principal amount of Notes have concurred in any notice, direction, waiver or consent, Notes owned by the Company or any other obligor on the Notes or by any Affiliate of the Company or of such other obligor shall be disregarded, except that, for
purposes of determining whether the Trustee shall be protected in relying on any such notice, direction, waiver or consent, only Notes which a Trust Officer of the Trustee actually knows are so owned shall be so disregarded. Notes so owned which
have been pledged in good faith shall not be disregarded if the pledgee establishes to the satisfaction of the Trustee the pledgee’s right so to act with respect to the Notes and that the pledgee is neither the Company nor any other obligor on
the Notes or any Affiliate of the Company or of such other obligor. 

Section 2.10    Temporary Notes. Until Definitive Notes are ready for delivery,
the Company may prepare and execute, and, upon receipt of a Company Order, the Trustee shall authenticate and deliver, temporary Notes. Temporary Notes shall be substantially in the form of Definitive Notes but may have variations that the Company
with the consent of the Trustee considers appropriate for temporary Notes. Without unreasonable delay, the Company shall prepare and the Trustee shall authenticate and deliver Definitive Notes in exchange for temporary Notes. 

Section 2.11    Cancellation. The Company at any time may deliver Notes to the
Trustee for cancellation. The Registrar and the Paying Agent shall forward to the Trustee or its agent any Notes surrendered to them for transfer, exchange, payment or conversion. The Trustee and no one else shall cancel, in accordance with its
standard procedures, all Notes surrendered for transfer, exchange, payment, conversion or cancellation and shall deliver the canceled Notes to the Company. All Notes which are purchased or otherwise acquired by the Company or any of its Subsidiaries
prior to the Final Maturity Date of such Notes may be delivered to the Trustee for cancellation or resold. The Company may not hold or resell such Notes or issue any new Notes to replace any Notes delivered for cancellation 

Section 2.12    Legend; Additional Transfer and Exchange Requirements. 

(a)    If Notes are issued upon the transfer, exchange or replacement of Notes subject to restrictions on transfer and
bearing the legends set forth on the form of Notes attached hereto as Exhibit A (collectively, the “Legend”), or if a request is made to remove the Legend on a Note, the Notes so issued shall bear the
Legend, or the Legend shall not be removed, as the case may be, unless there is delivered to the Company such satisfactory evidence, which shall include an opinion of counsel if requested by the Company, as may be reasonably required by the Company,
that neither the Legend nor the restrictions on transfer set forth therein are required to ensure that transfers thereof comply with the provisions of Rule 144 under the Securities Act or that such Notes are not “restricted” within
the meaning of Rule 144 under the Securities Act; provided that no such evidence need be supplied in connection with the sale of such Note pursuant to a registration statement that is effective at the time of such sale. Upon
(i) provision of satisfactory evidence if requested, or (ii) notification by the Company to the Trustee and Registrar of the sale of such Note pursuant to a registration statement that is effective at the time of such sale, the Trustee, at
the written direction of the Company, shall authenticate and deliver a Note that does not bear the Legend. If the Legend is removed from the face of a Note and the Note is subsequently held by an Affiliate of the Company, the Legend shall be
reinstated. 
 (b)    A Global Note may not be transferred, in whole or in part, to any Person other than the Depositary
or a nominee or any successor thereof, and no such transfer to any such other Person may be registered; provided that the foregoing shall not prohibit any transfer of a Note that is issued in exchange for a Global Note but is not itself a
Global Note; provided further that in no event shall a beneficial interest in a Regulation S Global Note be transferred to a U.S. Person prior to the receipt by the Registrar of any certificates required pursuant to
Regulation S, as determined by the Company. No transfer of a Note to any Person shall be effective under this Indenture or the Notes unless and until such Note has been registered in the name of such Person. Notwithstanding any other provisions
of this Indenture or the Notes, transfers of a Global Note, in whole or in part, shall be made only in accordance with this Section 2.12. 

  
 -28- 

 (c)    Subject to the succeeding paragraph, every Note shall be subject to
the restrictions on transfer provided in the Legend. Whenever any Restricted Note is presented or surrendered for registration of transfer or for exchange for a Note registered in a name other than that of the Holder, such Note must be accompanied
by a certificate in substantially the form set forth in Exhibit A dated the date of such surrender and signed by the Holder of such Note, as to compliance with such restrictions on transfer. The Registrar shall not be
required to accept for such registration of transfer or exchange any Note not so accompanied by a properly completed certificate. 

(d)    The restrictions imposed by the Legend upon the transferability of any Note shall cease and terminate when such
Note has been sold pursuant to an effective registration statement under the Securities Act or transferred in compliance with Rule 144 under the Securities Act (or any successor provision thereto) or, if earlier, upon the expiration of the holding
period applicable to sales thereof under Rule 144(d)(1)(ii) under the Securities Act (or any successor provision). Any Note as to which such restrictions on transfer shall have expired in accordance with their terms or shall have terminated may,
upon a surrender of such Note for exchange to the Registrar in accordance with the provisions of this Section 2.12 (accompanied, in the event that such restrictions on transfer have terminated by reason of a transfer in compliance with Rule 144
or any successor provision, by, if requested by the Company or the Registrar, an opinion of counsel reasonably acceptable to the Company and addressed to the Company to the effect that the transfer of such Note has been made in compliance with Rule
144 or such successor provision), be exchanged for a new Note, of like tenor, series and aggregate principal amount, which shall not bear the restrictive Legend. The Company shall inform the Trustee of the effective date of any registration
statement registering any Notes under the Securities Act. The Trustee shall not be liable for any action taken or omitted to be taken by it in good faith in accordance with the aforementioned opinion of counsel or registration statement. 

(e)    As used in this Section 2.12, the term “transfer” encompasses any sale, pledge, transfer,
hypothecation or other disposition of any Note. 
 (f)    The provisions of clauses (iii), (iv) and (v) below shall
apply only to Global Notes: 
 (i)    Notwithstanding any other provisions of this Indenture or the
Notes, a Global Note shall not be exchanged in whole or in part for a Note registered in the name of any Person other than the Depositary or one or more nominees thereof, provided that a Global Note may be exchanged for Notes registered in
the names of any person designated by the Depositary in the event that (A) the Depositary has notified the obligors that it is unwilling or unable to continue as Depositary for such Global Note and the Company fails to appoint a successor
Depositary or (B) an Event of Default has occurred and is continuing with respect to the Notes. Any Global Note exchanged pursuant to clause (A) above shall be so exchanged in whole and not in part, and any Global Note exchanged pursuant
to clause (B) above may be exchanged in whole or from time to time in part as directed by the applicable Depositary. Any Note issued in exchange for a Global Note or any portion thereof shall be a Global Note; provided that any such Note
so issued that is registered in the name of a Person other than the applicable Depositary or a nominee thereof shall not be a Global Note. 

(ii)    Notes issued in exchange for a Global Note or any portion thereof shall be issued in definitive,
fully registered form, without interest coupons, shall have an aggregate principal amount equal to that of such Global Note or portion thereof to be so exchanged, shall be registered in such names and shall be in such authorized denominations as the
Depositary shall designate and shall bear the applicable legends provided for herein. Any Global Note to be exchanged in whole shall be surrendered by the Depositary to the Trustee, as Registrar. With regard to any Global Note to be exchanged in
part, either such Global Note shall be so surrendered for exchange or, if the Trustee is acting as custodian for the Depositary or its nominee with respect to such Global Note, the principal amount thereof shall be reduced, by an amount equal to the
portion thereof to be so exchanged, by means of an appropriate adjustment made on the records of the Trustee. Upon any such surrender or adjustment, the Trustee shall authenticate and deliver Notes issuable on such exchange to or upon the order of
the Depositary or an authorized representative thereof. 

  
 -29- 

 (iii)    Subject to the provisions of clause (v) below,
the registered Holder may grant proxies and otherwise authorize any Person, including Agent Members and persons that may hold interests through Agent Members, to take any action which a Holder is entitled to take under this Indenture or the Notes.

 (iv)    In the event of the occurrence of any of the events specified in clause (i) above, the
obligors will promptly make available to the Trustee a reasonable supply of applicable Definitive Notes in definitive, fully registered form, without interest coupons. 

(v)    Neither Agent Members nor any other Persons on whose behalf Agent Members may act shall have any
rights under this Indenture with respect to any Global Note registered in the name of the Depositary or any nominee thereof, or under any such Global Note, and the Depositary or such nominee, as the case may be, may be treated by the Company, the
Trustee and any agent of the Company or the Trustee as the absolute owner and holder of such Global Note for all purposes whatsoever. Notwithstanding the foregoing, nothing herein shall prevent the Company, the Trustee or any agent of the Company or
the Trustee from giving effect to any written certification, proxy or other authorization furnished by the Depositary or such nominee, as the case may be, or impair, as between the Depositary, its Agent Members and any other Person on whose behalf
an Agent Member may act, the operation of customary practices of such Persons governing the exercise of the rights of a holder of any Note. 

(vi)    The Trustee shall have no obligation or duty to monitor, determine or inquire as to compliance with
any restrictions on transfer imposed under this Indenture or under applicable law with respect to any transfer of any interest in any Note (including any transfers between or among Agent Members or beneficial owners in any Global Note) other than to
require delivery of such certificates and other documentation or evidence as are expressly required by, and to do so as and when expressly required by, the terms or this Indenture, and to examine the same to determine substantial compliance as to
form with the express requirements hereof. 
 (g)    Euroclear and Clearstream Procedures Applicable. The
provisions of the “Operating Procedures of the Euroclear System” and “Terms and Conditions Governing Use of Euroclear” and the equivalent procedures of Clearstream shall be applicable to transfers of beneficial interests in
Global Notes that are held by Participants through Euroclear or Clearstream. 

Section 2.13    CUSIP, Common Code and ISIN Numbers. The Company in issuing the
Notes may use one or more “CUSIP” and “ISIN” numbers (if then generally in use), and, if so, the Trustee shall use “CUSIP” and “ISIN” numbers in notices of purchase as a convenience to Holders; provided
that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the Notes or as contained in any notice of a purchase and that reliance may be placed only on the other identification numbers
printed on the Notes, and any such purchase shall not be affected by any defect in or omission of such numbers. The Company will promptly notify the Trustee of any change in the “CUSIP” and “ISIN” numbers applicable to the Notes.

 ARTICLE 3 

REDEMPTION AND PURCHASES 
 
Section 3.1    Right to Redeem. The Company, at its option, may redeem the Notes in accordance with the provisions of Section 3.7 and 3.8(g) hereof. 

If the Company elects to redeem the Notes, it shall notify the Trustee at least 45 days prior to the Redemption Date (unless a shorter notice
period shall be satisfactory to the Trustee) of the Redemption Date, the aggregate principal amount of the Notes to be redeemed and the Section of this Indenture pursuant to which such Notes are being redeemed. 

Section 3.2    Selection of Notes to Be Redeemed. The Company will give not less
than 30 days’ nor more than 60 days’ notice of any redemption. If the Company elects to redeem less than all of the outstanding Notes, the Notes will be selected for redemption as follows: 

  
 -30- 

 (i)    in accordance with the procedures of The Depository
Trust Company and in compliance with the requirements of the applicable stock exchange to the extent the Notes are held in the form of Global Notes; or 

(ii)    on a pro rata basis, by lot or by such method as the Trustee deems fair and appropriate to
the extent the Notes are held in the form of Definitive Notes. 
 In the event of a partial redemption by lot, the particular Notes to be
redeemed will be selected, unless otherwise provided herein, not less than 30 nor more than 60 days prior to the Redemption Date from the outstanding Notes not previously called for redemption. 

The Notes and portions of the Notes selected for redemption will be in amounts of $2,000 or whole multiples of $1,000 except that if all of
the Notes of a Holder are to be redeemed, the entire outstanding amount of Notes held by such Holder, even if not a multiple of $1,000, shall be redeemed. Except as provided in the preceding sentence, provisions of this Indenture that apply to Notes
called for redemption also apply to portions of Notes called for redemption. 

Section 3.3    Notice of Redemption. At least 30 days but not more than
60 days before a Redemption Date, the Company shall mail, or shall cause to be mailed, a notice of redemption by first-class mail, postage prepaid, (or otherwise transmit in accordance with applicable procedures of DTC) to the Trustee and to
each Holder of Notes to be redeemed. 
 The notice shall identify the Notes to be redeemed and shall state: 

 

	 	•	 	the aggregate principal amount of the Notes to be redeemed; 

  

	 	•	 	the Redemption Date (which shall be a Business Day); 

  

	 	•	 	the redemption price; 

  

	 	•	 	the name and address of the Paying Agent; 

  

	 	•	 	that Notes called for redemption must be surrendered to the Paying Agent to collect the redemption price; 

  

	 	•	 	if fewer than all the outstanding Notes are to be redeemed, the certificate numbers, if any, and principal amounts of the particular Notes to be redeemed; 

 

	 	•	 	that, unless the Company defaults in the deposit of the redemption price, interest on Notes called for redemption will cease to accrue on and after the Redemption Date; 

 

	 	•	 	the Section of this Indenture pursuant to which the Notes are being redeemed; 

  

	 	•	 	the CUSIP numbers of the Notes; and 

  

	 	•	 	any conditions precedent to such redemption. 

 At the Company’s request, the Trustee shall give the notice
of redemption in the Company’s name and at the Company’s expense, provided that the Company makes such request at least three Business Days prior to the date by which such notice of redemption must be given to Holders in accordance
with this Section 3.3. Concurrently with the giving of any such notice of redemption, the Company shall issue a press release announcing such redemption, the form and content of which shall be determined by the Company. Redemption notices may
be given more than 60 days prior to a Redemption Date if the notice is issued in connection with a defeasance of the Notes pursuant to Sections 8.3 or 8.4 or a satisfaction and discharge of this Indenture with respect to the Notes pursuant to
Section 8.1. If a redemption is subject to satisfaction of one or more conditions precedent, the applicable redemption notice shall 

  
 -31- 

 
describe such condition, and if applicable, shall state that, in the Company’s discretion, the Redemption Date may be delayed until such time as any or all such conditions shall be
satisfied, without the requirement of an additional notice period to the Holders, or such redemption may not occur and such notice may be rescinded in the event that any or all such conditions shall not have been satisfied by the Redemption Date, or
by the Redemption Date as so delayed. The Trustee shall have no responsibility for calculating the Redemption Price. 
 
Section 3.4    Effect of Notice of Redemption. Once notice of redemption is given and any conditions set forth therein have been satisfied, Notes called for redemption become due and payable on the Redemption Date
and at the redemption price stated in the notice. Upon surrender to the Paying Agent, such Notes shall be paid at the redemption price stated in the notice. 

On and after the Redemption Date, unless the Company defaults in the deposit of the redemption price and subject to satisfaction of any
conditions precedent, interest will cease to accrue on the Notes or any portion of the Notes called for redemption, and all other rights of the Holder will terminate other than the right to receive the redemption price, without interest from the
Redemption Date, on surrender of the Notes. 
 Section 3.5    Deposit of Redemption
Price. Prior to 11:00 a.m. (New York City time) on the Redemption Date, the Company shall deposit with the Paying Agent (or the Trustee) money sufficient to pay the redemption price (as calculated by the Company) on all Notes to be redeemed
on that date. 
 Section 3.6    Notes Redeemed in Part. Upon surrender of a
Note that is redeemed in part, the Company shall execute and the Trustee shall authenticate and deliver to the Holder, without service charge, a new Note in an authorized denomination equal in principal amount to, and in exchange for, the unredeemed
portion of the Note surrendered. 
 Section 3.7    Optional Redemption. 

(a)    At any time prior to December 15, 2020, the Company may on any one or more occasions redeem up to 40% of the
aggregate principal amount of the Notes (including Notes issued after the Issue Date, if any) issued under this Indenture at a redemption price of 109.000% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the
redemption date, with the net cash proceeds of one or more Equity Offerings; provided that: 

(1)    at least 60% of the aggregate principal amount of the Notes (including Notes issued after the Issue
Date, if any) issued under this Indenture remains outstanding immediately after the occurrence of such redemption (excluding the Notes held by the Company and its Subsidiaries); and 

(2)    the redemption occurs within 180 days of the date of the closing of such Equity Offering. 

(b)    On or after December 15, 2021, the Company may redeem all or a part of the Notes upon not less than 30 nor
more than 60 days’ notice, at the redemption prices (expressed as percentages of principal amount) set forth below plus accrued and unpaid interest on the Notes redeemed, to, but not including, the applicable redemption date, if redeemed during
the twelve-month period beginning on December 15 of the years indicated below: 
  

					
	 Year
	  	Percentage	 
	 2021
	  	 	104.500	% 
	 2022
	  	 	102.250	% 
	 2023 and thereafter
	  	 	100.000	% 

 (c)    In addition, at any time prior to December 15, 2021, the Company may redeem
the Notes, in whole or in part, at a redemption price equal to the principal amount of the Notes redeemed plus the Applicable Premium plus accrued and unpaid interest to, but not including, the date of redemption. The Company shall calculate the
redemption price, including any Applicable Premium. 

  
 -32- 

 (d)    In connection with any optional redemption of the Notes, any such
redemption may, at the Company’s discretion, be subject to one or more conditions precedent. If a redemption is subject to satisfaction of one or more conditions precedent, the applicable redemption notice shall describe such condition, and if
applicable, shall state that, in the Company’s discretion, the redemption date may be delayed until such time as any or all such conditions shall be satisfied, without the requirement of an additional notice period to the Holders, or such
redemption may not occur and such notice may be rescinded in the event that any or all such conditions shall not have been satisfied by the Redemption Date, or by the Redemption Date as so delayed. 

(e)    If the Company or any Note Guarantor becomes obligated to pay, on the next date on which any amount will be payable
with respect to the Notes, any Additional Amounts as a result of (i) any amendment to, or change in, the laws or regulations of a Relevant Taxing Jurisdiction (as defined in Section 4.21 herein), which amendment or change is publicly
announced and becomes effective after December 4, 2017 (or, if the applicable Relevant Taxing Jurisdiction became a Relevant Taxing Jurisdiction on a date after December 4, 2017, after such later date) or (ii) any amendment to, or
change in, an official written interpretation or application of such laws or regulations (including by virtue of a holding by a court of competent jurisdiction) which amendment or change is publicly announced and becomes effective after
December 4, 2017 (or, if the applicable Relevant Taxing Jurisdiction became a Relevant Taxing Jurisdiction on a date after December 4, 2017, after such later date) (each of the foregoing clauses (i) and (ii), a “Change in Tax
Law”) and the Company or the applicable Note Guarantor cannot avoid any such payment obligation by taking reasonable measures available to it (including making payment through a paying agent located in another jurisdiction, but not
including the substitution of an obligor if the Company would be required to pay Additional Amounts), the Company may, at its option, redeem the Notes then outstanding, in whole but not in part, at a redemption price equal to 100% of the principal
amount thereof, plus accrued and unpaid interest, if any, to, but not including, the redemption date (subject to the right of Holders of record on the relevant record date to receive interest due on the relevant interest payment date),
provided, however, that if such right to redeem is triggered by the obligation of a Note Guarantor to pay Additional Amounts, such right to redeem will apply only if the payment giving rise to such obligation cannot be made by the
Company or another Note Guarantor without the obligation to pay Additional Amounts. Notice of the Company’s intent to redeem the Notes shall not be given until the Company delivers to the Trustee an opinion of independent tax counsel to the
effect that there has been such Change in Tax Law which would entitle the Company to redeem the Notes hereunder and an Officers’ Certificate to the effect that the Company or the applicable Note Guarantor cannot avoid its obligation to pay
Additional Amounts by taking reasonable measures available to it. The foregoing provisions shall apply mutatis mutandis to any successor Person to the Company or the applicable Note Guarantor, after such successor Person becomes a party to
this Indenture, with respect to a Change in Tax Law that is publicly announced and becomes effective after such successor Person becomes a party to this Indenture. 

(f)    Any redemption pursuant to this Section 3.7 shall be made pursuant to the provisions of Sections 3.1 through
3.6 hereof. 
 (g)    In connection with any redemption under this Section 3.7, the Company shall deliver to the
Trustee an Officers’ Certificate and Opinion of Counsel to the effect that all conditions precedent in this Indenture to the Redemption have been complied with. 

Section 3.8    Purchase of Notes at Option of the Holder Upon Change of Control.

 (a)    If at any time that Notes remain outstanding there shall occur a Change of Control, the Notes shall be
purchased by the Company at the option of the Holders, as of the Change of Control Purchase Date, at a purchase price equal to 101% of the principal amount of the Notes, together with accrued and unpaid interest, including interest on any unpaid
overdue interest, if any, to, but excluding, the Change of Control Purchase Date (the “Change of Control Purchase Price”), subject to satisfaction by or on behalf of any Holder of the requirements set forth in subsection (c) of
this Section 3.8. 
 (b)    Within 30 days after the occurrence of a Change of Control with respect to Notes,
the Company shall transmit a written notice (“Company Notice”) of the Change of Control to the Trustee and to each Holder of Notes (and to beneficial owners as required by applicable law) pursuant to which the Company shall make an
offer (a “Change of Control Offer”) to each Holder to repurchase all or any part (equal to $2,000 or an integral multiple of $1,000 in excess thereof) of each Holder’s Notes at the Change of Control Purchase Price. The notice
shall include the form of a Change of Control Purchase Notice to be completed by the Holder, shall describe the transaction or transactions that constitute the Change of Control and shall state: 

  
 -33- 

 (i)    that the Change of Control Offer is being made
pursuant to this Section 3.8 and that all Notes tendered will be accepted for payment; 

(ii)    the date by which the Change of Control Purchase Notice pursuant to this Section 3.8 must be
given; 
 (iii)    the purchase date, which date shall be no earlier than 30 days and no later than 60
days after the date the Company Notice is mailed (the “Change of Control Purchase Date”); 

(iv)    the Change of Control Purchase Price; 

(v)    the Holder’s right to require the Company to purchase the Notes; 

(vi)    the name and address of the Paying Agent; 

(vii)    that, unless the Company defaults in making such payment, any Note accepted for payment pursuant
to the Change of Control Offer will cease to accrue interest after the Change of Control Purchase Date; 

(viii)    the procedures that the Holder must follow to exercise rights under this Section 3.8; and

 (ix)    the procedures for withdrawing a Change of Control Purchase Notice, including a form of notice
of withdrawal. 
 If any of the Notes is in the form of a Global Note, then the Company shall modify such notice to the extent necessary to
accord with the procedures of the Depositary applicable to the repurchase of Global Notes. 
 (c)    A Holder may
exercise its rights specified in subsection (a) of this Section 3.8 upon delivery of a written notice (which shall be in substantially the form included in Exhibit A hereto, as applicable, and which may be
delivered by letter, overnight courier, hand delivery, facsimile transmission or in any other written form and, in the case of Global Notes, may be delivered electronically or by other means in accordance with the Depositary’s customary
procedures) of the exercise of such rights (a “Change of Control Purchase Notice”) to any Paying Agent at any time prior to the close of business on the Business Day next preceding the Change of Control Purchase Date. 

The delivery of such Note to any Paying Agent (together with all necessary endorsements) at the office of such Paying Agent shall be a
condition to the receipt by the Holder of the Change of Control Purchase Price therefor. 
 The Company shall purchase from the Holder
thereof, pursuant to this Section 3.8, a portion of a Note if the principal amount of such portion is $2,000 or an integral multiple of $1,000 in excess thereof. Provisions of this Indenture that apply to the purchase of all of a Note pursuant
to Sections 3.8 through 3.13 also apply to the purchase of such portion of such Note. 
 Notwithstanding anything herein to the contrary,
any Holder delivering to a Paying Agent the Change of Control Purchase Notice contemplated by this subsection (c) shall have the right to withdraw such Change of Control Purchase Notice in whole or in a portion thereof that is a principal
amount of $2,000 or an integral multiple of $1,000 in excess thereof at any time prior to the close of business on the Business Day next preceding the Change of Control Purchase Date by delivery of a written notice of withdrawal to the Paying Agent
in accordance with Section 3.9 hereof. 

  
 -34- 

 A Paying Agent shall promptly notify the Company of the receipt by it of any Change of Control
Purchase Notice or written withdrawal thereof. 
 Anything herein to the contrary notwithstanding, in the case of Global Notes, any Change
of Control Purchase Notice may be delivered or withdrawn and such Notes may be surrendered or delivered for purchase in accordance with the Applicable Procedures as in effect from time to time. 

(d)    The Company will not be required to make a Change of Control Offer upon a Change of Control with respect to the
Notes if (1) a third party makes the Change of Control Offer with respect to the Notes in the manner, at the times and otherwise in compliance with the requirements applicable to a Change of Control Offer made by the Company set forth in
subsection (b) of this Section 3.8 and purchases all Notes properly tendered and not withdrawn under the Change of Control Offer, (2) notice of redemption with respect to the Notes has been given pursuant to Section 3.1 or 3.7
hereof, unless and until there is a default in payment of the applicable redemption price, or (3) after giving effect to such Change of Control, (i) no Default or Event of Default has occurred and is continuing, (ii) the Change of
Control transaction has been approved by the Board of Directors of the Company, and (iii) the Notes have received an Investment Grade Rating. In addition, a Change of Control Offer may be made in advance of a Change of Control, conditional upon
such Change of Control, if a definitive agreement is in place for the Change of Control at the time of launching the Change of Control Offer. 

(e)    The Company will publicly announce the results of the Change of Control Offer on or as soon as practicable after
the Change of Control Purchase Date. 
 (f)    The provisions under this Indenture relative to the Company’s
obligation to make an offer to repurchase the Notes as a result of a Change of Control (including any required notice period) may be waived or modified with respect to the Notes with the written consent of the Holders of a majority in principal
amount of the Notes, including after the entry into an agreement that would result in the need to make a Change of Control Offer. 

(g)    In the event that Holders of not less than 90% in aggregate principal amount of the outstanding Notes validly
tender and do not withdraw such Notes in a Change of Control Offer and the Company purchases all of the Notes validly tendered and not withdrawn by such Holders, within 60 days of such purchase, the Company will have the right, upon not less
than 30 days’ nor more than 60 days’ prior notice, to redeem all of the Notes that remain outstanding following such purchase at a redemption price in cash equal to 101% of the principal amount thereof plus accrued and unpaid
interest on the Notes to, but excluding, the date of redemption. Any redemption pursuant to this Section 3.8(g) shall be made pursuant to the provisions of Sections 3.1 through 3.6 hereof. 

Section 3.9    Effect of Change of Control Purchase Notice. Upon receipt by any
Paying Agent of the Change of Control Purchase Notice specified in Section 3.8(c) hereof, the Holder of the Note in respect of which such change of Control Purchase Notice was given shall (unless such Change of Control Purchase Notice is
withdrawn as specified below) thereafter be entitled to receive the Change of Control Purchase Price with respect to such Note. Such Change of Control Purchase Price shall be paid to such Holder promptly following the later of (a) the Change of
Control Purchase Date with respect to such Note (provided the conditions in Section 3.8(c) hereof have been satisfied) and (b) the time of delivery of such Note to a Paying Agent by the Holder thereof in the manner required by
Section 3.8(c) hereof. 
 A Change of Control Purchase Notice may be withdrawn by means of a written notice (which may be delivered by
mail, overnight courier, hand delivery, facsimile transmission or in any other written form and, in the case of Global Notes, may be delivered electronically or by other means in accordance with the Depositary’s customary procedures) of
withdrawal delivered by the Holder to a Paying Agent at any time prior to the close of business on the Business Day immediately preceding the Change of Control Purchase Date, specifying the principal amount of the Note or portion thereof (which must
be a principal amount of $2,000 or an integral multiple of $1,000 in excess thereof) with respect to which such notice of withdrawal is being submitted. 

Section 3.10    Deposit of Change of Control Purchase Price. On or before
11:00 a.m., New York City time on the Change of Control Purchase Date, the Company shall deposit with the Trustee or with a Paying Agent (other than the Company or an Affiliate of the Company) an amount of money (in immediately available funds
if deposited on such Change of Control Purchase Date) sufficient to pay the aggregate Change of Control Purchase 

  
 -35- 

 
Price of all the Notes or portions thereof that are to be purchased as of such Change of Control Purchase Date. The manner in which the deposit required by this Section 3.10 is made by the
Company shall be at the option of the Company, provided that such deposit shall be made in a manner such that the Trustee or a Paying Agent shall have immediately available funds on the Change of Control Purchase Date. 

If a Paying Agent holds, in accordance with the terms hereof, money sufficient to pay the Change of Control Purchase Price of any Note for
which a Change of Control Purchase Notice has been tendered and not withdrawn in accordance with this Indenture then, on the Change of Control Purchase Date, interest will cease to accrue on such Notes or any portion of such Notes as to which a
Change of Control Purchase Notice has been tendered and not withdrawn in accordance with this Indenture and all other rights of the Holder of such Notes will terminate other than the right to receive the Change of Control Purchase Price, without
interest from the Change of Control Purchase Date, on surrender of such Notes. 

Section 3.11    Notes Purchased in Part. Any Note that is to be purchased only in
part shall be surrendered at the office of a Paying Agent, and promptly after the Change of Control Purchase Date the Company shall execute and the Trustee shall authenticate and deliver to the Holder of such Note, without service charge, a new Note
or Notes, of such authorized denomination or denominations as may be requested by such Holder, in aggregate principal amount equal to, and in exchange for, the portion of the principal amount of the Note so surrendered that is not purchased. 

Section 3.12    Compliance with Securities Laws upon Purchase of Notes. In
connection with any offer to purchase or purchase of Notes under Section 3.8 hereof, the Company shall (a) comply with Rule 14e-1 (or any successor to such Rule), if applicable, under the
Exchange Act, and (b) otherwise comply with all United States federal and state securities laws and Canadian federal, provincial and territorial securities laws in connection with such offer to purchase or purchase of Notes, all so as to permit
the rights of the Holders and obligations of the Company under Sections 3.8 through 3.11 hereof to be exercised in the time and in the manner specified therein. To the extent that the provisions of any securities laws or regulations conflict
with the Change of Control provisions of this Article 3, the Company will comply with the applicable securities laws and regulations and will not be deemed to have breached its obligations under this Article 3 by virtue of such conflict. 

Section 3.13    Repayment to the Company. To the extent that the aggregate amount
of cash deposited by the Company pursuant to Section 3.10 with respect to any Notes hereof exceeds the aggregate Change of Control Purchase Price (including interest thereon) of the Notes or portions thereof that the Company is obligated to
purchase, then promptly after the Change of Control Purchase Date, and upon request, the Trustee or a Paying Agent, as the case may be, shall return any such excess cash to the Company. 

Section 3.14    Offer to Purchase by Application of Excess Proceeds. In the event
that, pursuant to Section 4.14 hereof, the Company is required to commence an offer to all Holders to purchase Notes (“Asset Sale Offer”), it shall follow the procedures specified below. 

The Asset Sale Offer shall be made to all Holders of Notes and all holders of other pari passu Indebtedness containing provisions
similar to those set forth in this Indenture with respect to offers to purchase or redeem with the proceeds of sales of assets. The Asset Sale Offer shall remain open for a period of at least 20 Business Days following its commencement and not
more than 30 Business Days, except to the extent that a longer period is required by applicable law (the “Offer Period”). No later than three Business Days after the termination of the Offer Period (the “Purchase
Date”), the Company shall apply a portion of the Excess Proceeds as calculated pursuant to Section 4.14 hereof (the “Offer Amount”) to the purchase of Notes and such other pari passu Indebtedness (on a pro rata
basis, if applicable) or, if less than the Offer Amount has been tendered, all of such Notes and other pari passu Indebtedness tendered in response to the Asset Sale Offer. Payment for any Notes so purchased shall be made in the same manner
as interest payments are made. 
 Upon the commencement of an Asset Sale Offer, the Company shall send, by first-class mail, a notice to the
Trustee and each of the applicable Holders. The notice will contain all instructions and materials necessary to enable such Holders to tender Notes pursuant to the Asset Sale Offer. The notice, which will govern the terms of the Asset Sale Offer,
will state: 

  
 -36- 

 (1)    that the Asset Sale Offer is being made pursuant to
this Section 3.14 and Section 4.14 hereof and the length of time the Asset Sale Offer will remain open; 

(2)    the Offer Amount, the purchase price and the Purchase Date; 

(3)    that with respect to any Notes, any Note not tendered or accepted for payment will continue to
accrue interest; 
 (4)    that, unless the Company defaults in making such payment, any Note accepted
for payment pursuant to the Asset Sale Offer shall cease to accrue interest after the Purchase Date; 

(5)    that, with respect to any of Notes, Holders electing to have a Note purchased pursuant to an Asset
Sale Offer may elect to have such Notes purchased in a principal amount of $2,000 (or in integral multiples of $1,000 in excess thereof) only; 

(6)    that Holders electing to have a Note purchased pursuant to any Asset Sale Offer shall be required to
surrender the Note, with the form entitled “Option of Holder to Elect Purchase” on the reverse of the Note completed, or transfer by book-entry transfer, to the Company, the Depositary, if appointed by the Company, or a Paying Agent at the
address specified in the notice at least three days before the Purchase Date; 
 (7)    that Holders
shall be entitled to withdraw their election if the Company or the Paying Agent, as the case may be, receives, not later than the expiration of the Offer Period, a facsimile transmission or letter setting forth the name of the Holder, the principal
amount of the Note the Holder delivered for purchase and a statement that such Holder is withdrawing his election to have such Note purchased; 

(8)    that, if the aggregate principal amount of any Notes and other pari passu Indebtedness
surrendered in connection with the Asset Sale Offer exceeds the Offer Amount, the Company shall select Notes and other pari passu Indebtedness to be purchased on a pro rata basis based on the principal amount of Notes and such other pari
passu Indebtedness surrendered (with such adjustments as may be deemed appropriate by the Company so that only such Notes in denominations of $2,000 (or integral multiples of $1,000 in excess thereof), will be purchased); and 

(9)    that Holders of any Notes whose Notes were purchased only in part will be issued new Notes equal in
principal amount to the unpurchased portion of such Notes surrendered (or transferred by book-entry transfer). 
 On or before the Purchase
Date, the Company shall, to the extent lawful, accept for payment, on a pro rata basis to the extent necessary, the Offer Amount of the applicable Notes or portions thereof tendered pursuant to the Asset Sale Offer, or if less than the Offer Amount
has been tendered, all such Notes tendered, and shall deliver to the Trustee an Officers’ Certificate stating that such Notes or portions thereof were accepted for payment by the Company in accordance with the terms of this Section 3.14.
The Company, the Depositary or the Paying Agent, as the case may be, shall promptly (but in any case not later than five days after the Purchase Date) mail or deliver to each tendering Holder an amount equal to the purchase price of Notes tendered
by such Holder and accepted by the Company for purchase, and the Company shall promptly issue a new Note, and the Trustee, upon written request from the Company, shall authenticate and mail or deliver such new Note to such Holder, in a principal
amount equal to any unpurchased portion of the Note surrendered. Any Note not so accepted shall be promptly mailed or delivered by the Company to the Holder thereof. The Company shall publicly announce the results of the Asset Sale Offer on or as
soon as practicable after the Purchase Date. 
 Other than as specifically provided in this Section 3.14, any purchase pursuant to this
Section 3.14 shall be made pursuant to the provisions of Sections 3.1 through 3.6 hereof. 

  
 -37- 

 ARTICLE 4 

COVENANTS 
 
Section 4.1    Payment of Notes. The Company shall promptly make all payments in respect of the Notes on the dates and in the manner provided in the Notes and this Indenture. An installment of principal or
interest shall be considered paid on the date it is due if the Paying Agent (other than the Company) holds by 11:00 a.m., New York City time, on that date money, deposited by the Company or an Affiliate thereof, sufficient to pay the installment.
Except in the case of a redemption, a Change of Control Offer or an Asset Sale Offer, accrued and unpaid interest on any Note that is payable, and is punctually paid or duly provided for, on any interest payment date shall be paid to the Person in
whose name that Note is registered at the close of business on the record date for such interest at the office or agency of the Company maintained for such purpose. The Company shall (in immediately available funds), to the fullest extent permitted
by law, pay interest on overdue principal (including premium, if any) and overdue installments of interest from the original due date to the date paid, at the rate applicable to the Note, which interest shall be payable on demand. 

The Company will make payments in respect of the Notes represented by the Global Notes (including principal, premium, if any, and interest) by
wire transfer of immediately available funds to the accounts specified by the Holder of the Global Note. The Company will make all payments of principal, interest and premium, if any, with respect to Definitive Notes by wire transfer of immediately
available funds to the accounts specified by the Holders of the Definitive Notes, in the case of a Holder holding an aggregate principal amount of Notes of $1,000,000 or more, or, if no such account is specified or in the case of a Holder holding an
aggregate principal amount of Notes of less than $1,000,000, by mailing a check to each such Holder’s registered address. All payments shall be made in immediately available funds in U.S. dollars. Payments to any Holder holding an aggregate
principal amount of Notes in excess of $1,000,000 shall be made by wire transfer in immediately available funds to an account maintained by such Holder in the United States, if such Holder has provided wire transfer instructions to the Company at
least 10 Business Days prior to the payment date. Any wire transfer instructions received by the Trustee will remain in effect until revoked by the Holder. 

Section 4.2    Maintenance of Office or Agency. 

(a)    The Company shall maintain in the Borough of Manhattan, The City of New York, an office or agency (which may be an
office of the Trustee or an affiliate of the Trustee, Registrar or co registrar) where Notes may be surrendered for payment, registration of transfer or for exchange and where notices and demands to or upon the Company in respect of the Notes and
this Indenture may be served. The Company shall give prompt written notice to the Trustee of the location, and any change in the location, of such office or agency. If at any time the Company shall fail to maintain any such required office or agency
or shall fail to furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office of the Trustee. 

(b)    The Company may also from time to time designate one or more other offices or agencies where the Notes may be
presented or surrendered for any or all such purposes and may from time to time rescind such designations; provided, however, that no such designation or rescission shall in any manner relieve the Company of its obligation to maintain
an office or agency in the Borough of Manhattan, The City of New York, for such purposes. The Company shall give prompt written notice to the Trustee of any such designation or rescission and of any change in the location of any such other office or
agency. 
 (c)    The Company hereby designates the offices of the Trustee set forth in Section 2.3 hereof as one
such office or agency of the Company. 
 Section 4.3    Reports. 

(a)    Whether or not required by the SEC’s rules and regulations, so long as any Notes are outstanding, the Company
shall furnish (to the extent not publicly available on the SEC’s EDGAR system) to the Trustee and the Holders of Notes and post on the Company’s website (in a format that is accessible to Holders of Notes as well as prospective Holders of
Notes), within the time periods specified in the SEC’s rules and regulations: 

  
 -38- 

 (i)    all quarterly and annual reports that would be
required to be filed with the SEC on Forms 10-Q and 10-K if the Company were required to file such reports; and 

(ii)    all current reports that would be required to be filed with the SEC on Form 8-K if the Company were required to file such reports. 
 All such reports shall be prepared in
all material respects in accordance with all of the rules and regulations applicable to such reports (other than consolidating financial information required by Rule 3-10 or
3-16 of Regulation S-X or any comparable provision so long as the Company complies with Section 4.3(d)). Each annual report on
Form 10-K shall include a report on the Company’s consolidated financial statements by the Company’s independent registered public accountants. In addition, the Company shall file a copy of each
of the reports referred to in clauses (i) and (ii) above with the SEC for public availability within the time periods specified in the rules and regulations applicable to such reports (unless the SEC will not accept such a filing or the Company
is no longer subject to the periodic reporting requirements of the Exchange Act for any reason) and make such information available to securities analysts and prospective investors upon request. 

(b)    If, at any time, the Company is no longer subject to the periodic reporting requirements of the Exchange Act for
any reason, and regardless of whether it continues to file reports with the SEC, the Company shall nevertheless continue making the reports specified in Section 4.3(a) hereof available to the Holders of the Notes, prospective investors and
securities analysts by posting such information on its website. While the Company remains subject to the periodic reporting requirements of the Exchange Act, the Company agrees that it shall not take any action for the purpose of causing the SEC not
to accept any such filings. If, notwithstanding the foregoing, the SEC will not accept the Company’s filings for any reason, the Company shall post the reports referred to in Section 4.3(a) hereof on its website within the time periods
that would apply if the Company were required to file those reports with the SEC. 
 (c)    The Company further agrees
that, for so long as any Notes remain outstanding, at any time it is not required to file the reports required by Section 4.3(a) or (b) hereof with the SEC, it shall furnish to the Holders and to securities analysts and prospective
investors, upon their request, the information required to be delivered pursuant to Rule 144A(d)(4) under the Securities Act. 

(d)    The quarterly and annual financial information required by Sections 4.3(a) and (b) hereof shall include a
reasonably detailed presentation, either on the face of the financial statements, in the footnotes of the financial statements or in Management’s Discussion and Analysis of Financial Condition and Results of Operations that discloses the total
assets, liabilities, revenues and income from operations of Subsidiaries of the Company that do not Guarantee the Notes. The Trustee shall not be responsible for determining whether this clause 4.3(d) has been satisfied, nor shall it have any
liability in connection therewith. 
 (e)    Delivery of such reports, information and documents to the Trustee is for
informational purposes only and the Trustee’s receipt of such shall not constitute constructive notice of any information contained therein or determinable from information contained therein, including the Company’s compliance with any of
its covenants hereunder (as to which the Trustee is entitled to rely exclusively on Officers’ Certificates). 

(f)    Notwithstanding anything herein to the contrary, in the event that the Company fails to comply with its obligation
to file or provide such information, documents and reports as required by this Section 4.3, the Company will be deemed to have cured such Default with respect to the Notes for purposes of Section 6.1(d) upon the filing or provision of all
such information, documents and reports required hereunder prior to the expiration of 90 days after written notice to the Company of such failure from the Trustee or the Holders of at least 25% of the principal amount of the Notes. 

Section 4.4    Compliance Certificates. The Company shall deliver to the Trustee,
within 90 days after the end of each fiscal year of the Company (beginning with the fiscal year ending December 31, 2017), an Officers’ Certificate as to the signer’s knowledge of the Company’s compliance with all conditions
and covenants on their part contained in this Indenture and stating whether or not the signer knows of any Default or Event of Default. If such signer knows of such a Default or Event of Default, the Officers’ Certificate shall describe the
Default or Event of Default and the efforts to remedy the same. For the purposes of this Section 4.4, compliance shall be determined without regard to any grace period or requirement of notice provided pursuant to the terms of this Indenture.

  
 -39- 

 Section 4.5    Further Instruments and
Acts. Upon request of the Trustee, the Company will execute and deliver such further instruments and do such further acts as may be reasonably necessary or proper to carry out more effectively the purposes of this Indenture. 

Section 4.6    Maintenance of Corporate Existence. Subject to Article 5 hereof,
the Company will do or cause to be done all things necessary to preserve and keep in full force and effect its corporate existence and the corporate existence of each Restricted Subsidiary; provided, however, that the Company shall not
be required to preserve the corporate existence of any Restricted Subsidiary if (a) the Board of Directors or management of the Company shall determine that the preservation thereof is no longer desirable in the conduct of the business of the
Company and the Restricted Subsidiaries, taken as a whole, and that the loss thereof is not adverse in any material respect to the Holders of the Notes, (b) if a Subsidiary is to be dissolved or merged or consolidated in compliance with this
Indenture or (c) such Subsidiary has no assets. 
 Section 4.7    Changes in
Covenants When Notes Rated Investment Grade. In the event of the occurrence of a Fall Away Event with respect to the Notes (and notwithstanding the failure of the Company subsequently to maintain an Investment Grade Rating with respect to such
Notes), the provisions of Sections 4.8, 4.9, 4.12, 4.13 and 4.14 hereof and clause (iv) of Section 5.1(a) hereof will no longer be applicable to the Notes. 

Section 4.8    Restricted Payments. 

(a)    The Company shall not, and shall not permit any of its Restricted Subsidiaries to, directly or indirectly: 

(i)    declare or pay any dividend or make any other payment or distribution on account of the
Company’s or any of its Restricted Subsidiaries’ Equity Interests (including, without limitation, any payment in connection with any merger or consolidation involving the Company or any of its Restricted Subsidiaries) or to the direct or
indirect holders of the Company’s or any of its Restricted Subsidiaries’ Equity Interests in their capacity as such (other than dividends or distributions payable in Equity Interests (other than Disqualified Stock) of the Company or to the
Company or a Restricted Subsidiary of the Company); 
 (ii)    purchase, redeem or otherwise acquire or
retire for value (including, without limitation, in connection with any merger or consolidation involving the Company) any Equity Interests of the Company or any direct or indirect parent of the Company; 

(iii)    purchase, redeem, defease or otherwise acquire or retire for value, prior to scheduled maturity,
scheduled repayment or scheduled sinking fund payment, any Indebtedness of the Company or any Note Guarantor that is subordinated in right of payment to the Notes or a Note Guarantee, except (i) from the Company or a Restricted Subsidiary of
the Company or (ii) the purchase, redemption, defeasance or other acquisition or retirement of any such Indebtedness made in anticipation of satisfying a sinking fund obligation, principal installment or final maturity, in each case due within
one year of the date of such purchase, redemption, defeasance or other acquisition or retirement; or 

(iv)    make any Restricted Investment 

(all such payments and other actions set forth in clauses (i) through (iv) above being collectively referred to as “Restricted
Payments”), unless, at the time of and after giving effect to such Restricted Payment: 

(1)    no Default or Event of Default has occurred and is continuing or would occur as a consequence of
such Restricted Payment; 

  
 -40- 

 (2)    the Company would, at the time of such Restricted
Payment and after giving pro forma effect thereto as if such Restricted Payment had been made at the beginning of the applicable four-quarter period, have been permitted to incur at least $1.00 of additional Indebtedness pursuant to the Fixed Charge
Coverage Ratio test set forth in Section 4.9(a) hereof; and 
 (3)    such Restricted Payment,
together with the aggregate amount of all other Restricted Payments made by the Company and its Restricted Subsidiaries after January 30, 2015 (excluding Restricted Payments permitted by clauses (ii) through (ix), (xi), (xii) and
(xiii) of Section 4.8(b)), is less than the sum, without duplication, of: 
 (A)    50% of the
Consolidated Net Income of the Company for the period (taken as one accounting period) from October 1, 2014 to the end of the Company’s most recently ended fiscal quarter for which internal financial statements are available at the time of
such Restricted Payment (or, if such Consolidated Net Income for such period is a deficit, less 100% of such deficit), plus 

(B)    100% of the aggregate net cash proceeds (or fair market value of assets) received by the Company
since January 30, 2015 as a contribution to its common equity capital or from the issue or sale of Equity Interests of the Company (other than Disqualified Stock) or from the issue or sale of convertible or exchangeable Disqualified Stock or
convertible or exchangeable debt securities of the Company that have been converted into or exchanged for such Equity Interests (other than Equity Interests (or Disqualified Stock or debt securities) sold to a Subsidiary of the Company), plus

 (C)    to the extent that any Restricted Investment that was made after January 30, 2015 is sold
for cash or otherwise liquidated or repaid for cash, the lesser of (i) the cash return of capital with respect to such Restricted Investment (less the cost of disposition, if any) or (ii) the initial amount of such Restricted Investment,
plus 
 (D)    to the extent that any Unrestricted Subsidiary of the Company is redesignated as a
Restricted Subsidiary after January 30, 2015, the lesser of (i) the Fair Market Value of the Company’s Investment in such Subsidiary as of the date of such redesignation or (ii) such Fair Market Value as of the date on which such
Subsidiary was originally designated as an Unrestricted Subsidiary, plus 

(E)    $3.7 billion. 

(b)    The preceding provisions shall not prohibit: 

(i)    the payment of any dividend within 60 days after the date of declaration of the dividend, if at
the date of declaration the dividend payment would have complied with the provisions of this Indenture (it being understood that the amount of any such dividend shall be included in the aggregate amount of Restricted Payments determined in
Section 4.8(a)(3) only once and not as separate Restricted Payments made at both declaration and payment); 

(ii)    any Restricted Payment made in exchange for, or in an amount equal to the net cash proceeds of, the
substantially concurrent sale (other than to the Company or a Restricted Subsidiary of the Company) of, Equity Interests of the Company (other than Disqualified Stock); provided, that an amount equal to such Restricted Payment will be
excluded from clause (3)(B) of Section 4.8(a) hereof; 
 (iii)    the defeasance, redemption,
repurchase or other acquisition or retirement of subordinated Indebtedness of the Company or any Note Guarantor with the net cash proceeds from, or in exchange for, an incurrence of Permitted Refinancing Indebtedness; 

  
 -41- 

 (iv)    the payment of any dividend or any other payment or
distribution by a Restricted Subsidiary of the Company to the holders of its Equity Interests or any class on a pro rata basis to the holders of such class; 

(v)    so long as no Default or Event of Default has occurred and is continuing, the repurchase, redemption
or other acquisition or retirement for value of Equity Interests of the Company or any Restricted Subsidiary of the Company held by any present or former employee, director, officer or consultant of, or service provider to, the Company or any of its
Restricted Subsidiaries pursuant to any management equity plan or stock option plan or any other management or employee benefit plan or agreement (including, for the avoidance of doubt, any principal and interest payable on any notes issued by the
Company in connection with any such repurchase, retirement or other acquisition), or any stock subscription or shareholder agreement; provided that the aggregate amount of Restricted Payments made under this clause (v) shall not exceed
in any calendar year $25.0 million (with unused amounts for any year being carried over to the next succeeding year, but not to any subsequent year, with the permitted amount for each year being used prior to any amount carried over from the
previous year); provided further that such amount in any calendar year may be increased by an amount not to exceed: 

(i)    the cash proceeds of key man life insurance policies received by the Company or its Restricted
Subsidiaries after the Issue Date; less 
 (ii)    the amount of any Restricted Payments previously made
with the cash proceeds described in subclause (i) of this clause (v); 
 (vi)    payments to
holders of Equity Interests (or to the holders of Indebtedness that is convertible into or exchangeable for Equity Interests upon such conversion or exchange) in lieu of the issuance of fractional shares; 

(vii)    repurchases of Equity Interests deemed to occur in connection with the exercise or vesting of
stock options or similar instruments to the extent necessary to pay withholding or similar taxes related to such exercise or vesting of stock options or similar instruments; 

(viii)    [reserved]; 

(ix)    repurchases or retirement for value of Equity Interests deemed to occur upon exercise of stock
options or warrants if such Equity Interests represent a portion of the exercise price of such options or warrants; 

(x)    the repurchase, redemption or other acquisition or retirement for value of any subordinated
Indebtedness or Disqualified Stock pursuant to provisions similar to those described under Section 3.8 and Section 4.14; provided that, prior thereto, all Notes tendered by Holders in connection with a Change of Control Offer or
Asset Sale Offer, as applicable, have been repurchased, redeemed or acquired for value; 
 (xi)    so
long as no Default or Event of Default has occurred and is continuing, the declaration and payment of dividends to holders of any class or series of Disqualified Stock of the Company or its Restricted Subsidiaries issued in accordance with
Section 4.9; 
 (xii)    so long as no Default or Event of Default has occurred and is continuing,
other Restricted Payments; provided, however, that if the Total Leverage Ratio as of the date of any Restricted Payment to be made pursuant to this clause (xii) is greater than or equal to 3.50 to 1.0, such Restricted Payment
shall be permitted to be made pursuant to this clause (xii) only if the amount of such Restricted Payment, when taken together with the amount of all other Restricted Payments previously made pursuant to this clause (xii) when the Total
Leverage Ratio was greater than or equal to 3.50 to 1.0, does not exceed $500.0 million in the aggregate; and 

  
 -42- 

 (xiii)    the distribution, as a dividend or otherwise, of
shares of Capital Stock of, or Indebtedness owed to the Company or a Restricted Subsidiary by, Unrestricted Subsidiaries. 

(c)    The amount of all Restricted Payments (other than cash) shall be the Fair Market Value (determined, for purposes of
this covenant, by the Company or, in the case of any asset(s) valued in excess of $750.0 million, by the Board of Directors of the Company) on the date of the Restricted Payment of the asset(s) or securities proposed to be transferred or issued
by the Company or such Restricted Subsidiary, as the case may be, pursuant to the Restricted Payment. For purposes of determining compliance with this Section 4.8, in the event that a Restricted Payment meets the criteria of more than one of
the categories described in clauses (i) through (xiii) of clause (b) of this Section 4.8, including Section 4.8(a) or the definition of “Permitted Investment,” the Company will be permitted to classify such Restricted
Payment and later reclassify all or a portion of such Restricted Payment in any manner that complies with this covenant. In addition, a Restricted Payment need not be permitted solely by reference to one provision permitting such Restricted Payment
but may be permitted in part by one such provision and in part by one or more other provisions of this covenant permitting such Restricted Payment. 

Section 4.9    Incurrence of Indebtedness and Issuance of Preferred Stock. 

(a)    The Company shall not, and shall not permit any of its Restricted Subsidiaries to, directly or indirectly, create,
incur, issue, assume, guarantee or otherwise become directly or indirectly liable, contingently or otherwise (collectively, “incur”), with respect to any Indebtedness (including Acquired Debt), and the Company shall not issue any
Disqualified Stock and shall not permit any of its Restricted Subsidiaries to issue any Disqualified Stock or preferred stock; provided, however, that the Company or any Restricted Subsidiary may incur Indebtedness (including Acquired
Debt) or issue Disqualified Stock and any Restricted Subsidiary may issue preferred stock if the Fixed Charge Coverage Ratio for the Company’s most recently ended four full fiscal quarters for which internal financial statements are available
immediately preceding the date on which such additional Indebtedness is incurred or such Disqualified Stock or preferred stock is issued would have been at least 2.0 to 1.0, determined on a pro forma basis (including a pro forma application of the
net proceeds therefrom), as if the additional Indebtedness had been incurred or the Disqualified Stock or preferred stock had been issued, as the case may be, at the beginning of such four-quarter period. 

(b)    Subsection (a) of this Section 4.9 shall not prohibit the incurrence of any of the following items of
Indebtedness (collectively, “Permitted Debt”): 
 (i)    the incurrence by the Company
and its Restricted Subsidiaries of Indebtedness under Credit Facilities in an aggregate principal amount at any one time outstanding under this clause (i) not to exceed $2,500.0 million; 

(ii)    the incurrence by the Company and its Restricted Subsidiaries of the Existing Indebtedness
including the Existing Secured Notes; 
 (iii)    the incurrence by the Company and the Note Guarantors
of Indebtedness represented by the Initial Notes (including the Note Guarantees and any future Note Guarantees); 

(iv)    the incurrence by the Company or any of its Restricted Subsidiaries of Indebtedness represented by
Capital Lease Obligations, in an aggregate amount, including all Permitted Refinancing Indebtedness incurred to refund, refinance or replace any Indebtedness incurred pursuant to this clause (iv), not to exceed the greater of
(x) $275.0 million and (y) 1.0% of Consolidated Total Assets at any time outstanding; 

(v)    mortgage financings or purchase money obligations, in each case, incurred for the purpose of
financing all or any part of the purchase price or cost of construction or improvement of property, plant or equipment used in the business of the Company or any Restricted Subsidiary of the Company, in an aggregate principal amount, including all
Permitted Refinancing Indebtedness incurred to refund, refinance or replace any Indebtedness incurred pursuant to this clause (v), not to exceed the greater of (x) $675.0 million and (y) 2.5% of Consolidated Total Assets at any
time outstanding; 

  
 -43- 

 (vi)    the incurrence by the Company or any of its
Restricted Subsidiaries of Permitted Refinancing Indebtedness in exchange for, or the net proceeds of which are used to refund, refinance or replace, Indebtedness (other than intercompany Indebtedness) that was permitted by this Indenture to be
incurred under Section 4.9(a) hereof or clauses (ii), (iii), (xii) or (xiv) of this Section 4.9(b) or this clause (vi) or, solely to the extent of the excess (if any) of the amount of Indebtedness incurred and outstanding under
clause (xx) of this Section 4.9(b) prior to the applicable refinancing over the maximum aggregate amount permitted to be incurred and outstanding under clause (xx) of this Section 4.9(b) at the time of such refinancing, clause
(xx) of this Section 4.9(b); 
 (vii)    the incurrence by the Company or any of its Restricted
Subsidiaries of intercompany Indebtedness between or among the Company and any of its Restricted Subsidiaries; provided, however, that: 

(A)    if a Note Guarantor is the obligor on such Indebtedness and the obligee is not the Company or
another Note Guarantor, such Indebtedness must be expressly subordinated to the prior payment in full in cash of all Obligations with respect to the Notes; and 

(B)    (i) any subsequent issuance or transfer of Equity Interests that results in any such Indebtedness
being held by a Person other than the Company or a Restricted Subsidiary of the Company and (ii) any sale or other transfer of any such Indebtedness to a Person that is not either the Company or a Restricted Subsidiary of the Company shall be
deemed, in each case, to constitute an incurrence of such Indebtedness by the Company or such Restricted Subsidiary, as the case may be, that is not permitted by this clause (vii); 

(viii)    (i) the incurrence by the Company or any of its Restricted Subsidiaries of Hedging Obligations
that are incurred and not for speculative purposes and (ii) the incurrence by a Securitization Special Purpose Entity of Indebtedness in a Qualified Securitization Transaction that is without recourse to the Company or to any other Restricted
Subsidiary of the Company or their assets (other than Standard Securitization Undertakings); 

(ix)    the Guarantee by the Company or any Restricted Subsidiary of the Company of Indebtedness of the
Company or any Restricted Subsidiary that was permitted to be incurred under this Section 4.9 (other than the Note Guarantees); provided that if the Indebtedness being guaranteed is subordinated to or pari passu with the Notes or
any Note Guarantee, then the Guarantee shall be subordinated to the same extent as the Indebtedness guaranteed (without regard to security interest); 

(x)    the accrual of interest, the accretion or amortization of original issue discount, the payment of
interest on any Indebtedness in the form of additional Indebtedness with the same terms, and the payment of dividends on Disqualified Stock in the form of additional shares of the same class of Disqualified Stock will not be deemed to be an
incurrence of Indebtedness or an issuance of Disqualified Stock for purposes of this covenant; provided, in each such case, that the amount thereof is included in Fixed Charges of the Company as accrued; 

(xi)    obligations in respect of performance and surety bonds and completion guarantees or similar
obligations provided by the Company or any Restricted Subsidiary of the Company in each case in the normal course of business (whether or not consistent with past practice); 

(xii)    the incurrence by the Company or any of its Restricted Subsidiaries of Acquired Debt;
provided, however, that on the date of acquisition and after giving effect thereto on a pro forma basis, the Fixed Charge Coverage Ratio of the Company (A) would be at least 2.0 to 1.0 or (B) would be equal to or greater than
such Fixed Charge Coverage Ratio immediately prior to such acquisition; 
 (xiii)    the incurrence by
any Foreign Subsidiary of Indebtedness in an aggregate principal amount at any time outstanding, including all Permitted Refinancing Indebtedness incurred to refund, refinance or replace any Indebtedness incurred pursuant to this clause (xiii), not
to exceed the greater of (x) $675.0 million or (y) 2.5% of Consolidated Total Assets; 

  
 -44- 

 (xiv)    Indebtedness of the Company or any Restricted
Subsidiary incurred in connection with or in contemplation of, or to provide all or any portion of the funds or credit support utilized to consummate, the acquisition by the Company or any Restricted Subsidiary of the Company of property used or
useful in a Permitted Business (whether through the direct purchase of assets or the purchase of Capital Stock of, or merger or consolidation with, any Person owning such assets); provided, however, on the date of such incurrence and
after giving effect thereto on a pro forma basis, the Fixed Charge Coverage Ratio of the Company (A) would be at least 2.0 to 1.0 or (B) would be equal to or greater than such Fixed Charge Coverage Ratio immediately prior to such
incurrence; 
 (xv)    Indebtedness incurred by the Company or any of its Restricted Subsidiaries
constituting reimbursement obligations with respect to letters of credit issued in the ordinary course of business, including letters of credit in respect of workers’ compensation claims, death, disability or other employee benefits or
property, casualty or liability insurance or self-insurance, or other Indebtedness with respect to reimbursement-type obligations regarding workers’ compensation claims; provided, however, that upon the drawing of such letters of
credit or the incurrence of such Indebtedness, such obligations are reimbursed within 30 days following such drawing or incurrence; 

(xvi)    Indebtedness arising from the honoring by a bank or other financial institution of a check, draft
or similar instrument drawn against insufficient funds, provided that such Indebtedness is extinguished within five Business Days of notice of its incurrence; 

(xvii)    Indebtedness of the Company or any of its Restricted Subsidiaries supported by a letter of credit
issued pursuant to the Credit Facilities, in a principal amount not in excess of the stated amount of such letter of credit; 

(xviii)    Indebtedness of the Company or any of its Restricted Subsidiaries consisting of (i) the
financing of insurance premiums or (ii) take-or-pay or similar obligations contained in supply arrangements, in each case, incurred in the ordinary course of
business; 
 (xix)    the incurrence by the Company or any of its Restricted Subsidiaries of additional
Indebtedness in an aggregate principal amount (or accreted value, as applicable) at any time outstanding, including all Permitted Refinancing Indebtedness incurred to refund, refinance or replace any Indebtedness incurred pursuant to this clause
(xix), not to exceed the greater of (x) $675.0 million and (y) 2.5% of Consolidated Total Assets; and 

(xx)    the incurrence by the Company or any of its Restricted Subsidiaries of Indebtedness secured by a
Lien under Credit Facilities in an aggregate principal amount such that, on a pro forma basis (including a pro forma application of the proceeds therefrom), the Secured Leverage Ratio would not exceed 3.50 to 1.00. 

(c)    The Company shall not, and shall not permit any Note Guarantor to, incur any Indebtedness (including Permitted
Debt) that is contractually subordinated in right of payment to any other Indebtedness of the Company or the Note Guarantors unless such Indebtedness is also contractually subordinated in right of payment to the Notes on substantially identical
terms; provided, however, that no Indebtedness of the Company or the Note Guarantors shall be deemed to be contractually subordinated in right of payment to any other Indebtedness of the Company or any Note Guarantor solely by virtue
of being unsecured or having a junior lien priority. 
 (d)    For purposes of determining compliance with this
Section 4.9, in the event that an item of proposed Indebtedness meets the criteria of more than one of the categories of Permitted Debt described in clauses (i) through (xx) of Section 4.9(b) hereof, or is entitled to be incurred
pursuant to subsection (a) of this Section 4.9, the Company shall be permitted to classify such item of Indebtedness on the date of its incurrence, or later reclassify from time to time all or a portion of such item of Indebtedness, in any
manner that complies with this Section 4.9. 

  
 -45- 

 
Indebtedness permitted by this Section 4.9 need not be permitted solely by reference to one clause permitting such Indebtedness but may be permitted in part by one such clause and in part by
one or more other clauses of this Section 4.9 permitting such Indebtedness. Indebtedness under Credit Facilities outstanding on the Issue Date will be deemed to have been incurred on such date in reliance on the exception provided by clause
(xx) of Section 4.9(b) hereof. 
 (e)    In addition, for purposes of determining compliance with this
Section 4.9, the Company or the applicable Restricted Subsidiary may, pursuant to an Officers’ Certificate delivered to the Trustee, elect to treat all or any portion of the commitment under any Indebtedness (including with respect to any
revolving loan commitment) as being incurred at the time of such commitment, in which case any subsequent incurrence of Indebtedness under such commitment shall not be deemed to be an incurrence at such subsequent time. 

Section 4.10    [Reserved]. 

Section 4.11    Liens. 

(a)    The Company shall not, and shall not permit any of its Restricted Subsidiaries to, directly or indirectly, create,
incur, assume or suffer to exist any Lien securing Indebtedness of any kind on any asset now owned or hereafter acquired, except Permitted Liens, unless contemporaneously therewith: 

(i)    in the case of any Lien securing Indebtedness that ranks pari passu with the Notes or a Note
Guarantee, effective provision is made to secure the Notes or such Note Guarantee, as the case may be, equally and ratably with or prior to such obligation with a Lien on the same assets of the Company or such Restricted Subsidiary, as the case may
be; and 
 (ii)    in the case of any Lien securing Indebtedness that is subordinated in right of payment
to the Notes or a Note Guarantee, effective provision is made to secure the Notes or such Note Guarantee, as the case may be, with a Lien on the same assets of the Company or such Restricted Subsidiary, as the case may be, that is prior to the Lien
securing such subordinated obligation. 
 Any Lien created for the benefit of Holders pursuant to the preceding paragraph shall provide by
its terms that such Lien shall be automatically and unconditionally released and discharged, without any action on the part of the Holders, upon the release and discharge of each Lien described in clauses (i) and (ii) in this Section 4.11.

 Section 4.12    Dividend and Other Payment Restrictions Affecting Restricted
Subsidiaries. 
 (a)    The Company shall not, and shall not permit any of its Restricted Subsidiaries to, directly
or indirectly, create or permit to exist or become effective any consensual encumbrance or restriction on the ability of any such Restricted Subsidiary to: 

(i)    pay dividends or make any other distributions on its Capital Stock to the Company or any of its
Restricted Subsidiaries or pay any indebtedness owed to the Company or any of its Restricted Subsidiaries; 

(ii)    make loans or advances to the Company or any of its Restricted Subsidiaries; or 

(iii)    transfer any of its properties or assets to the Company or any of its Restricted Subsidiaries.

 (b)    The restrictions set forth in Section 4.12(a) hereof shall not apply to encumbrances or restrictions
existing under or by reason of: 
 (i)    agreements, including agreements governing Existing
Indebtedness as in effect on the date of this Indenture and any amendments, modifications, restatements, renewals, increases, supplements, refundings, replacements or refinancings of those agreements, provided that the amendments,

  
 -46- 

 
modifications, restatements, renewals, increases, supplements, refundings, replacements or refinancings are, in the good faith judgment of the Company, not materially more restrictive, taken as a
whole, with respect to such dividend and other payment restrictions than those contained in those agreements on the date of this Indenture; 

(ii)    this Indenture, the Notes and the Note Guarantees; 

(iii)    any encumbrance or restriction pursuant to Credit Facilities incurred under clause (i) or
(xx) of Section 4.9(b) hereof; 
 (iv)    applicable law, rule, regulation or order, approval,
license, permit or similar restriction, including under contracts with foreign governments or agencies thereof entered into in the ordinary course of business; 

(v)    any instrument governing Indebtedness, Capital Stock or assets of a Person acquired by the Company
or any of its Restricted Subsidiaries as in effect at the time of such acquisition (except to the extent such Indebtedness was incurred, or such Capital Stock was issued, in connection with or in contemplation of such acquisition), which encumbrance
or restriction is not applicable to any Person, or the properties or assets of any Person, other than the Person, or the property or assets of the Person, so acquired and any amendments, modifications, restatements, renewals, increases, supplements,
refundings, replacements or refinancings of those agreements provided that the amendments, modifications, restatements, renewals, increases, supplements, refundings, replacements or refinancings are, in the good faith judgment of the Company, not
materially more restrictive, taken as a whole, with respect to such dividend and other payment restrictions than those contained in those agreements on the date of the acquisition, provided that, in the case of Indebtedness, such Indebtedness
was permitted to be incurred under Section 4.9 hereof; 
 (vi)    customary non-assignment provisions in leases, contracts and licenses entered into in the ordinary course of business; 

(vii)    purchase money obligations for property that impose restrictions on that property of the nature
described in clause (iii) of Section 4.12(a) hereof; 
 (viii)    any agreement for the sale or
other disposition of a Restricted Subsidiary that restricts distributions, transfers, loans or advances by that Restricted Subsidiary pending its sale or other disposition; 

(ix)    Permitted Refinancing Indebtedness; provided that the restrictions contained in the
agreements governing such Permitted Refinancing Indebtedness are not, in the good faith judgment of the Company, materially more restrictive, taken as a whole, than those contained in the agreements governing the Indebtedness being refinanced; 

(x)    Permitted Liens securing Indebtedness that limit the right of the debtor to dispose of the assets
subject to such Liens; 
 (xi)    customary provisions in joint venture agreements, asset sale
agreements, stock sale agreements and other similar agreements entered into with the approval of the Board of Directors of the Company or otherwise in the ordinary course of business; 

(xii)    restrictions on cash or other deposits or net worth imposed by customers under contracts entered
into in the ordinary course of business; 
 (xiii)    restrictions in agreements or instruments which
prohibit the payment or making of dividends or other distributions other than on a pro rata basis; 

  
 -47- 

 (xiv)    contractual requirements of a Securitization Special
Purpose Entity in connection with a Qualified Securitization Transaction; provided that such restrictions apply only to such Securitization Special Purpose Entity; and 

(xv)    any agreement or instrument governing Indebtedness or preferred stock permitted to be incurred
subsequent to the Issue Date pursuant to Section 4.9 hereof which encumbrances or restrictions (x) are not, in the good faith judgment of the Company, materially more restrictive, taken as a whole, than those contained in this Indenture or
(y) will not, in the good faith judgment of the Company, affect the ability of the Company to make anticipated payments of principal, interest or premium on the Notes. 

Section 4.13    Transactions with Affiliates. 

(a)    The Company shall not, and shall not permit any of its Restricted Subsidiaries to, make any payment to, or sell,
lease, transfer or otherwise dispose of any of its properties or assets to, or purchase any property or assets from, or enter into or make or amend any transaction, contract, agreement, understanding, loan, advance or guarantee with, or for the
benefit of, any Affiliate (each, an “Affiliate Transaction”) involving aggregate payments or consideration in excess of $100.0 million, unless: 

(i)    the Affiliate Transaction is on terms that are no less favorable, taken as a whole, to the Company
or the relevant Restricted Subsidiary than those that would have been obtained in a comparable transaction by the Company or such Restricted Subsidiary with an unrelated Person, as determined by the Company in good faith; and 

(ii)    with respect to any Affiliate Transaction or series of related Affiliate Transactions involving
aggregate consideration in excess of $750.0 million, such Affiliate Transaction has been approved by a majority of the disinterested members of the Board of Directors of the Company. 

(b)    The following items shall be deemed not to be Affiliate Transactions and, therefore, will not be subject to the
provisions of Section 4.13(a) hereof: 
 (i)    any employment agreement or benefit or similar plan
entered into by the Company or any of its Restricted Subsidiaries in the ordinary course of business of the Company or such Restricted Subsidiary; 

(ii)    transactions between or among the Company and/or its Restricted Subsidiaries; 

(iii)    transactions with a Person that is an Affiliate of the Company solely because the Company owns,
directly or through a Restricted Subsidiary, an Equity Interest in, or controls, such Person; 

(iv)    the payment of reasonable compensation and fees to, and the provision of customary indemnities to,
current or former officers, directors, employees or consultants of the Company or any of its Restricted Subsidiaries; 

(v)    issuances or sales of Equity Interests (other than Disqualified Stock) of the Company to Affiliates
or employees of or consultants to the Company; 
 (vi)    Restricted Payments that are permitted by the
provisions of Section 4.8 hereof and Permitted Investments; 
 (vii)    transactions effected
pursuant to agreements in effect on the date of this Indenture and any amendment, modification or replacement to such agreement (so long the as amendment, modification or replacement is not, in the good faith judgment of the Company, materially more
disadvantageous to the Company or such Restricted Subsidiary, taken as a whole, than the terms of those agreements in effect on the date of this Indenture); 

  
 -48- 

 (viii)    [reserved]; 

(ix)    transactions with a Permitted Joint Venture in which the Company or any Restricted Subsidiary holds
or acquires an ownership interest (whether by way of Capital Stock or otherwise) so long as the terms of any such transactions, in the good faith judgment of the Company, are not materially less favorable, taken as a whole, to the Company or such
Restricted Subsidiary than they are to other joint venture partners; 
 (x)    any agreement that grants
registration and other customary rights in connection therewith or otherwise to the direct or indirect security holders of the Company or any Restricted Subsidiary (and the performance of such agreements); 

(xi)    transactions with Affiliates solely in their capacity as Holders of Indebtedness or Capital Stock
of the Company or any of its Restricted Subsidiaries, where such Affiliates receive the same consideration as non-Affiliates in such transactions; 

(xii)    transactions affected as part of a Qualified Securitization Transaction; and 

(xiii)    transactions in which the Company or any Restricted Subsidiary, as the case may be, delivers to
the Trustee a copy of a letter from an accounting, appraisal or investment banking firm of national standing addressed to the Company stating that such transaction meets the requirements of Section 4.13(a)(i). 

Section 4.14    Asset Sales. 

(a)    The Company shall not, and shall not permit any of its Restricted Subsidiaries to, consummate an Asset Sale unless:

 (i)    the Company (or its Restricted Subsidiary, as the case may be) receives consideration at the
time of the Asset Sale at least equal to the Fair Market Value (determined, for purposes of this clause (i), by the Company or, in the case of any asset(s) valued in excess of $750.0 million, by the Board of Directors of the Company) of the
assets or Equity Interests issued or sold or otherwise disposed of; and 
 (ii)    except in the case of
a Permitted Asset Swap, at least 75% of the consideration received in the Asset Sale by the Company or such Restricted Subsidiary is in the form of cash or Cash Equivalents. For purposes of this provision, each of the following will be deemed to be
cash: 
 (A)    any liabilities, as shown on the Company’s most recent consolidated balance sheet,
of the Company or any Restricted Subsidiary (other than contingent liabilities and liabilities that are by their terms subordinated to the Notes and the Note Guarantees) (i) that are assumed by the transferee of any such assets pursuant to an
agreement that releases the Company or such Restricted Subsidiary from further liability or (ii) that are discharged by the transferee in a transaction pursuant to which neither the Company nor any Restricted Subsidiary has any liability
following such Asset Sale; 
 (B)    any securities, notes or other obligations received by the Company
or any such Restricted Subsidiary from such transferee that are converted by the Company or such Restricted Subsidiary into cash within 180 days after the consummation of the applicable Asset Sale, to the extent of the cash received in that
conversion; and 
 (C)    any Designated Noncash Consideration having an aggregate Fair Market Value
that, when taken together with all other Designated Noncash Consideration previously received and then outstanding, does not exceed at the time of the receipt of such Designated Noncash Consideration (with the Fair Market Value of each item of
Designated Noncash Consideration being measured at the time received and without giving effect to subsequent changes in value) the greater of $800.0 million or 3.0% of Consolidated Total Assets. 

  
 -49- 

 (b)    Within 450 days after the receipt of any Net Proceeds from an Asset
Sale, the Company or the applicable Restricted Subsidiary may apply an amount equal to those Net Proceeds: 

(i)    to repay (w) Indebtedness and other Obligations under the Credit Agreement and, if the
Indebtedness repaid under the Credit Agreement is revolving credit Indebtedness, to correspondingly reduce commitments with respect thereto, (x) other secured indebtedness, (y) other Indebtedness which ranks pari passu in right of
payment with the Notes (provided in the case of this clause (y) the Company shall equally and ratably reduce obligations under the Notes in accordance with Section 3.7 hereof, through privately negotiated transactions or open market
purchases (in each case, provided that such purchases are at or above 100% of the principal amount thereof), or by making an offer (in accordance with Section 4.14(c)) to all Holders to purchase, at a purchase price equal to 100% of the
principal amount thereof, plus accrued and unpaid interest, the pro rata principal amount of Notes) or (z) other Indebtedness of a Subsidiary that does not Guarantee the Notes, so long as the relevant assets were assets of such Subsidiary; 

(ii)    to acquire all or substantially all of the assets of, or a majority of the Voting Stock of, another
Permitted Business or the minority interest in any Permitted Business; 
 (iii)    to make payments with
respect to the acquisition or license of intellectual property rights that are used in a Permitted Business; 

(iv)    to make a capital expenditure in or that is useful in a Permitted Business; 

(v)    to retire Notes (x) pursuant to Section 3.7 hereof, (y) through privately negotiated
transactions or open market purchases or (z) by making an offer to purchase Notes in accordance with Section 4.14(c); or 

(vi)    to acquire other assets that are not classified as current assets (for the avoidance of doubt,
including acquisitions of in-process research and development) under GAAP and that are used or useful in a Permitted Business; 

provided that a binding commitment to apply any Net Proceeds from an Asset Sale as set forth in clauses (ii), (iii), (iv) or (vi) of this
Section 4.14(b) shall be treated as a permitted application of the Net Proceeds from the date of such commitment so long as the Company or such Restricted Subsidiary enters into such commitment with the good faith expectation that such Net
Proceeds will be applied to satisfy such commitment within 180 days of the end of such 450-day period (an “Acceptable Commitment”) and, in the event any Acceptable Commitment is later
cancelled or terminated for any reason before the Net Proceeds are applied in connection therewith, then the Company or such Restricted Subsidiary shall be permitted to apply the Net Proceeds in any manner set forth above before the expiration of
such 180-day period and, in the event the Company or such Restricted Subsidiary fails to do so, then such Net Proceeds shall constitute Excess Proceeds. 

Notwithstanding Sections 4.14(a) and 4.14(b), the Company and its Restricted Subsidiaries will not be required to apply an amount equal to any
Net Proceeds in accordance with this covenant except to the extent that the aggregate Net Proceeds from all Asset Sales which are not applied in accordance with this covenant exceed the greater of $275.0 million or 1.0% of Consolidated Total
Assets at the time of receipt of such Net Proceeds. Pending application of an amount equal to Net Proceeds pursuant to this Section 4.14, the Company or a Restricted Subsidiary may temporarily reduce revolving credit borrowings or otherwise
invest the Net Proceeds in any manner that is not prohibited by this Indenture. 
 (c)    Any Net Proceeds from Asset
Sales that are not applied or invested as provided in Section 4.14(b) hereof shall constitute “Excess Proceeds.” When the aggregate amount of Excess Proceeds exceeds the greater of $275.0 million or 1.0% of Consolidated
Total Assets, the Company shall make an offer (an “Asset Sale Offer”) to all Holders of Notes and all holders of other Indebtedness that is pari passu with the Notes containing provisions

  
 -50- 

 
similar to those set forth in this Indenture with respect to offers to purchase or redeem with the proceeds of sales of assets to purchase the maximum principal amount of Notes and such other
pari passu Indebtedness that may be purchased out of the amount of such Excess Proceeds. The offer price in any Asset Sale Offer shall be equal to 100% of principal amount plus accrued and unpaid interest to, but not including, the date of
purchase, and shall be payable in cash. If any Excess Proceeds remain after consummation of an Asset Sale Offer, the Company and its Restricted Subsidiaries may use the amount of such Excess Proceeds for any purpose not otherwise prohibited by this
Indenture. If the aggregate principal amount of Notes and other pari passu Indebtedness tendered into such Asset Sale Offer exceeds the amount of Excess Proceeds, the Company shall select the Notes and such other pari passu
Indebtedness to be purchased on a pro rata basis. Upon completion of each Asset Sale Offer, the amount of Excess Proceeds shall be reset at zero. 

(d)    The Company shall comply with the requirements of Rule 14e-1 under the
Exchange Act and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with each repurchase of Notes pursuant to an Asset Sale Offer. To the extent that the provisions of any
securities laws or regulations conflict with the Asset Sale provisions of this Indenture, the Company shall comply with the applicable securities laws and regulations and shall not be deemed to have breached its obligations under the Asset Sale
provisions of this Indenture by virtue of such compliance. 

Section 4.15    Additional Note Guarantees. If any one of the Company’s
Subsidiaries that is not a Note Guarantor Guarantees any Indebtedness of the Company or any Guarantor under any syndicated Credit Facility or Capital Markets Indebtedness, that Subsidiary shall (i) execute and deliver to the Trustee a
supplemental indenture in form reasonably satisfactory to the Trustee and a notation of Note Guarantee substantially in the form of Exhibit B hereto or, in the case that such Subsidiary of the Company is a Canadian Note
Guarantor, a Canadian Note Guarantee, pursuant to which such Subsidiary shall unconditionally Guarantee, on a senior secured basis, all of the Company’s obligations under the Notes and this Indenture on the terms set forth in this Indenture
and, if applicable, the Canadian Note Guarantee, and (ii) deliver to the Trustee an Opinion of Counsel that such supplemental indenture and notation of Note Guarantee or, if applicable, Canadian Note Guarantee, has been duly authorized,
executed and delivered by such Subsidiary and constitutes a legal, valid, binding and enforceable obligation of such Subsidiary. Thereafter, such Subsidiary shall be a Note Guarantor for all purposes hereof until such Note Guarantee is released in
accordance herewith. 
 Notwithstanding the foregoing, the supplemental indenture and notation of Note Guarantee may be modified in respect
of any Note Guarantor organized outside the United States of America as necessary or appropriate to (1) comply with applicable law, (2) avoid any general legal limitations such as general statutory limitations, financial assistance,
corporate benefit, “thin capitalization” rules, retention of title claims or similar matters or (3) avoid a conflict with the fiduciary duties of such company’s directors, contravention of any legal prohibition or regulatory
condition, or the material risk of personal or criminal liability for any officers or directors (collectively referred to as “Agreed Guarantee Principles”), in each case as determined by the Company in its sole discretion. 

Section 4.16    Designation of Restricted and Unrestricted Subsidiaries. The
Company’s Board of Directors may designate any Restricted Subsidiary (other than Valeant) to be an Unrestricted Subsidiary if that designation would not cause a Default. Any designation of a Subsidiary as an Unrestricted Subsidiary will be
deemed to be a designation of each of such entity’s Subsidiaries as Unrestricted Subsidiaries. If a Restricted Subsidiary is designated as an Unrestricted Subsidiary, the aggregate Fair Market Value of all outstanding Investments owned by the
Company and its Restricted Subsidiaries in the Subsidiary designated as an Unrestricted Subsidiary shall be deemed to be an Investment made as of the time of the designation and will reduce the amount available for Restricted Payments under
Section 4.8 hereof or under one or more of the clauses of the definition of “Permitted Investments,” as determined by the Company. That designation will only be permitted if the Investment would be permitted at that time and if the
Restricted Subsidiary otherwise meets the definition of an Unrestricted Subsidiary. The Company’s Board of Directors may redesignate any Unrestricted Subsidiary to be a Restricted Subsidiary if the redesignation would not cause a Default;
provided that such redesignation will be deemed to be an incurrence of Indebtedness and, if applicable, an incurrence of related Liens by a Restricted Subsidiary of the Company of any outstanding Indebtedness and, if applicable, related Liens
of such Unrestricted Subsidiary and such redesignation will only be permitted if such Indebtedness and, if applicable, related Liens are permitted under Section 4.9 hereof and, if applicable, Section 4.11 hereof (other than clause
(3) under the definition of “Permitted Liens”), calculated, if applicable, on a pro forma basis as if such designation had occurred at the beginning of the four-quarter reference period. 

  
 -51- 

 Section 4.17    Business Activities.
The Company shall not, and shall not permit any of its Restricted Subsidiaries to, engage in any business other than Permitted Businesses, except to such extent as would not be material to the Company and its Restricted Subsidiaries, taken as a
whole. 
 Section 4.18    [Reserved]. 

Section 4.19    Stay, Extension and Usury Laws. The Company covenants (to the
extent that it may lawfully do so) that it shall not at any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other law which would prohibit or forgive the Company
from paying all or any portion of the principal of, premium, if any, or interest on the Notes as contemplated herein, wherever enacted, now or at any time hereafter in force, or which may affect the covenants or the performance of this Indenture,
and the Company (to the extent it may lawfully do so) hereby expressly waives all benefit or advantage of any such law and covenant that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the
Trustee, but will suffer and permit the execution of every such power as though no such law had been enacted. 

Section 4.20    Notice of Default. In the event that any Default or Event of
Default under Section 6.1 hereof shall occur, the Company shall give prompt written notice of such Default or Event of Default to the Trustee. 

Section 4.21    Payment of Additional Amounts. 

(a)    All payments made by or on behalf of the Company under or with respect to the Notes, or by or on behalf of any Note
Guarantor under or with respect to any Note Guarantee (each such Person, a “Payor”) will be made free and clear of any withholding or deduction for or on account of any tax, duty, levy, impost, assessment or other governmental
charge of whatever nature (collectively, “Tax”) imposed or levied by or on behalf of any jurisdiction in which such Payor is organized, resident or carrying on business for tax purposes or from or through which such Payor makes any
payment on the Notes or its Note Guarantee or any department or political subdivision of any of the foregoing (each, a “Relevant Taxing Jurisdiction”), unless the Payor (or an applicable withholding agent) is required to withhold or
deduct Taxes by law. If the Payor (or an applicable withholding agent) is required by law to withhold or deduct any amount for or on account of Taxes of any Relevant Taxing Jurisdiction from any payment made under or with respect to any Notes or
Note Guarantee, the Payor, subject to the exceptions listed below, will pay additional amounts (“Additional Amounts”) as may be necessary to ensure that the net amount received by each Holder or beneficial owner of the Notes after
such withholding or deduction (including withholding or deduction attributable to Additional Amounts payable hereunder) will not be less than the amount the Holder or beneficial owner would have received if such Taxes had not been required to be so
withheld or deducted. 
 (b)    A Payor will not, however, pay Additional Amounts to a Holder or beneficial owner of
Notes: 
 (i)    to the extent the Taxes giving rise to such Additional Amounts would not have been
imposed but for the existence of any present or former connection between the Holder or beneficial owner (or between a fiduciary, settler, beneficiary, member or shareholder of, or possessor of a power over, such Holder or beneficial owner, if such
Holder or beneficial owner is an estate, trust, partnership or corporation) and the Relevant Taxing Jurisdiction (other than any connection resulting solely from the acquisition, ownership, holding or disposition of Notes, the receipt of payments
thereunder or under any Note Guarantee and/or the exercise or enforcement of rights under any Notes or any Note Guarantee); 

(ii)    to the extent the Taxes giving rise to such Additional Amounts would not have been imposed but for
the failure of the Holder or beneficial owner of Notes, following the Company’s or the Payor’s written request addressed to the Holder, to the extent such Holder or beneficial owner is legally eligible to do so, to comply with any
certification, identification, information or other reporting requirements, whether required by statute, treaty, regulation or administrative practice of a Relevant Taxing Jurisdiction, as a precondition to exemption from, or reduction in the rate
of deduction or withholding of, Taxes imposed by the Relevant Taxing Jurisdiction (including, without limitation, a certification that the Holder or beneficial owner is not resident in the Relevant Taxing Jurisdiction); 

  
 -52- 

 (iii)    with respect to any estate, inheritance, gift,
sales, transfer, capital gains, excise or personal property tax or any similar Taxes; 
 (iv)    to the
extent the Taxes giving rise to such Additional Amounts would not have been imposed but for the presentation by the Holder or beneficial owner of any Note, where presentation is required, for payment on a date more than 30 days after the date
on which payment became due and payable or the date on which payment thereof is duly provided for, whichever occurs later; 

(v)    to the extent the Taxes giving rise to such Additional Amounts would not have been imposed but for
the Holder or beneficial owner not dealing at arm’s length, within the meaning of the Income Tax Act (Canada), with such Payor; 

(vi)    to the extent the Taxes giving rise to such Additional Amounts would not have been imposed but for
such Holder or beneficial owner being, or not dealing at arm’s length (within the meaning of the Income Tax Act (Canada)) with, a “specified shareholder” of the Company as defined in subsection 18(5) of the Income Tax
Act (Canada) for purposes of the thin capitalization rules in the Income Tax Act (Canada); 

(vii)    to the extent the Taxes giving rise to such Additional Amounts are United States federal
withholding taxes imposed pursuant to Sections 1471 through 1474 of the Internal Revenue Code of 1986, as amended (the “Code”), as in effect on the date hereof (or any amended or successor version that is substantively comparable
and not materially more onerous to comply with), any current or future regulations, official interpretations or administrative authority promulgated thereunder and any agreements entered into pursuant to Section 1471(b)(1) of the Code as in
effect on the date hereof (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), and, for the avoidance of doubt, any intergovernmental agreement (and related legislation, rules or
practices) implementing the foregoing (taken together, “FATCA”), except to the extent that such Taxes result from a failure of any Paying Agent to comply with FATCA; and 

(viii)    any combination of items (i), (ii), (iii), (iv), (v), (vi) and (vii). 

Additional Amounts also shall not be paid with respect to any payment on a Note to a beneficial owner who is a fiduciary, a partnership (or
entity treated as a partnership for tax purposes) or anyone other than the sole beneficial owner of that payment to the extent that payment would be required by the laws of the Relevant Taxing Jurisdiction to be included in the income, for tax
purposes, of a beneficiary or settlor with respect to the fiduciary, a member of that partnership or a beneficial owner who would not have been entitled to the Additional Amounts had that beneficiary, settlor, member or interest holder been the
beneficial owner. 
 (c)    The Payor or applicable withholding agent will (i) make any such withholding or
deduction required by applicable law and (ii) timely remit the full amount deducted or withheld to the relevant authority in accordance with applicable law. The Payor, or the applicable withholding agent, will make reasonable efforts to obtain
certified copies of tax receipts evidencing the payment of any Taxes so deducted or withheld from each Relevant Taxing Jurisdiction imposing such Taxes. The Payor, or the applicable withholding agent, will provide to the Trustee, within a reasonable
time after the date the payment of any Taxes so deducted or withheld are due pursuant to applicable law, either a certified copy of tax receipts evidencing such payment, or, if such tax receipts are not reasonably available to the Payor, such other
documentation that provides reasonable evidence of such payment by the Payor. 
 (d)    Where Tax is payable pursuant to
Regulation 803 of the Income Tax Act (Canada) by a Holder or beneficial owner of the Notes in respect of any amount payable under the Notes to the Holder (other than by reason of a transfer of the Notes to a person resident in Canada with
whom the transferor does not deal at arm’s length for the purposes of such Act), but no Additional Amount is paid in respect of such Tax, the Payor will pay as or on 

  
 -53- 

 
account of interest to the Holder an amount equal to such Tax (a “Regulation 803 Reimbursement”) plus an amount equal to any Tax required to be paid by the Holder or
beneficial owner as a result of such Regulation 803 Reimbursement within 45 days after receiving from the Holder a notice containing reasonable particulars of the Tax so payable, provided such Holder or beneficial owner would have
been entitled to receive Additional Amounts on account of such Tax (and only to the extent of such Additional Amounts that such Holder or beneficial owner would have been entitled to receive) but for the fact that it is payable otherwise than by
deduction or withholding from payments made under or with respect to the Notes. 
 (e)    The Payor will deliver to the
Trustee an Officers’ Certificate stating that such Additional Amounts will be payable prior to the date on which such payments will be made, and the amounts so payable, and will set forth such other information necessary to enable the Trustee
(or applicable paying agent) to pay such Additional Amounts to Holders on the payment date. Any such Officers’ Certificate will be delivered at least two Business Days in advance of when the payments in question are required to be made (unless
a shorter period of time is acceptable to the Trustee in its reasonable discretion). The Payor will promptly publish a notice in accordance with Section 11.2 hereof stating that such Additional Amounts will be payable and describing the
obligation to pay such amounts. 
 (f)    The Payors, jointly and severally, will reimburse the Holders or beneficial
owners of Notes, upon written request of such Holder or beneficial owner of Notes and certified proof of payment for the amount of (i) any Taxes levied or imposed by a Relevant Taxing Jurisdiction and payable by such Holder or beneficial owner
in connection with payments made under or with respect to the Notes or under or with respect to any Note Guarantee; and (ii) any Taxes levied or imposed with respect to any reimbursement under the foregoing clause (i) or this
clause (ii), so that the net amount received by such Holder or beneficial owner after such reimbursement will not be less than the net amount such Holder or beneficial owner would have received if the Taxes giving rise to the reimbursement
described in clauses (i) and/or (ii) had not been imposed, provided, however, that the indemnification obligation provided for in this Section 4.21(f) shall not extend to Taxes imposed for which the Holder or beneficial
owner of the Notes would not have been eligible to receive payment of Additional Amounts hereunder by virtue of clauses (i) through (viii) of Section 4.21(b) hereof, or to the extent such Holder or beneficial owner received Additional
Amounts with respect to such payments. 
 (g)    In addition, the Payor will pay any stamp, issue, registration, court,
documentary, excise or other similar taxes, charges and duties, including interest and penalties with respect thereto, imposed by any Relevant Taxing Jurisdiction at any time in respect of the execution, issuance, registration or delivery of the
Notes or any Note Guarantee or any other document or instrument referred to thereunder and any such taxes, charges or duties imposed by any Relevant Taxing Jurisdiction at any time as a result of, or in connection with, (i) any payments made
pursuant to the Notes, any Note Guarantee or any other such document or instrument referred to thereunder and/or (ii) the enforcement of the Notes or any Note Guarantee or any other such document or instrument referred to thereunder. 

(h)    The obligations described under this Section 4.21 will survive any termination, defeasance or discharge of
this Indenture and will apply mutatis mutandis to any successor Person to any Payor and to any jurisdiction in which such successor is organized, carrying on business or is otherwise resident for Tax purposes or any jurisdiction from or
through which payment is made by such successor or its respective agents. 
 (i)    Whenever this Indenture refers to,
in any context, the payment of principal, premium, if any, interest or any other amount payable under or with respect to any Note or under any Note Guarantee, such reference includes the payment of Additional Amounts or other payments that would be
payable pursuant to this Section 4.21, if applicable. 
 ARTICLE 5 

MERGER, CONSOLIDATION OR SALE OF ASSETS 

Section 5.1    Merger, Consolidation or Sale of Assets. 

(a)    The Company shall not, directly or indirectly: (1) consolidate, amalgamate or merge with or into another
Person (whether or not the Company is the surviving corporation) or (2) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company and its Restricted Subsidiaries, taken as a
whole, in one or more related transactions, to another Person, unless: 

  
 -54- 

 (i)    either (x) the Company is the surviving
corporation; or (y) the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or to which such sale, assignment, transfer, conveyance or other disposition has been made is organized and validly
existing under the laws of the U.S., any state of the U.S. or the District of Columbia or under the laws of Canada or any province thereof, any member state of the European Union as in effect on the Issue Date, Bermuda, Cayman Islands, any Channel
Island or Switzerland (provided that if such entity is not a corporation, a co-obligor of the Notes is a corporation); 

(ii)    the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the
Company) or the Person to which such sale, assignment, transfer, conveyance or other disposition has been made expressly assumes all the obligations of the Company under the Notes and this Indenture pursuant to agreements reasonably satisfactory to
the Trustee; 
 (iii)    immediately after such transaction, no Default or Event of Default exists; 

(iv)    either (a) the Company or the Person formed by or surviving any such consolidation,
amalgamation or merger (if other than the Company), or to which such sale, assignment, transfer, conveyance or other disposition has been made shall, on the date of such transaction after giving pro forma effect thereto and any related financing
transactions as if the same had occurred at the beginning of the applicable four-quarter period, be permitted to incur at least $1.00 of additional Indebtedness pursuant to the Fixed Charge Coverage Ratio test set forth in Section 4.9(a) hereof
or (b) the Company or the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or to which such sale, assignment, transfer, conveyance or other disposition has been made would, on the date of
such transaction after giving pro forma effect thereto and any related financing transactions as if the same had occurred at the beginning of the applicable four-quarter period, have a Fixed Charge Coverage Ratio for such Person and its
Restricted Subsidiaries that would be equal to or greater than such ratio for such Person and its Restricted Subsidiaries immediately prior to such action; and 

(v)     the Company has delivered to the Trustee an Officers’ Certificate stating that such
consolidation, amalgamation, merger, conveyance, transfer or lease and, if a supplemental indenture is required in connection with such transaction, such supplemental indenture, complies with this Article and that all conditions precedent herein
provided for relating to such transaction have been complied with. 
 (b)    The Company may not, directly or
indirectly, lease all or substantially all of its properties or assets, in one or more related transactions, to any other Person. 

(c)    The Company will not permit any Note Guarantor to, directly or indirectly, (1) consolidate, amalgamate or
merge with or into another Person; or (2) sell, assign, transfer, convey or otherwise dispose (collectively, “dispose”) of all or substantially all of its properties or assets, in one or more related transactions, to another
Person unless: 
 (i)    except in the case of a Note Guarantor (x) that has disposed of all or
substantially all of its assets, whether through a merger, amalgamation, consolidation or sale of Capital Stock or assets or (y) that, as a result of the disposition of all or a portion of its Capital Stock, ceases to be a Subsidiary of the
Company, in both cases in compliance with Section 4.14, the resulting, surviving or transferee Person (if not such Note Guarantor) shall expressly assume, by a guarantee agreement in a form reasonably satisfactory to the Trustee, all the
obligations of such Note Guarantor under its Note Guarantee; and 
 (ii)    immediately after such
transaction, no Default or Event of Default exists. 
 Notwithstanding the foregoing: (A) any Restricted Subsidiary may consolidate or
amalgamate with, merge into or transfer all or part of its properties and assets to the Company or any Note Guarantor and (B) the Company 

  
 -55- 

 
may merge or amalgamate with an Affiliate of the Company solely for the purpose of reincorporating the Company in another jurisdiction within the United States of America, any state thereof or
the District of Columbia, Canada or any province thereof, any member state of the European Union as in effect on the Issue Date, Bermuda, Cayman Islands, any Channel Island, Singapore or Switzerland or converting the Company into a limited liability
company organized under the United States of America, any state thereof or the District of Columbia, Canada or any province thereof, any member state of the European Union as in effect on the Issue Date, Bermuda, Cayman Islands, any Channel Island,
Singapore or Switzerland (provided that a co-obligor of the Notes is a corporation). 
 
Section 5.2    Successor Substituted. Upon any consolidation of the Company with, or merger or amalgamation of the Company into, any other Person or any conveyance, transfer or lease of all or substantially all of
the properties and assets of the Company in accordance with Section 5.1 hereof, the successor Person formed by such consolidation or into which the Company is merged or to which such conveyance, transfer or lease is made shall succeed to, and
be substituted for, and may exercise every right and power of, the Company under this Indenture with the same effect as if such successor Person had been named as the Company herein, and thereafter, except in the case of a lease, the predecessor
Person shall be relieved of all obligations and covenants under this Indenture and the Notes. 
 ARTICLE 6 

DEFAULT AND REMEDIES 
 
Section 6.1    Events of Default. Each of the following is an “Event of Default” with respect to the Notes: 

(a)    default in the payment of any principal of (including, without limitation, any premium, if any, on)
of the Notes when the same becomes due and payable (whether at maturity, upon a Redemption Date, Change of Control Purchase Date, Purchase Date or otherwise); 

(b)    default in the payment of any interest payable on Notes when the same becomes due and payable and
the Default continues for a period of 30 days; 
 (c)    failure by the Company or any of its Restricted
Subsidiaries 
 (i)    to comply with any of the provisions of Sections 3.8, 3.14 or 4.14 of this
Indenture, which failure remains uncured for 30 days after written notice to the Company from the Trustee or to the Company and the Trustee from the Holders of at least 25% in principal amount of the Notes; or 

(ii)    to comply with the provisions described in Section 5.1 of this Indenture; 

(d)    the Company or any of its Restricted Subsidiaries fails to comply with any of the other covenants
contained in the Notes or this Indenture and the Default continues for 60 days (or 90 days in the case of the provisions of Section 4.3) after written notice to the Company from the Trustee or to the Company and the Trustee from the
Holders of at least 25% in aggregate principal amount of the Notes then outstanding; 
 (e)    default
under any mortgage, indenture or instrument under which there may be issued or by which there may be secured or evidenced any Indebtedness for money borrowed by the Company or any of its Restricted Subsidiaries (or the payment of which is Guaranteed
by the Company or any of its Restricted Subsidiaries) whether such Indebtedness or Guarantee now exists, or is created after the date of this Indenture, if that default: 

(i)    is caused by a failure to pay principal when due on such Indebtedness within any applicable grace
period provided in such Indebtedness (a “Payment Default”); or 

  
 -56- 

 (ii)    results in the acceleration of such Indebtedness
prior to its express maturity, and, in each case, the principal amount of any such Indebtedness, together with the principal amount of any other such Indebtedness under which there has been a Payment Default or the maturity of which has been so
accelerated, aggregates $250.0 million or more; 
 (f)    failure by the Company or any of its
Restricted Subsidiaries to pay final non-appealable judgments aggregating in excess of $250.0 million, which judgments are not paid, discharged, stayed or subject to insurance for a period of 60 days
after becoming final; 
 (g)    any Note Guarantee by a Significant Subsidiary ceases to be in full force
and effect in all material respects (except as contemplated by the terms thereof) or any Note Guarantor that is a Significant Subsidiary denies or disaffirms such Note Guarantor’s obligations under this Indenture or any Note Guarantee and such
Default continues for 10 days after receipt of the notice as specified in this Indenture; 
 (h)    the
Company, any Restricted Subsidiary that is a Significant Subsidiary or any group of Restricted Subsidiaries that, taken together, would constitute a Significant Subsidiary, pursuant to or within the meaning of any Bankruptcy Law: 

(i)    commences a voluntary case or proceeding; 

(ii)    consents to the entry of an order for relief against it in an involuntary case or proceeding; 

(iii)    consents to the appointment of a Custodian of it or for all or substantially all of its property;
or 
 (iv)    makes a general assignment for the benefit of its creditors; and 

(i)    a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that: 

(i)    is for relief against the Company, any Restricted Subsidiary that is a Significant Subsidiary or any
group of Restricted Subsidiaries that, taken together, would constitute a Significant Subsidiary in an involuntary case or proceeding; 

(ii)    appoints a Custodian of the Company, any Restricted Subsidiary that is a Significant Subsidiary or
any group of Restricted Subsidiaries that, taken together, would constitute a Significant Subsidiary or for all or substantially all of the property of the Company, any Restricted Subsidiary that is a Significant Subsidiary or any group of
Restricted Subsidiaries that, taken together, would constitute a Significant Subsidiary; or 

(iii)    orders the liquidation of the Company, any Restricted Subsidiary that is a Significant Subsidiary
or any group of Restricted Subsidiaries that, taken together, would constitute a Significant Subsidiary; 
 and in each case the order or decree described
in this clause (i) remains unstayed and in effect for 60 consecutive days. 
 Any notice given pursuant to Section 6.1(d)
hereof must be in writing and must specify the Default, demand that it be remedied and state that the notice is a “Notice of Default.” When any Default under this Section 6.1 is cured, it ceases. 

Section 6.2    Acceleration. If an Event of Default (other than an Event of
Default specified in clause (i) or (j) of Section 6.1 hereof with respect to the Company) with respect to the Notes occurs and is continuing, the Trustee may, by notice to the Company, or the Holders of at least 25% in aggregate principal
amount of the Notes 

  
 -57- 

 
then outstanding may, by notice to the Company and the Trustee, declare all unpaid principal to the date of acceleration on the Notes then outstanding (if not then due and payable) to be due and
payable upon any such declaration, and the same shall become and be immediately due and payable. If an Event of Default specified in clause (i) or (j) of Section 6.1 hereof with respect to the Company occurs, all unpaid principal
(including, without limitation, any premium, if any, then outstanding), and accrued interest, if any, on the Notes then outstanding shall ipso facto become and be immediately due and payable without any declaration or other act on the part of the
Trustee or any Holder. The Holders of a majority in aggregate principal amount of Notes then outstanding by notice to the Trustee may rescind an acceleration and its consequences if (a) all existing Events of Default, other than the nonpayment
of the principal of Notes which has become due solely by such declaration of acceleration, have been cured or waived; (b) the rescission would not conflict with any judgment or decree of a court of competent jurisdiction; and (c) all
payments due to the Trustee and any predecessor Trustee under Section 7.7 hereof in respect of the Notes have been made. No such rescission shall affect any subsequent default or impair any right consequent thereto. 

Section 6.3    Other Remedies. If an Event of Default occurs and is continuing in
respect of the Notes, the Trustee may, but shall not be obligated to, pursue any available remedy by proceeding at law or in equity to collect the payment of the principal of or interest on the Notes or to enforce the performance of any provision of
such Notes or this Indenture. 
 The Trustee may maintain a proceeding even if it does not possess any of the Notes or does not produce any
of them in the proceeding. A delay or omission by the Trustee or any Noteholder in exercising any right or remedy accruing upon an Event of Default shall not impair the right or remedy or constitute a waiver of or acquiescence in the Event of
Default. No remedy is exclusive of any other remedy. All available remedies are cumulative to the extent permitted by law. 
 
Section 6.4    Waiver of Defaults and Events of Default. Subject to Sections 6.7 and 9.2 hereof, the Holders of a majority in aggregate principal amount of the Notes then outstanding by notice to the Trustee may
waive an existing Default or Event of Default and its consequences, except a Default or Event of Default in the payment of the principal of, premium, if any, or interest on any Notes when due or any Default or Event of Default in respect of any
provision of this Indenture or the Notes which, under Section 9.2 hereof, cannot be modified or amended without the consent of the Holder of each Note affected (with respect to any Notes held by a
non-consenting Holder). When a Default or Event of Default is waived, it is cured and ceases. 
 
Section 6.5    Control by Majority. The Holders of a majority in aggregate principal amount of the Notes then outstanding may direct the time, method and place of conducting any proceeding for exercising any
remedy or power available to the Trustee or exercising any trust or power conferred on it. However, the Trustee may refuse to follow any direction that it determines, in consultation with its counsel conflicts with law or this Indenture, that the
Trustee determines may be unduly prejudicial to the rights of another Holder of Notes or the Trustee, or that may involve the Trustee in personal liability unless the Trustee is offered indemnity satisfactory to it; provided, however,
that the Trustee may take any other action deemed proper by the Trustee which is not inconsistent with such direction. 
 
Section 6.6    Limitations on Suits. A Holder may not pursue any remedy with respect to this Indenture or the Notes (except actions for payment of overdue principal, premium, if any, or interest) unless: 

(a)    the Holder gives to the Trustee written notice of a continuing Event of Default; 

(b)    the Holders of at least 25% in aggregate principal amount of the then outstanding Notes make a
written request to the Trustee to pursue the remedy; 
 (c)    such Holder or Holders offer to the
Trustee reasonable indemnity satisfactory to the Trustee against any loss, liability or expense; 

(d)    the Trustee does not comply with the request within 60 days after receipt of the request and
the offer of indemnity; and 

  
 -58- 

 (e)    no direction inconsistent with such written request
has been given to the Trustee during such 60-day period by the Holders of a majority in aggregate principal amount of the Notes. 

Section 6.7    Rights of Holders to Receive Payment. Notwithstanding any other
provision of this Indenture, with respect to the Notes, the contractual right of any Holder of a Note to receive payment of the principal of, or interest on such Note, on or after the respective due dates expressed in such Note and this Indenture
and to bring suit for the enforcement of any such payment on or after such respective dates, is absolute and unconditional and shall not be impaired or affected without the consent of the Holder. 

Section 6.8    Collection Suit by Trustee. If an Event of Default in the payment
of principal or interest specified in clause (a) or (b) of Section 6.1 hereof occurs and is continuing with respect to the Notes, the Trustee may recover judgment in its own name and as trustee of an express trust against the Company or
another obligor on the Notes for the whole amount of principal and accrued interest remaining unpaid, together with, to the extent that payment of such interest is lawful, interest on overdue principal and overdue installments of interest, in each
case at a rate equal to the interest rate then in effect on such Note and such further amount as shall be sufficient to cover the costs and expenses of collection, including the reasonable compensation, expenses, disbursements and advances of the
Trustee, its agents and counsel. 
 Section 6.9    Trustee May File Proofs of
Claim. The Trustee may file such proofs of claim and other papers or documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for the reasonable compensation, expenses, disbursements and advances
of the Trustee, its agents and counsel) and the Holders allowed in any judicial proceedings relative to the Company (or any other obligor on the Notes), its creditors or its property and shall be entitled and empowered to collect and receive any
money or other property payable or deliverable on any such claims and to distribute the same, and any Custodian in any such judicial proceeding is hereby authorized by each Holder to make such payments to the Trustee and, in the event that the
Trustee shall consent to the making of such payments directly to the Holders, to pay to the Trustee any amount due to it for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, and any other
amounts due the Trustee under Section 7.7 hereof, and to the extent that such payment of the reasonable compensation, expenses, disbursements and advances in any such proceedings shall be denied for any reason, payment of the same shall be
secured by a lien on, and shall be paid out of, any and all distributions, dividends, money, securities and other property which the Holders may be entitled to receive in such proceedings, whether in liquidation or under any plan of reorganization
or arrangement or otherwise. Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to, or, on behalf of any Holder, to authorize, accept or adopt any plan of reorganization, arrangement, adjustment or composition
affecting the Notes or the rights of any Holder thereof, or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding. 

Section 6.10    Priorities. If the Trustee collects any money pursuant to this
Article 6, it shall pay out the money in the following order: 
 First, to the Trustee for amounts due under
Section 7.7 hereof; 
 Second, to Holders for amounts due and unpaid on the Notes for principal and interest
ratably, without preference or priority of any kind, according to the amounts due and payable on such Notes for principal and interest respectively; and 

Third, the balance, if any, to the Company. 

The Trustee may fix a record date and payment date for any payment to Holders pursuant to this Section 6.10. 

Section 6.11    Undertaking for Costs. In any suit for the enforcement of any
right or remedy under this Indenture or in any suit against the Trustee for any action taken or omitted by it as Trustee, a court in its discretion may require the filing by any party litigant in the suit of an undertaking to pay the costs of the
suit, and the court in its discretion may assess reasonable costs, including reasonable attorneys’ fees and expenses, against any party litigant in the suit, having due regard to the merits and good faith of the claims or defenses made by the
party litigant. This Section 6.11 does not apply to a suit made by the Trustee, a suit by a Holder pursuant to Section 6.7 hereof, or a suit by Holders of more than 10% in aggregate principal amount of the Notes then outstanding. 

  
 -59- 

 ARTICLE 7 

TRUSTEE 
 
Section 7.1    Duties of Trustee. 
 (a)    If an Event of Default has occurred and
is continuing, the Trustee shall exercise such of the rights and powers vested in it by this Indenture and use the same degree of care and skill in its exercise as a prudent person would exercise or use under the circumstances in the conduct of his
or her own affairs. 
 (b)    Except during the continuance of an Event of Default: 

(A)    the Trustee need perform only those duties as are specifically set forth in this Indenture and no
others; and 
 (B)    in the absence of bad faith on its part, the Trustee may conclusively rely, as to
the truth of the statements and the correctness of the opinions expressed therein, upon certificates or opinions furnished to the Trustee and conforming to the requirements of this Indenture. The Trustee, however, shall examine any certificates and
opinions which by any provision hereof are specifically required to be delivered to the Trustee to determine whether or not they conform to the requirements of this Indenture (but need not confirm or investigate the accuracy of mathematical
calculations or other facts stated therein). 
 (c)    The Trustee may not be relieved from liability for its own
negligent action, its own negligent failure to act, or its own willful misconduct, except that: 

(A)    this paragraph does not limit the effect of subsection (b) of this Section 7.1; 

(B)    the Trustee shall not be liable for any error of judgment made in good faith by a Trust Officer,
unless it is proved that the Trustee was negligent in ascertaining the pertinent facts; and 
 (C)    the
Trustee shall not be liable with respect to any action it takes or omits to take in good faith in accordance with a direction received by it pursuant to Section 6.5 hereof. 

(d)    No provision of this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur any
financial liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers unless the Trustee shall have received satisfactory indemnity in its opinion against potential costs and liabilities incurred by
it relating thereto. 
 (e)    Every provision of this Indenture that in any way relates to the Trustee is subject to
subsections (a), (b), (c) and (d) of this Section 7.1. 
 (f)    The Trustee shall not be liable for interest
on any money received by it except as the Trustee may agree in writing with the Company. Money held in trust by the Trustee need not be segregated from other funds except to the extent required by law. 

Section 7.2    Rights of Trustee. Subject to Section 7.1 hereof: 

(a)    The Trustee may rely conclusively on any document believed by it to be genuine and to have been
signed or presented by the proper person. The Trustee need not investigate any fact or matter stated in the document. 

  
 -60- 

 (b)    Before the Trustee acts or refrains from acting, it
may require an Officers’ Certificate or an Opinion of Counsel (or both), which shall conform to Section 11.4(b) hereof. The Trustee shall not be liable for any action it takes or omits to take in good faith in reliance on such
Officers’ Certificate or Opinion of Counsel. 
 (c)    The Trustee may act through its agents and
shall not be responsible for the misconduct or negligence of any agent appointed with due care. 

(d)    The Trustee shall not be liable for any action it takes or omits to take in good faith which it
believes to be authorized or within its rights or powers. 
 (e)    The Trustee may consult with counsel
of its selection, and the advice or opinion of such counsel as to matters of law shall be full and complete authorization and protection in respect of any such action taken, omitted or suffered by it hereunder in good faith and in accordance with
the advice or opinion of such counsel. 
 (f)    The Trustee shall be under no obligation to exercise any
of the rights or powers vested in it by this Indenture at the request or direction of any of the Holders pursuant to this Indenture, unless such Holders shall have offered to the Trustee security or indemnity satisfactory to the Trustee against the
costs, expenses and liabilities which might be incurred by it in compliance with such request or direction. 

(g)    The Trustee shall not be bound to make any investigation into the facts or matters stated in any
resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document, but the Trustee, in its discretion, may make such further
inquiry or investigation into such facts or matters as it may see fit, and, if the Trustee shall determine to make such further inquiry or investigation, it shall be entitled to examine the books, records and premises of the Company, personally or
by agent or attorney at the sole cost of the Company and shall incur no liability or additional liability of any kind by reason of such inquiry or investigation. 

(h)    The Trustee shall not be deemed to have notice of any Default or Event of Default unless written
notice of any event which is in fact such a default is received by a responsible Trust Officer of the Trustee at the Corporate Trust Office, and such notice references the Notes and this Indenture. 

(i)    The rights, privileges, protections, immunities and benefits given to BNY Mellon as Trustee,
including, without limitation, its right to be indemnified, are extended to, and shall be enforceable by, BNY Mellon in each of its capacities hereunder, and to each agent, custodian and other Person employed to act hereunder. 

(j)    In no event shall the Trustee be responsible or liable for special, punitive, indirect, or
consequential loss or damage of any kind whatsoever (including, but not limited to, loss of profit) irrespective of whether the Trustee has been advised of the likelihood of such loss or damage and regardless of the form of action. 

(k)    In no event shall the Trustee be responsible or liable for any failure or delay in the performance
of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or
natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services; it being understood that the Trustee shall use reasonable efforts which are consistent with
accepted practices in the banking industry to resume performance as soon as practicable under the circumstances. 
 
Section 7.3    Individual Rights of Trustee. The Trustee in its individual or any other capacity may become the owner or pledgee of Notes and may otherwise deal with the Company or an Affiliate of the Company with
the same rights it would have if it were not Trustee. Any Agent may do the same with like rights. However, the Trustee is subject to Sections 7.10 and 7.11 hereof. 

  
 -61- 

Section 7.4    Trustee’s Disclaimer. The Trustee makes no
representation as to the validity or adequacy of this Indenture or the Notes, it shall not be accountable for the Company’s use of the proceeds from the Notes, and it shall not be responsible for any statement in the Notes other than its
certificate of authentication. 
 Section 7.5    Notice of Default or Events of
Default. If a Default or an Event of Default occurs and is continuing and if a Trust Officer of the Trustee has received written notice of such Default or Event of Default at its Corporate Trust Office and such notice references the Notes and
this Indenture, the Trustee shall notify each Noteholder of the Default or Event of Default within 90 days after it is known by the Trustee. However, the Trustee may withhold the notice if and so long as a committee of its Trust Officers in
good faith determines that withholding notice is in the interests of Noteholders, except in the case of a Default or an Event of Default in payment of the principal (including premium, if any) of or interest on any Note. 

Section 7.6    [Reserved]. 

Section 7.7    Compensation and Indemnity. The Company shall pay to the Trustee
from time to time such compensation (as agreed to from time to time by the Company and the Trustee in writing) for its services (which compensation shall not be limited by any provision of law in regard to the compensation of a trustee of an express
trust). The Company shall reimburse the Trustee upon request for all reasonable disbursements, expenses and advances incurred or made by it. Such expenses may include the reasonable compensation, disbursements and expenses of the Trustee’s
agents and counsel. 
 Each of the Company and each Guarantor, jointly and severally, shall indemnify the Trustee or any predecessor Trustee
(which for purposes of this Section 7.7 shall include its officers, directors, employees and agents) for, and hold it harmless against, any and all loss, liability or expense including taxes (other than taxes based upon, measured by or
determined by the income of the Trustee), (including reasonable legal fees and expenses) incurred by it in connection with the acceptance or administration of its duties under this Indenture or any action or failure to act as authorized or within
the discretion or rights or powers conferred upon the Trustee hereunder or thereunder including the reasonable costs and expenses of the Trustee and its counsel in defending itself against any claim or liability in connection with the exercise or
performance of any of its powers or duties hereunder or thereunder. The Trustee shall notify the Company promptly of any claim asserted against the Trustee for which it may seek indemnity. The Company need not pay for any settlement effected without
its prior written consent, which shall not be unreasonably withheld. 
 The Company need not reimburse the Trustee for any expense or
indemnify it against any loss or liability determined by a court of competent jurisdiction to have been caused by its own gross negligence or willful misconduct. 

To secure the Company’s payment obligations in this Section 7.7, the Trustee shall have a senior claim to which the Notes are hereby
made subordinate on all money or property held or collected by the Trustee, except such money or property held in trust to pay the principal of and interest on the Notes. The obligations of the Company under this Section 7.7 shall survive the
satisfaction and discharge of this Indenture or the resignation or removal of the Trustee. 
 When the Trustee incurs expenses or renders
services after an Event of Default specified in clause (h) or (i) of Section 6.1 hereof occurs, the expenses and the compensation for the services are intended to constitute expenses of administration under any Bankruptcy Law to the extent
permitted by law. The provisions of this Section shall survive the termination of this Indenture. 

Section 7.8    Replacement of Trustee. The Trustee may resign by so notifying the
Company. The Holders of a majority in aggregate principal amount of the Notes then outstanding may remove the Trustee by so notifying the Trustee. The Company may remove the Trustee if: 

  
 -62- 

 (a)    the Trustee fails to comply with Section 7.10
hereof; 
 (b)    the Trustee is adjudged a bankrupt or an insolvent; 

(c)    a Custodian or other public officer takes charge of the Trustee or its property; or 

(d)    the Trustee becomes incapable of acting. 

If the Trustee resigns or is removed or if a vacancy exists in the office of the Trustee for any reason, the Company shall promptly appoint a
successor Trustee. The resignation or removal of a Trustee shall not be effective until a successor Trustee shall have delivered the written acceptance of its appointment as described below. 

If a successor Trustee does not take office within 45 days after the retiring Trustee resigns or is removed, the retiring Trustee, the Company
or the Holders of 10% in principal amount of the Notes then outstanding may petition any court of competent jurisdiction for the appointment of a successor Trustee at the expense of the Company. 

If the Trustee fails to comply with Section 7.10 hereof, any Holder may petition any court of competent jurisdiction for the removal of
the Trustee and the appointment of a successor Trustee. 
 A successor Trustee shall deliver a written acceptance of its appointment to the
retiring Trustee and to the Company. Immediately after that, the retiring Trustee, upon payment of its charges hereunder, shall transfer all property held by it as Trustee of the Notes to the successor Trustee and be released from its obligations
(exclusive of any liabilities that the retiring Trustee may have incurred while acting as Trustee) hereunder, the resignation or removal of the retiring Trustee shall become effective, and the successor Trustee shall have all the rights, powers and
duties of the Trustee of the Notes under this Indenture. A successor Trustee shall mail notice of its succession to each affected Holder. 

A retiring Trustee shall not be liable for the acts or omissions of any successor Trustee after its succession. 

Notwithstanding replacement of the Trustee pursuant to this Section 7.8, the Company’s obligations under Section 7.7 hereof
shall continue for the benefit of the retiring Trustee. 
 Section 7.9    Successor
Trustee by Merger, Etc. If the Trustee consolidates with, merges or converts into, or transfers all or substantially all of its corporate trust assets (including the administration of this Indenture) to, another corporation, the resulting,
surviving or transferee corporation, without any further act, shall be the successor Trustee, provided such transferee corporation shall qualify and be eligible under Section 7.10 hereof. Such successor Trustee shall promptly mail notice
of its succession to the Company and each affected Holder. 

Section 7.10    Eligibility; Disqualification. The Trustee shall always satisfy
the requirements of paragraphs (1), (2) and (5) of TIA Section 310(a). The Trustee (or its parent holding company) shall have a combined capital and surplus of at least $50,000,000. If at any time the Trustee shall cease to satisfy any
such requirements, it shall resign immediately in the manner and with the effect specified in this Article 7. The Trustee shall be subject to the provisions of TIA Section 310(b). 

Section 7.11    Preferential Collection of Claims Against the Company. The
Trustee shall comply with TIA Section 311(a), excluding any creditor relationship listed in TIA Section 311(b). A Trustee who has resigned or been removed shall be subject to TIA Section 311(a) to the extent indicated therein. 

  
 -63- 

 ARTICLE 8 

DEFEASANCE; SATISFACTION AND 

DISCHARGE OF INDENTURE 
 
Section 8.1    Satisfaction and Discharge of Indenture. This Indenture shall cease to be of further effect with respect to the Notes and all Note Guarantees and the Trustee, on demand of and at the expense of the
Company, shall execute proper instruments acknowledging satisfaction and discharge of this Indenture and release of such Guarantees, when 

(a)    either 

(i)    all Notes theretofore authenticated and delivered (other than (i) Notes which have been
destroyed, lost or stolen and which have been replaced or paid as provided in Section 2.7 hereof and (ii) Notes for whose payment money has theretofore been deposited in trust and thereafter repaid to the Company as provided in
Section 8.5 hereof) have been delivered to the Trustee for cancellation; or 
 (ii)    all Notes not
theretofore delivered to the Trustee for cancellation have become due and payable by reason of the mailing of a notice of redemption or otherwise or will become due and payable within one year and the Company has irrevocably deposited or caused to
be irrevocably deposited cash in U.S. dollars, non-callable Government Securities or a combination thereof with the Trustee or a Paying Agent (other than the Company or any of their Affiliates) as trust funds
in trust for the purpose of and in an amount sufficient, without consideration of any reinvestment of interest, to pay and discharge the entire indebtedness on the Notes not theretofore delivered to the Trustee for cancellation, for principal,
premium, if any, and accrued interest to the date of maturity or redemption, provided that with respect to any redemption that requires the payment of the Applicable Premium, the amount deposited shall be sufficient for purpose of this
Indenture to the extent that an amount is deposited with the Trustee equal to the Applicable Premium calculated by the Company as of the date of the notice of redemption, with any Applicable Premium deficit only required to be deposited with the
Trustee on or prior to the date of redemption; 
 (b)    no Default or Event of Default has occurred and
is continuing on the date of the deposit or will occur as a result of the deposit and the deposit will not result in a breach or violation of or constitute a default under, any other instrument to which the Company is a party or by which the Company
is bound, and as to which the rights of the other parties thereto are senior to those of the Holders; 

(c)    the Company has paid or caused to be paid all other sums payable hereunder by the Company; 

(d)    the Company has delivered irrevocable instructions to the Trustee to apply the deposited money
toward payment of the Notes at maturity or Redemption Date, as the case may be; and 
 (e)    the Company
has delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel, each stating that all conditions precedent herein relating to the satisfaction and discharge of this Indenture have been complied with. 

Notwithstanding the satisfaction and discharge of this Indenture, the obligations of the Company to the Trustee under Section 7.7 hereof
shall survive and, if cash in U.S. dollars, non-callable Government Securities or a combination thereof shall have been deposited with the Trustee pursuant to subclause (ii) of clause (a) of this
Section, the provisions of Sections 2.3, 2.4, 2.5, 2.6, 2.7, 2.12, 4.2 and 7.8, this Article 8 and Section 11.5, shall survive until the Notes have been paid in full. 

  
 -64- 

 Section 8.2    Legal Defeasance. The
Company and the Note Guarantors shall be deemed to have paid and will be discharged from any and all obligations in respect of this Indenture and the Notes and the related Note Guarantees released on the date of the deposit referred to in clause
(a) of this Section 8.2, and the provisions of this Indenture shall no longer be in effect (“Legal Defeasance”), and the Trustee, at the expense of the Company, shall execute proper instruments acknowledging the same,
except for the following provisions, which shall survive until otherwise terminated or discharged hereunder: (i) the rights of Holders of outstanding Notes to receive solely from the trust fund described in clause (a) below payments in
respect of the principal of, premium, if any, and interest on the Notes when such payments are due, (ii) the Company’s obligations with respect to the Notes under Article 2 and Section 4.2 hereof, (iii) the rights, powers,
trusts, duties, indemnities and immunities of the Trustee hereunder, including, without limitation, Section 7.7 hereof and the Company’s obligations in connection therewith and (iv) this Section 8.2. Subject to compliance with
this Section 8.2, the Company may exercise its option under this Section 8.2 notwithstanding the prior exercise of its option under Section 8.3 hereof. The following conditions shall apply to Legal Defeasance: 

(a)    the Company shall have irrevocably deposited with the Trustee, in trust, for the benefit of the
Holders of the Notes, cash in U.S. dollars, Government Securities, or a combination thereof, in such amounts as shall be sufficient, in the opinion of a nationally recognized firm of independent public accountants, to pay the principal of, or
interest and premium, if any, on the outstanding Notes on the Stated Maturity or on the applicable Redemption Date, as the case may be, and the Company must specify whether the Notes are being defeased to their Stated Maturity or to a particular
Redemption Date; 
 (b)    the Company shall have delivered to the Trustee an Opinion of Counsel (based
on a ruling received from or published by the United States Internal Revenue Service or a change in the applicable U.S. federal income tax law since the date of this Indenture) in the United States reasonably acceptable to the Trustee to the effect
that the beneficial owners of the outstanding Notes will not recognize income, gain or loss for U.S. federal income tax purposes as a result of such Legal Defeasance and will be subject to U.S. federal income tax on the same amounts, in the same
manner and at the same times as would have been the case if such Legal Defeasance had not occurred; 

(c)    the Company shall have delivered to the Trustee either (i) an Opinion of Counsel in Canada
reasonably acceptable to the Trustee to the effect that, based upon Canadian law then in effect and having regard to any applicable proposed amendments thereto which have been publicly announced prior to the date of such defeasance, the beneficial
owners of the outstanding Notes will not recognize income, gain or loss for Canadian federal, provincial or territorial or other tax purposes, as a result of such Legal Defeasance and will be subject to Canadian taxes on the same amounts and in the
same manner and at the same time as would have been the case if such Legal Defeasance had not occurred or (ii) a ruling directed to the Trustee received from tax authorities of Canada to the same effect as the Opinion of Counsel described in
clause (i) above; 
 (d)    no Default or Event of Default shall have occurred and be continuing on
the date of such deposit (other than a Default or an Event of Default resulting from the borrowing of funds to be applied to such deposit); 

(e)    the Legal Defeasance shall not result in a breach or violation of, or constitute a default under,
any material agreement or instrument (other than this Indenture) to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound; and 

(f)    the Company must deliver to the Trustee an Officers’ Certificate and an Opinion of Counsel,
each stating that all conditions precedent relating to the Legal Defeasance have been complied with. 
 After any such irrevocable deposit,
the Trustee upon request shall acknowledge in writing the discharge of the Company’s obligations under the Notes and this Indenture except for those surviving obligations in the immediately preceding paragraph. 

  
 -65- 

 Notwithstanding the foregoing, the Opinion of Counsel required by Section 8.2(b) hereof with
respect to a Legal Defeasance need not be delivered if all Notes not theretofore delivered to the Trustee for cancellation (1) have become due and payable or (2) shall become due and payable upon maturity or redemption within one year
under arrangements satisfactory to the Trustee for the giving of notice of redemption by the Trustee in the name, and at the expense, of the Company. 

Section 8.3    Covenant Defeasance. The Company may omit to comply with any term,
provision or condition set forth in clause (iv) of Section 5.1(a) hereof, and the Company and its Restricted Subsidiaries may omit to comply with any term, provision or condition set forth in Section 3.8, Section 4.3,
Sections 4.8 through 4.17 hereof and any breach of clauses (c), (d), (e) or (f) of this Section 8.3, or with respect to Significant Subsidiaries only, clauses (i) or (j) under Section 6.1 hereof shall be deemed not to be an
Event of Default and all Guarantees and Liens shall be released on the date of deposit referred to in clause (a) of this Section 8.3 (“Covenant Defeasance”), if in each case: 

(a)    the Company shall have irrevocably deposited with the Trustee, in trust, for the benefit of the
Holders of the Notes, cash in U.S. dollars, Government Securities, or a combination thereof, in such amounts as shall be sufficient, in the opinion of a nationally recognized firm of independent public accountants, to pay the principal of, or
interest and premium, if any, on the outstanding Notes on the Stated Maturity or on the applicable Redemption Date, as the case may be, and the Company must specify whether the Notes are being defeased to their Stated Maturity or to a particular
Redemption Date; 
 (b)    the Company shall have delivered to the Trustee an Opinion of Counsel in the
United States reasonably acceptable to such Trustee confirming that the beneficial owners of the outstanding Notes will not recognize income, gain or loss for U.S. federal income tax purposes as a result of such Covenant Defeasance and will be
subject to U.S. federal income tax on the same amounts, in the same manner and at the same times as would have been the case if the Covenant Defeasance had not occurred; 

(c)    the Company shall have delivered to the Trustee either (i) an Opinion of Counsel in Canada
reasonably acceptable to the Trustee, to the effect that, based upon Canadian law then in effect and having regard to any applicable proposed amendments thereto which have been public announced prior to the date of such defeasance, the beneficial
owners of the outstanding Notes will not recognize income, gain or loss for Canadian federal, provincial or territorial or other tax purposes, as a result of such Covenant Defeasance and will be subject to Canadian taxes on the same amounts and in
the same manner and at the same time as would have been the case if such Covenant Defeasance had not occurred or (ii) a ruling directed to the Trustee received from tax authorities of Canada to the same effect as the Opinion of Counsel
described in clause (i) above; 
 (d)    no Default or Event of Default shall have occurred and be
continuing on the date of such deposit (other than a Default or Event of Default resulting from the borrowing of funds to be applied to such deposit); 

(e)    the Covenant Defeasance shall not result in a breach or violation of, or constitute a default under
any material agreement or instrument (other than this Indenture) to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound; and 

(f)    the Company must deliver to the Trustee an Officers’ Certificate and an Opinion of Counsel,
each stating that all conditions precedent relating to the Covenant Defeasance have been complied with. 
 If the funds deposited with the
Trustee to effect Covenant Defeasance are insufficient to pay the principal of and interest on the Notes when due, then the obligations of the Company and the Note Guarantors under this Indenture will be revived and no such defeasance will be deemed
to have occurred. 
 Notwithstanding the foregoing, the Opinion of Counsel required by Section 8.3(b) hereof with respect to a Covenant
Defeasance need not be delivered if all Notes not theretofore delivered to the Trustee for cancellation (1) have become due and payable or (2) shall become due and payable upon maturity or redemption within one year under arrangements
satisfactory to the Trustee for the giving of notice of redemption by the Trustee in the name, and at the expense, of the Company. 

  
 -66- 

 Section 8.4    Application of Trust
Money. Subject to the provisions of Section 8.5 hereof, the Trustee or a Paying Agent shall hold in trust, for the benefit of the Holders, all money deposited with it pursuant to Section 8.1, 8.2 or 8.3 hereof and shall apply the
deposited money in accordance with this Indenture and the Notes to the payment of the principal of and interest on the Notes. 
 
Section 8.5    Repayment to the Company. The Trustee and each Paying Agent shall promptly pay to the Company upon request any excess money (i) deposited with them pursuant to Section 8.1, 8.2 or 8.3
hereof and (ii) held by them at any time. 
 The Trustee and each Paying Agent shall pay to the Company upon request any money held by
them for the payment of principal or interest that remains unclaimed for two years after a right to such money has matured; provided, however, that the Trustee or such Paying Agent, before being required to make any such payment, may
at the expense of the Company cause to be mailed to each Holder entitled to such money notice that such money remains unclaimed and that after a date specified therein, which shall be at least 30 days from the date of such mailing, any unclaimed
balance of such money then remaining will be repaid to the Company. After payment to the Company, Holders entitled to money must look to the Company for payment as general creditors unless an applicable abandoned property law designates another
person. 
 Section 8.6    Reinstatement. If the Trustee or any Paying Agent is
unable to apply any money in accordance with Section 8.5 hereof by reason of any legal proceeding or by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting such application,
then the Company’s obligations under this Indenture and the Notes shall be revived and reinstated as though no deposit had occurred pursuant to Section 8.1, 8.2 or 8.3 hereof until such time as the Trustee or such Paying Agent is permitted
to apply all such money or Government Securities in accordance with Section 8.4 hereof; provided, however, that if the Company has made any payment of the principal of or interest on any Notes because of the reinstatement of its
obligations, the Company shall be subrogated to the rights of the Holders of such Notes to receive any such payment from the money or Government Securities held by the Trustee or such Paying Agent. 

ARTICLE 9 

AMENDMENTS, SUPPLEMENTS AND WAIVERS 

Section 9.1    Without Consent of Holders. The Company and the Trustee may amend
or supplement this Indenture with respect to the Notes without notice to or consent of any Holder of Notes: 

(a)    to comply with Section 5.1 hereof; 

(b)    to cure any ambiguity, defect or inconsistency; 

(c)    to provide for uncertificated Notes in addition to or in place of certificated Notes; 

(d)    to provide for the assumption of the Company’s or any Note Guarantor’s obligations to
Holders of Notes in the case of a consolidation or merger or sale of all or substantially all of the Company’s or a Note Guarantor’s assets; 

(e)    to make any change that would provide any additional rights or benefits to the Holders of Notes or
that does not adversely affect the legal rights under this Indenture of any such Holder of Notes; 

(f)    to comply with requirements of the SEC in order to effect or maintain the qualification of this
Indenture under the TIA; 

  
 -67- 

 (g)    to conform the text of this Indenture, the Notes or
the Note Guarantees to any provision of the section of the Offering Memorandum dated December 4, 2017 captioned “Description of the Notes”; 

(h)    to provide for the issuance of Additional Notes in accordance with the limitations set forth in this
Indenture as of the date hereof; 
 (i)    to add additional Note Guarantees with respect to the Notes or
to confirm and evidence the release, termination or discharge of any Note Guarantee with respect to such Notes when such release, termination or discharge is permitted under this Indenture; or 

(j)    to appoint a successor Trustee. 

Section 9.2    With Consent of Holders. The Company and the Trustee may amend or supplement
this Indenture and the Notes with the written consent of the Holders of at least a majority in aggregate principal amount of the Notes then outstanding (including, without limitation, consents obtained in connection with a purchase of, or tender
offer or exchange offer for, Notes). The Holders of at least a majority in aggregate principal amount of the Notes then outstanding may waive compliance in a particular instance by the Company with any provision of this Indenture, or such Notes
without notice to any Holder (including, without limitation, consents obtained in connection with a purchase of, or tender offer or exchange offer for, the Notes). However, notwithstanding the foregoing but subject to Section 9.4 hereof,
without the written consent of each Holder of Notes affected hereby, an amendment, supplement or waiver, including a waiver pursuant to Section 6.4 hereof, may not (with respect to any Notes held by a
non-consenting Holder): 
 (a)    reduce the principal amount of
such Notes whose Holders must consent to an amendment, supplement or waiver; 
 (b)    reduce the
principal of or change the Stated Maturity of any such Note or alter the provisions with respect to the redemption of such Notes (excluding, for the avoidance of doubt, provisions relating to Sections 3.8, 3.14 and 4.14); 

(c)    reduce the rate of or change the time for payment of interest on any such Note; 

(d)    make any such Note payable in money other than U.S. dollars; 

(e)    make any change in the provisions of this Indenture relating to waivers of past Defaults or the
rights of Holders of such Notes to receive payments of principal of, or interest or premium, if any, on such Notes; 

(f)    waive a redemption payment with respect to any such Note (excluding, for the avoidance of doubt, a
payment required by Sections 3.8, 3.14 and 4.14); 
 (g)    impair the right to institute suit for the
enforcement of any payment on or with respect to such Notes; 
 (h)    modify the Note Guarantees with
respect to such Notes in any manner adverse to the Holders of such Notes; or 
 (i)    make any change in
the preceding amendment and waiver provisions with respect to the Notes; 
 provided that the written consent of the Holders of at least a majority
in aggregate principal amount of the Notes then outstanding shall be required. 
 In addition, without the consent of Holders of at least 66 2⁄3% in principal amount of the Notes then outstanding (including, without limitation, consents obtained in connection with a purchase of, or tender offer or
exchange offer for, Notes), except as set forth in Section 10.5, no amendment or supplement may release the Note Guarantees with respect to the Notes. 

  
 -68- 

 It shall not be necessary for the consent of the Holders under this Section 9.2 to approve
the particular form of any proposed amendment, supplement or waiver, but it shall be sufficient if such consent approves the substance thereof. 

Section 9.3    Notice of Amendment, Supplement or Waiver. After an amendment,
supplement or waiver under Section 9.1 or Section 9.2 becomes effective, the Company shall mail to the Holders affected thereby a notice briefly describing the amendment, supplement or waiver. Any failure of the Company to mail such
notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such amendment, supplement or waiver. 
 
Section 9.4    Revocation and Effect of Consents. Until an amendment, supplement or waiver becomes effective, a consent to it by a Holder is a continuing consent by the Holder and every subsequent Holder of a Note
or portion of a Note that evidences the same debt as the consenting Holder’s Note, even if notation of the consent is not made on any Note. However, any such Holder or subsequent Holder may revoke the consent as to its Note or portion of a Note
if the Trustee receives the notice of revocation before the date the amendment, supplement or waiver becomes effective. 
 After an
amendment, supplement or waiver becomes effective, it shall bind every Holder, unless it makes a change described in any of clauses (a) through (i) of Section 9.2 hereof. In that case the amendment, supplement or waiver shall bind each
Holder of a Note who has consented to it and every subsequent Holder of a Note or portion of a Note that evidences the same debt as the consenting Holder’s Note. 

Section 9.5    Notation on or Exchange of Notes. If an amendment, supplement or
waiver changes the terms of a Note, the Trustee may require the Holder of the Note to deliver it to the Trustee. The Trustee may place an appropriate notation on the Note about the changed terms and return it to the Holder. Alternatively, if the
Company or the Trustee so determines, the Company in exchange for the Note shall issue and the Trustee shall authenticate a new Note that reflects the changed terms. 

Section 9.6    Trustee to Sign Amendments, Etc. The Trustee shall sign any
amendment or supplemental indenture authorized pursuant to this Article 9 if the amendment or supplemental indenture does not adversely affect the rights, duties, liabilities or immunities of the Trustee. If it does, the Trustee may, in its sole
discretion, but need not sign it. In signing or refusing to sign such amendment or supplemental indenture, the Trustee shall be provided with and, subject to Section 7.1 hereof, shall be fully protected in relying upon, an Opinion of Counsel
and an Officers’ Certificate stating that such amendment or supplemental indenture is authorized or permitted by this Indenture and all conditions precedent in this Indenture to such execution have been complied with. The Company may not sign
an amendment or supplemental indenture until its Board of Directors approves it in writing. 

Section 9.7    Effect of Supplemental Indentures. Upon the execution of any
supplemental indenture under this Article 9, this Indenture shall be modified in accordance therewith, and such supplemental indenture shall form a part of this Indenture for all purposes; and every Holder of Notes theretofore or thereafter
authenticated and delivered hereunder shall be bound thereby. 
 ARTICLE 10 

NOTE GUARANTEES 
 
Section 10.1    Note Guarantees. 
 (a)    Each of the Note Guarantors, jointly and
severally, hereby unconditionally Guarantees (and subject in each case to the Agreed Guarantee Principles set forth in any notation of Note Guarantee, supplemental indenture, or as contemplated by Section 4.15 hereof) to each Holder of a Note
authenticated and delivered by the 

  
 -69- 

 
Trustee and to the Trustee and its successors and assigns, irrespective of the validity and enforceability of this Indenture, the Notes or the obligations of the Company hereunder or thereunder
that: (i) the due and punctual payment of principal, premium and interest on the Notes shall be promptly paid in full when due, whether at maturity, by acceleration, redemption or otherwise, (ii) the due and punctual payment of interest on
the overdue principal of and interest on the Notes, if any, if lawful, and all other obligations of the Company to the Holders or the Trustee under this Indenture or any Note shall be promptly paid in full or performed, all in accordance with the
terms hereof and thereof, and (iii) in case of any extension of time of payment or renewal of any Notes or any of such other obligations, that same shall be promptly paid in full when due or performed in accordance with the terms of the
extension or renewal, whether at stated maturity, by acceleration pursuant to Section 6.2 hereof or otherwise. Failing payment when due of any amount so guaranteed or any performance so guaranteed for whatever reason, the Note Guarantors shall
be jointly and severally obligated to pay the same immediately. Each Note Guarantor shall agree that this is a Guarantee of payment and not a Guarantee of collection. 

(b)    Each of the Note Guarantors hereby agrees that its obligations with regard to its Guarantee shall be joint and
several, unconditional, irrespective of the validity or enforceability of the Notes or the obligations of the Company under this Indenture, the absence of any action to enforce the same, the recovery of any judgment against the Company or any other
obligor with respect to this Indenture, the Notes or the obligations of the Company under this Indenture or the Notes, any action to enforce the same or any other circumstances (other than complete performance) which might otherwise constitute a
legal or equitable discharge or defense of a Note Guarantor. Each Note Guarantor further, to the extent permitted by law, hereby waives and relinquishes all claims, rights and remedies accorded by applicable law to guarantors and agrees not to
assert or take advantage of any such claims, rights or remedies, including but not limited to: (i) any right to require any of the Trustee, the Holders or the Company (each a “Benefited Party”), as a condition of payment or
performance by such Note Guarantor, to (A) proceed against the Company, any other guarantor (including any other Note Guarantor) of the obligations under the Note Guarantees or any other person, (B) proceed against or exhaust any security
held from the Company, any such other guarantor or any other person, (C) proceed against or have resort to any balance of any deposit account or credit on the books of any Benefited Party in favor of the Company or any other person, or
(D) pursue any other remedy in the power of any Benefited Party whatsoever; (ii) any defense arising by reason of the incapacity, lack of authority or any disability or other defense of the Company including any defense based on or arising
out of the lack of validity or the unenforceability of the obligations under the Note Guarantees or any agreement or instrument relating thereto or by reason of the cessation of the liability of the Company from any cause other than payment in full
of the obligations under the Note Guarantees; (iii) any defense based upon any statute or rule of law which provides that the obligation of a surety must be neither larger in amount nor in other respects more burdensome than that of the
principal; (iv) any defense based upon any Benefited Party’s errors or omissions in the administration of the obligations under the Note Guarantees, except behavior which amounts to bad faith; (v) (A) any principles or provisions
of law, statutory or otherwise, which are or might be in conflict with the terms of the Note Guarantees and any legal or equitable discharge of such Note Guarantor’s obligations hereunder and under its Note Guarantee, (B) the benefit of
any statute of limitations affecting such Note Guarantor’s liability hereunder and under its Note Guarantee or the enforcement hereof and thereof, (C) any rights to set-offs, recoupments and
counterclaims and (D) promptness, diligence and any requirement that any Benefited Party protect, secure, perfect or insure any security interest or lien or any property subject thereto; (vi) notices, demands, presentations, protests,
notices of protest, notices of dishonor and notices of any action or inaction, including acceptance of the Note Guarantees, notices of default under the Notes or any agreement or instrument related thereto, notices of any renewal, extension or
modification of the obligations under the Note Guarantees or any agreement related thereto, and notices of any extension of credit to the Company and any right to consent to any thereof; (vii) to the extent permitted under applicable law, the
benefits of any “One Action” rule; and (viii) any defenses or benefits that may be derived from or afforded by law which limit the liability of or exonerate guarantors or sureties, or which may conflict with the terms of the Note
Guarantees. Except as set forth in Section 10.5, each Note Guarantor covenants that its Note Guarantee shall not be discharged except by complete performance of the obligations contained in its Note Guarantee and this Indenture. 

(c)    If any Holder or the Trustee is required by any court or otherwise to return to the Company, the Note Guarantors or
any custodian, trustee, liquidator or other similar official acting in relation to either the Company or the Note Guarantors, any amount paid to either the Trustee or such Holder, any Guarantee, to the extent theretofore discharged, shall be
reinstated in full force and effect. 

  
 -70- 

 (d)    Each Note Guarantor agrees that it shall not be entitled to any right
of subrogation in relation to the Holders in respect of any obligations guaranteed hereby until payment in full of all obligations guaranteed hereby. Each Note Guarantor shall further agree that, as between the Note Guarantors, on the one hand, and
the Holders and the Trustee, on the other hand, (i) the maturity of the obligations guaranteed hereby may be accelerated as provided in Section 6.2 hereof for the purposes of any Guarantee, notwithstanding any stay, injunction or other
prohibition preventing such acceleration in respect of the obligations guaranteed hereby and (ii) in the event of any declaration of acceleration of such obligations as provided in Section 6.2 hereof, such obligations (whether or not due
and payable) shall forthwith become due and payable by the Note Guarantors for the purpose of any such Guarantee. The Note Guarantors shall have the right to seek contribution from any non-paying Note
Guarantor so long as the exercise of such right does not impair the rights of the Holders under the applicable Guarantee. 
 
Section 10.2    Execution and Delivery of Note Guarantees. To evidence its Guarantee set forth in Section 10.1 hereof, each Note Guarantor hereby agrees that a notation of such Note Guarantee substantially in
the form of Exhibit B hereto (as modified to reflect Agreed Guarantee Principles to the extent contemplated by Section 4.15) or, in the case of a Note Guarantor organized under the laws of Canada or any province or
territory thereof, a Canadian Note Guarantee, shall be endorsed by an officer of such Note Guarantor, which notation shall be applicable to each Note authenticated and delivered by the Trustee, and that this Indenture shall be executed on behalf of
such Note Guarantor by any of its Officers. Each of the Note Guarantors, jointly and severally, hereby agrees that its Guarantee set forth in Section 10.1 hereof shall remain in full force and effect notwithstanding any failure to endorse a
notation of such Note Guarantee. If an officer or Officer whose signature is on this Indenture or on the Note Guarantee of a Note Guarantor no longer holds that office at the time the Trustee authenticates a Note, the Note Guarantee of such Note
Guarantor shall be valid nevertheless. The delivery of any Note by the Trustee, after the authentication thereof hereunder, shall constitute due delivery of the Note Guarantees set forth in this Indenture on behalf of the Note Guarantors. 

Section 10.3    Limitation on Note Guarantor Liability. Each Note Guarantor
confirms, and by its acceptance of Notes, each Holder hereby confirms, that it is the intention of all such parties that any Guarantee of such Note Guarantor not constitute a fraudulent transfer or conveyance for purposes of Bankruptcy Law, the
Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act or any similar applicable law to the extent applicable to any Note Guarantee. To effectuate the foregoing intention, the Trustee and the Holders irrevocably agree, and the Note
Guarantors irrevocably agree, that the obligations of such Note Guarantor under this Article 10 shall be limited to the maximum amount as will, after giving effect to such maximum amount and all other contingent and fixed liabilities of such Note
Guarantor that are relevant under such laws, and after giving effect to any collections from, rights to receive contribution from or payments made by or on behalf of any other Note Guarantor in respect of the obligations of such other Note Guarantor
under this Article 10, result in the obligations of such Note Guarantor under its Note Guarantee not constituting a fraudulent transfer or conveyance. 

Section 10.4    Merger and Consolidation of Note Guarantors. 

(a)    In case of any sale or other disposition, consolidation, amalgamation, merger, sale or conveyance and upon the
assumption by the successor person, by supplemental indenture, executed and delivered to the Trustee and satisfactory in form to the Trustee, of the Note Guarantee endorsed upon the Notes and the due and punctual performance of all of the covenants
and conditions of this Indenture to be performed by the Note Guarantor, such successor person shall succeed to and be substituted for the Note Guarantor with the same effect as if it had been named herein as a Note Guarantor. Such successor person
thereupon may cause to be signed any or all of the Note Guarantees to be endorsed upon all of the Notes available hereunder which theretofore shall not have been signed by the Company and delivered to the Trustee. All the Note Guarantees so issued
shall in all respects have the same legal rank and benefit under this Indenture as the Note Guarantees theretofore and thereafter issued in accordance with the terms of this Indenture as though all of such Note Guarantees had been issued at the date
of the execution hereof. 
 (b)    Except as set forth in Articles 4 and 5 hereof, and notwithstanding
clause (a) of this Section 10.4, nothing contained in this Indenture or in any of the Notes shall prevent any consolidation, amalgamation or merger of a Note Guarantor with or into the Company or another Note Guarantor, or shall prevent
any sale or conveyance of the property of a Note Guarantor as an entirety or substantially as an entirety to the Company or another Note Guarantor. 

  
 -71- 

 Section 10.5    Release. 

(a)    In the event (i) of a sale or other disposition of all or substantially all of the assets of any Note
Guarantor, by way of merger, amalgamation, consolidation or otherwise, or a sale or other disposition of all the Equity Interests of any Note Guarantor, then held by the Company and its Restricted Subsidiaries to a person that is not (either before
or after giving effect to such transactions) a Subsidiary of the Company, in each case so long as such sale or other disposition is permitted by this Indenture, including without limitation Section 4.14 hereof, (ii) of a designation by the
Company of any Restricted Subsidiary that is a Note Guarantor as an Unrestricted Subsidiary in accordance with the definition thereof or in the event that such Note Guarantor ceases to be a Restricted Subsidiary in accordance with the provisions of
this Indenture, (iii) in the case of any Guarantee issued on the Issue Date, upon the release or discharge of the Guarantee by such Note Guarantor in respect of the Credit Agreement, and in any other case upon the release or discharge of any
Guarantee in respect of any Indebtedness that resulted in the issuance after the Issue Date of the Note Guarantee by such Note Guarantor or (iv) the Company discharges the Notes and its Obligations under this Indenture under Section 8.1 or
exercises its legal or covenant defeasance options under Section 8.2 or 8.3, respectively, with respect to the Notes, such Note Guarantor shall be released and relieved of any obligations under its Note Guarantee without any further action
being required by the Trustee or any Holder. If the Company discharges this Indenture under Section 8.1 or exercises its legal or covenant defeasance options under Section 8.2 or 8.3, each Note Guarantor shall be released and relieved
of any obligations under its Note Guarantee without any further action being required by the Trustee or any Holder. 

(b)    Upon delivery by the Company to the Trustee of an Officers’ Certificate and an Opinion of Counsel to the
effect that such sale or other disposition was made by the Company in accordance with the provisions of this Indenture, including without limitation Sections 4.8 and 4.14 hereof, the Trustee shall execute any documents reasonably required in order
to evidence the release of any Note Guarantor from its obligations under its Guarantee. 
 (c)    Any Note Guarantor not
released from its obligations under its Note Guarantee shall remain liable for the full amount of principal of and interest on the Notes and for the other obligations of any Note Guarantor under this Indenture as provided in this Article 10.

 ARTICLE 11 

MISCELLANEOUS 
 
Section 11.1    Certain Trust Indenture Act Sections. The Company shall comply with Sections 314(a)(4), 314(c) and 314(e) of the TIA. No other provision of the TIA shall apply except where otherwise specifically
provided. 
 Section 11.2    Notices. Any demand, authorization notice,
request, consent or communication shall be given in writing and delivered in person or mailed by first-class mail, postage prepaid, addressed as follows or transmitted by facsimile transmission (confirmed by delivery in person or mail by first-class
mail, postage prepaid, or by guaranteed overnight courier) to the following facsimile numbers: 
 If to the Company, to: 

Valeant Pharmaceuticals International, Inc. 

400 Somerset Corporate Boulevard 

Bridgewater, NJ 08807 

Attention: Corporate Secretary 

Facsimile No.: (949) 461-6661 

  
 -72- 

 With a copy to: 

Davis Polk & Wardwell LLP 

450 Lexington Avenue 
 New York,
New York 10017 
 Attention: Michael Kaplan 

Facsimile No.: (212) 701-5111 

If to the Trustee, to: 
 The Bank
of New York Mellon 
 101 Barclay Street, Floor 7E 

New York, New York 10286 
 Attn:
Corporate Trust Administration 
 Facsimile No.: (212) 815-5366 

Such notices or communications shall be effective when received. 

The Company or the Trustee by notice to the other may designate additional or different addresses for subsequent notices or communications.

 Any notice or communication mailed to a Holder shall be mailed by first-class mail or delivered by an overnight delivery service to it at
its address shown on the register kept by the Registrar. 
 Failure to mail a notice or communication to a Holder or any defect in it shall
not affect its sufficiency with respect to other Holders. If a notice or communication to a Holder is mailed in the manner provided above, it is duly given, whether or not the addressee receives it. 

The Trustee agrees to accept and act upon instructions or directions pursuant to this Indenture sent by unsecured e-mail, facsimile transmission or other similar unsecured electronic methods (including pdf files). If the party elects to give the Trustee e-mail or facsimile instructions
(or instructions by a similar electronic method) and the Trustee in its discretion elects to act upon such instructions, the Trustee’s understanding of such instructions shall be deemed controlling. The Trustee shall be liable for any losses,
costs or expenses arising directly or indirectly from such party’s reliance upon and compliance with such instructions notwithstanding such instructions conflict or are inconsistent with a subsequent written instruction. The party providing
electronic instructions agrees to assume all risks arising out of the use of such electronic methods to submit instructions and directions to the Trustee including without limitation the risk of the Trustee acting on unauthorized instructions, and
the risk or interception and misuse by third parties. 
 Notwithstanding anything to the contrary contained herein, as long as the Notes are
in the form of a Global Note, notice to the Holders of such Notes may be made electronically in accordance with procedures of the Depositary. 

Section 11.3    Communications by Holders With Other Holders. Noteholders may
communicate pursuant to TIA Section 312(b) with other Noteholders with respect to their rights under this Indenture or the Notes. The Company, the Trustee, the Registrar and any other person shall have the protection of TIA Section 312(c).

 Section 11.4    Certificate and Opinion of Counsel as to Conditions
Precedent. 
 (a)    Upon any request or application by the Company to the Trustee to take any action under this
Indenture other than the initial issuance of the Notes and the Note Guarantees, the Company shall furnish to the Trustee at the request of the Trustee: 

  
 -73- 

 (A)    an Officers’ Certificate stating that, in the
opinion of the signers, all conditions precedent (including any covenants, compliance with which constitutes a condition precedent), if any, provided for in this Indenture relating to the proposed action have been complied with; and 

(B)    an Opinion of Counsel stating that, in the opinion of such counsel, all such conditions precedent
(including any covenants, compliance with which constitutes a condition precedent) have been complied with. 

(b)    Each Officers’ Certificate and Opinion of Counsel with respect to compliance with a condition or covenant
provided for in this Indenture shall include: 
 (A)    a statement that the person making such
certificate or opinion has read such covenant or condition; 
 (B)    a brief statement as to the nature
and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based; 

(C)    a statement that, in the opinion of such person, he or she has made such examination or
investigation as is necessary to enable him or her to express an informed opinion as to whether or not such covenant or condition has been complied with; and 

(D)    a statement as to whether or not, in the opinion of such person, such condition or covenant has been
complied with; 
 provided, however, that with respect to matters of fact an Opinion of Counsel may rely on an Officers’ Certificate or
certificates of public officials. 
 Section 11.5    Record Date for Vote or
Consent of Holders. The Company (or, in the event deposits have been made pursuant to Section 8.1, 8.2 or 8.3 hereof, the Trustee) may set a record date for purposes of determining the identity of Holders of Notes entitled to vote or
consent to any action by vote or consent authorized or permitted under this Indenture, which record date shall not be more than thirty (30) days prior to the date of the commencement of solicitation of such action. Notwithstanding the
provisions of Section 9.4 hereof, if a record date is fixed, those persons who were Holders of Notes at the close of business on such record date (or their duly designated proxies), and only those persons, shall be entitled to take such action
with respect to the Notes by vote or consent or to revoke any vote or consent previously given, whether or not such persons continue to be Holders of Notes after such record date. 

Section 11.6    Rules by Trustee, Paying Agent and Registrar. The Trustee may
make reasonable rules (not inconsistent with the terms of this Indenture) for action by or at a meeting of Holders. Any Registrar or Paying Agent may make reasonable rules for its functions. 

Section 11.7    Legal Holidays. A “Legal Holiday” is a
Saturday, Sunday, or a day on which state or federally chartered banking institutions in New York, New York, Montreal, Canada or, if applicable, the state in which the Corporate Trust Office is located are not required to be open. If a payment date,
including any Redemption Date, Purchase Date, Change of Control Purchase Date and Final Maturity Date, is a Legal Holiday, payment shall be made on the next succeeding day that is not a Legal Holiday, and no interest shall accrue for the intervening
period on such payment. If an interest record date is a Legal Holiday, the record date shall not be affected. 

Section 11.8    Governing Law; Submission to Jurisdiction; Waiver of Jury Trial.

 (a)    Unless specifically noted herein, this Indenture and the Notes shall be governed by, and construed in
accordance with, the laws of the State of New York, without regard to principles of conflicts of laws. 

  
 -74- 

 (b)    The Company irrevocably submits to the
non-exclusive jurisdiction of any New York State or United States Federal court sitting in The City of New York over any suit, action or proceeding arising out of or relating to this Indenture. The Company
irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of venue of any such suit, action or proceeding brought in such a court and any claim that any such suit, action or proceeding
brought in such a court has been brought in an inconvenient forum. 
 (c)    EACH OF THE COMPANY AND THE TRUSTEE HEREBY
IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES, OR THE TRANSACTION CONTEMPLATED HEREBY. 

Section 11.9    No Adverse Interpretation of Other Agreements. This Indenture
may not be used to interpret another indenture, loan or debt agreement of the Company or a Subsidiary of the Company. Any such indenture, loan or debt agreement may not be used to interpret this Indenture. 

Section 11.10    No Recourse Against Others. All liability described in
paragraph 13 of the Form of the Notes attached hereto as Exhibit A of any director, officer, employee or shareowner, as such, of the Company or any Note Guarantor is waived and released. 

Section 11.11    Successors. All agreements of the Company in this Indenture and
the Notes shall bind their successors. All agreements of the Trustee in this Indenture shall bind its successor. 
 
Section 11.12    Multiple Counterparts. The parties may sign multiple counterparts of this Indenture. Each signed counterpart shall be deemed an original, but all of them together represent the same agreement.

 Section 11.13    Separability. In case any provisions in this Indenture or
in the Notes shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

Section 11.14    Table of Contents, Headings, etc. The table of contents and
headings of the Articles and Sections of this Indenture have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof. 

Section 11.15    Calculations in Respect of the Notes. The Company shall make
all calculations under this Indenture and the Notes in good faith. In the absence of manifest error, such calculations shall be final and binding on all Holders. The Company shall provide a copy of such calculations to the Trustee as required
hereunder. 
 Section 11.16    Agent for Service and Waiver of Immunities. By
the execution and delivery of this Indenture, the Company and each Note Guarantor that is not a Domestic Subsidiary, within 10 days of becoming a Note Guarantor that is not a Domestic Subsidiary, as applicable, will (i) acknowledge that they
will designate and appoint Valeant Pharmaceuticals North America LLC, 400 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807, or another Person satisfactory to the Trustee (the “Authorized Agent”), as their authorized
agent upon whom process may be served in any suit or proceeding arising out of or relating to this Indenture or the Notes that may be instituted in any federal or state court in the State of New York or brought under federal or state securities
laws, and acknowledge that the Authorized Agent has accepted such designation, (ii) submit to the jurisdiction of any such court in any such suit or proceeding, and (iii) agree that service of process upon the Authorized Agent and written
notice of said service to the Company or the Note Guarantor that is not a Domestic Subsidiary, as applicable, in accordance with Section 11.2 shall be deemed effective service of process in any such suit or proceeding. The Company and each Note
Guarantor that is not a Domestic Subsidiary further agrees to take any reasonable action, including the execution and filing of any and all such documents and instruments, as may be necessary to continue such designation and appointment of the
Authorized Agent in full force and effect so long as any of the Notes shall be outstanding; provided, however, that the Company and each Note Guarantor that is not a Domestic Subsidiary, as applicable, may, by written notice to the
Trustee, designate such additional or alternative agent for service of process 

  
 -75- 

 
under this Section 11.16 that (i) maintains an office located in the Borough of Manhattan, The City of New York, in the State of New York, (ii) is either (x) counsel for the
Company or such Note Guarantor, as applicable or (y) a corporate service company which acts as agent for service of process for other persons in the ordinary course of its business and (iii) agrees to act as agent for service of process in
accordance with this Section 11.16. Such written notice shall identify the name of such agent for process and the address of the office of such agent for process in the Borough of Manhattan, The City of New York, State of New York. Upon the
written request of any Holder, the Trustee shall deliver a copy of such notice to such Holder. 

Section 11.17    Judgment Currency. The Company and each Note Guarantor shall
indemnify each Holder and each Person, if any, who controls any Holder within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any loss incurred by such party as a result of any judgment or order
being given or made against the Company or any Note Guarantor for any U.S. dollar amount due under this Indenture and such judgment or order being expressed and paid in a currency (the “Judgment Currency”) other than U.S. dollars
and as a result of any variation as between (i) the rate of exchange at which the U.S. dollar amount is converted into the Judgment Currency for the purpose of such judgment or order and (ii) the spot rate of exchange in The City of
New York at which such party on the date of payment of such judgment or order is able to purchase U.S. dollars with the amount of the Judgment Currency actually received by such party if such party had utilized such amount of Judgment Currency
to purchase U.S. dollars upon such party’s receipt thereof. The foregoing indemnity shall continue in full force and effect notwithstanding any such judgment or order as aforesaid. The term “spot rate of exchange” shall include any
premiums and costs of exchange payable in connection with the purchase of, or conversion into, U.S. dollars. 

Section 11.18    Foreign Currency Equivalent. For purposes of determining
compliance with any U.S. dollar-denominated restriction or amount, the U.S. dollar equivalent principal amount of any amount denominated in a foreign currency will be the Dollar Equivalent calculated on the date the Indebtedness was incurred or
other transaction was entered into; provided that if any Permitted Refinancing Indebtedness denominated in a currency other than U.S. dollars is incurred to refinance Indebtedness denominated in the same currency, and such refinancing would
cause the applicable U.S. dollar-denominated restriction to be exceeded if calculated on the date of such refinancing, such Permitted Refinancing Indebtedness shall be deemed not to exceed the principal amount of such Indebtedness being refinanced.
Notwithstanding any other provision in this Indenture, no restriction or amount will be exceeded solely as a result of fluctuations in the exchange rate of currencies. 

Section 11.19    Usury Savings Clause. If any provision of this Indenture or any
Note would obligate the Company to make any payment of or on account of interest or other amount in an amount or calculated at a rate which would result in a receipt by any Holder of interest at a criminal rate (as such term is construed under the
Criminal Code (Canada)), then notwithstanding such provisions, such amount or rate shall be deemed to have been adjusted with retroactive effect to the maximum amount or rate of interest, as the case may be, as would not so result in a
receipt by such Holder of interest at a criminal rate, such adjustment to be effected, to the extent necessary, as follows: (1) firstly, by reducing the amount or rate of interest required to be paid to such Holder, and (2) thereafter, by
reducing any fees, commissions, premiums and other amounts required to be paid to such Holder which would constitute “interest” for purposes of Section 347 of the Criminal Code (Canada). 

Section 11.20    Interest Act (Canada). For purposes of disclosure pursuant to
the Interest Act (Canada), the annual rates of interest or fees to which the rates of interest or fees provided for in this Indenture and any Note (and stated herein or therein, as applicable, to be computed on the basis of a 360 day year or
any other period of time less than a calendar year) are equivalent are the rates so provided for multiplied by the actual number of days in the applicable calendar year and divided by 360 or the actual number of days in such other period of time,
respectively. 

  
 -76- 

 Section 11.21    Tax Matters. Each
of the parties hereto agree to cooperate and to provide the other with such information as each may have in its possession to enable the determination of whether any payments pursuant to this Indenture are subject to the withholding requirements
described in Section 1471(b) of the Code or otherwise imposed pursuant to Sections 1471 through 1474 of the Code and any regulations, or agreements thereunder or official interpretations thereof (“Applicable Law”). The Trustee
shall be entitled to make any withholding or deduction from payments under this Indenture to the extent necessary to comply with Applicable Law. Nothing in the immediately preceding sentence shall be construed as obligating the Trustee to make any
“gross up” payment or similar reimbursement in connection with a payment in respect of which amounts are so withheld or deducted or affecting a Payor’s obligation to make any payments of Additional Amount pursuant to Section 4.21
of this Indenture. 
 [SIGNATURE PAGES FOLLOW] 

  
 -77- 

 IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed as of the
date and year first above written. 
  

					
	VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer

  
 [Signature Page to
Indenture] 

 
					
	GUARANTORS:
	
	VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	VALEANT PHARMACEUTICALS INTERNATIONAL
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	BAUSCH & LOMB INCORPORATED
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	BAUSCH & LOMB HOLDINGS INCORPORATED
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Vice President and Treasurer
	
	SOLTA MEDICAL, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer

  
 [Signature Page to Indenture] 

 
					
	ATON PHARMA, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	CORIA LABORATORIES, LTD.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	DOW PHARMACEUTICAL SCIENCES, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	ONPHARMA INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer

  
 [Signature Page to Indenture] 

					
	Signed by	 		 	
	Valeant Holdco 2 Pty Ltd (ACN 154 341 367)	 		 	
	 in accordance with section 127 of the 

Corporations Act 2001 by two directors:
	 		 	
			
	/s/ Avinesh Prasad	 	  
	 	/s/ Linda A. LaGorga
	Signature of director	 		 	Signature of director
			
	Avinesh Prasad	 	  
	 	Linda A. LaGorga
	Name of director (please print)	 		 	Name of director (please print)
			
	Signed by	 		 	
	Wirra Holdings Pty Limited (ACN 122 216 577)	 		 	
	 in accordance with section 127 of the 

Corporations Act 2001 by two directors:
	 		 	
			
	/s/ Avinesh Prasad	 	  
	 	/s/ Linda A. LaGorga
	Signature of director	 		 	Signature of director
			
	Avinesh Prasad	 	  
	 	Linda A. LaGorga
	Name of director (please print)	 		 	Name of director (please print)
			
	Signed by	 		 	
	Wirra Operations Pty Limited (ACN 122 250 088)	 		 	
	 in accordance with section 127 of the 

Corporations Act 2001 by two directors:
	 		 	
			
	/s/ Avinesh Prasad	 	  
	 	/s/ Linda A. LaGorga
	Signature of director	 		 	Signature of director
			
	Avinesh Prasad	 	  
	 	Linda A. LaGorga
	Name of director (please print)	 		 	Name of director (please print)

  
 [Signature Page to Indenture] 

					
	Signed by	 		 	
	Wirra IP Pty Limited (ACN 122 536 350)	 		 	
	 in accordance with section 127 of the 

Corporations Act 2001 by two directors:
	 		 	
			
	/s/ Avinesh Prasad	 	  
	 	/s/ Linda A. LaGorga
	Signature of director	 		 	Signature of director
			
	Avinesh Prasad	 	  
	 	Linda A. LaGorga
	Name of director (please print)	 		 	Name of director (please print)
			
	Signed by	 		 	
	Bausch & Lomb (Australia) Pty Limited (ACN 000 222 408)	 		 	
	 in accordance with section 127 of the 

Corporations Act 2001 by two directors:
	 		 	
			
	/s/ Avinesh Prasad	 	  
	 	/s/ Linda A. LaGorga
	Signature of director	 		 	Signature of director
			
	Avinesh Prasad	 	  
	 	Linda A. LaGorga
	Name of director (please print)	 		 	Name of director (please print)

  
 [Signature Page to Indenture] 

					
	Signed by	 		 	
	 Valeant Pharmaceuticals Australasia Pty Limited

(ACN 001 083 352)
	 		 	
	 in accordance with section 127 of the 

Corporations Act 2001 by a director and

secretary/director:
	 		 	
			
	/s/ Avinesh Prasad	 	  
	 	/s/ Linda A. LaGorga
	Signature of director	 		 	Signature of director/secretary
			
	Avinesh Prasad	 	  
	 	Linda A. LaGorga
	Name of director (please print)	 		 	Name of director/secretary (please print)
			
	Signed by	 		 	
	DermaTech Pty Limited (ACN 003 982 161)	 		 	
	 in accordance with section 127 of the 

Corporations Act 2001 by a director and

secretary/director:
	 		 	
			
	/s/ Avinesh Prasad	 	  
	 	/s/ Linda A. LaGorga
	Signature of director	 		 	Signature of director/secretary
			
	Avinesh Prasad	 	  
	 	Linda A. LaGorga
	Name of director (please print)	 		 	Name of director/secretary (please print)
			
	Signed by	 		 	
	 Private Formula International Holdings Pty Ltd

(ACN 095 450 918)
	 		 	
	 in accordance with section 127 of the 

Corporations Act 2001 by a director and

secretary/director:
	 		 	
			
	/s/ Avinesh Prasad	 	  
	 	/s/ Linda A. LaGorga
	Signature of director	 		 	Signature of director/secretary
			
	Avinesh Prasad	 	  
	 	Linda A. LaGorga
	Name of director (please print)	 		 	Name of director/secretary (please print)

  
 [Signature Page to Indenture] 

					
	Signed by	 		 	
	Private Formula International Pty Ltd (ACN 095 451 442)	 		 	
	 in accordance with section 127 of the

Corporations Act 2001 by a director and

secretary/director:
	 		 	
			
	/s/ Avinesh Prasad	 	  
	 	/s/ Linda A. LaGorga
	Signature of director	 		 	Signature of director/secretary
			
	Avinesh Prasad	 	  
	 	Linda A. LaGorga
	Name of director (please print)	 		 	Name of director/secretary (please print)
			
	Signed by	 		 	
	Ganehill Pty Ltd (ACN 065 261 538)	 		 	
	 in accordance with section 127 of the

Corporations Act 2001 by a director and

secretary/director:
	 		 	
			
	/s/ Avinesh Prasad	 	  
	 	/s/ Linda A. LaGorga
	Signature of director	 		 	Signature of director/secretary
			
	Avinesh Prasad	 	  
	 	Linda A. LaGorga
	Name of director (please print)	 		 	Name of director/secretary (please print)
			
	Signed by	 		 	
	Valeant (Australia) Pty Limited (ACN 000 650 251)	 		 	
	 in accordance with section 127 of the 

Corporations Act 2001 by a director and

secretary/director:
	 		 	
			
	/s/ Avinesh Prasad	 	  
	 	/s/ Linda A. LaGorga
	Signature of director	 		 	Signature of director/secretary
			
	Avinesh Prasad	 	  
	 	Linda A. LaGorga
	Name of director (please print)	 		 	Name of director/secretary (please print)

  
 [Signature Page to Indenture] 

 
					
	HYTHE PROPERTY INCORPORATED
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Director

  
 [Signature Page to Indenture] 

 
					
	VALEANT PHARMACEUTICALS NOMINEE BERMUDA
		
	By:	 	/s/ Graham Jackson
		 	Name:	 	Graham Jackson
		 	Title:	 	Director

  
 [Signature Page to Indenture] 

 
					
	PROBIÓTICA LABORATÓRIOS LTDA.
		
	By:	 	/s/ Carlos Alberto Andrade Pires da Silva
		 	Name:	 	Carlos Alberto Andrade Pires da Silva
		 	Title:	 	Officer

  
 [Signature Page to Indenture] 

 
					
	TECHNOLAS PERFECT VISION, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Treasurer
	
	BAUSCH & LOMB PHARMA HOLDINGS CORP.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Treasurer
	
	BAUSCH & LOMB CHINA, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Treasurer
	
	BAUSCH & LOMB SOUTH ASIA, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Treasurer
	
	BAUSCH & LOMB TECHNOLOGY CORPORATION
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Treasurer

  
 [Signature Page to Indenture] 

 
					
	RHC HOLDINGS, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Treasurer
	
	SIGHT SAVERS, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Treasurer
	
	BAUSCH & LOMB INTERNATIONAL, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Treasurer
	
	BAUSCH & LOMB REALTY CORPORATION
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Treasurer
	
	ISTA PHARMACEUTICALS, LLC
		
	By:	 	Bausch & Lomb Pharma Holdings Corporation, its member
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Treasurer

  
 [Signature Page to Indenture] 

 
					
	VRX HOLDCO, LLC
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Treasurer

  
 [Signature Page to
Indenture] 

 
					
	VALEANT CANADA GP LIMITED
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	VALEANT CANADA S.E.C./VALEANT CANADA LP
		
	By:	 	Valeant Canada GP Limited, its general partner
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda LaGorga
		 	Title:	 	Senior Vice President and
		 		 	Treasurer
	
	V-BAC HOLDING CORP.
		
	By:	 	/s/ Jeremy Lipshy
		 	Name:	 	Jeremy Lipshy
		 	Title:	 	Vice President
	
	0938638 B.C. ULC
		
	By:	 	/s/ D. Alexander Matheson
		 	Name:	 	D. Alexander Matheson
		 	Title:	 	Assistant Secretary

  
 [Signature Page to
Indenture] 

 
					
	MEDICIS PHARMACEUTICAL CORPORATION
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	OCEANSIDE PHARMACEUTICALS, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	DR. LEWINN’S PRIVATE FORMULA INTERNATIONAL, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	PRINCETON PHARMA HOLDINGS, LLC
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	PRIVATE FORMULA CORP.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	RENAUD SKIN CARE LABORATORIES, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer

  
 [Signature Page to
Indenture] 

 
					
	VALEANT BIOMEDICALS, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	VALEANT PHARMACEUTICALS NORTH AMERICA LLC
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	ORAPHARMA, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	ORAPHARMA TOPCO HOLDINGS, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	PRESTWICK PHARMACEUTICALS, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer

  
 [Signature Page to
Indenture] 

 
					
	SALIX PHARMACEUTICALS, LTD.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	SALIX PHARMACEUTICALS, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	OCEANA THERAPEUTICS, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	SANTARUS, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	INKINE PHARMACEUTICAL COMPANY, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer

  
 [Signature Page to
Indenture] 

 
					
	COVELLA PHARMACEUTICALS, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer

  
 [Signature Page to
Indenture] 

 
					
	BIOVAIL INTERNATIONAL S.Á.R.L.
		
	By:	 	/s/ Daniela Italia
		 	Name:	 	Daniela Italia
		 	Title:	 	Manager
	
	VALEANT PHARMACEUTICALS LUXEMBOURG S.Á.R.L.
		
	By:	 	/s/ Daniela Italia
		 	Name:	 	Daniela Italia
		 	Title:	 	Class B Manager
	
	VALEANT INTERNATIONAL LUXEMBOURG S.Á.R.L.
		
	By:	 	/s/ Daniela Italia
		 	Name:	 	Daniela Italia
		 	Title:	 	Class B Manager
	
	BAUSCH & LOMB LUXEMBOURG S.Á.R.L.
		
	By:	 	/s/ Daniela Italia
		 	Name:	 	Daniela Italia
		 	Title:	 	Class B Manager
	
	VALEANT FINANCE LUXEMBOURG S.À R.L.
		
	By:	 	/s/ Daniela Italia
		 	Name:	 	Daniela Italia
		 	Title:	 	Class B Manager
	
	VALEANT HOLDINGS LUXEMBOURG S.À R.L.
		
	By:	 	/s/ Daniela Italia
		 	Name:	 	Daniela Italia
		 	Title:	 	Class B Manager

  
 [Signature Page to
Indenture] 

 
					
	LABORATOIRE CHAUVIN S.A.S.
		
	By:	 	/s/ Linda LaGorga
		 	Name:	 	Linda LaGorga
		 	Title:	 	General Manager
	
	BAUSCH & LOMB FRANCE S.A.S.
		
	By:	 	/s/ Linda LaGorga
		 	Name:	 	Linda LaGorga
		 	Title:	 	General Manager
	
	BCF S.A.S.
		
	By:	 	/s/ Linda LaGorga
		 	Name:	 	Linda LaGorga
		 	Title:	 	General Manager

  
 [Signature Page to
Indenture] 

 
					
	VALEANT PHARMA HUNGARY LLC
		
	By:	 	/s/ dr. Gárdi Lajos István
		 	Name:	 	dr. Gárdi Lajos István
		 	Title:	 	General Manager
		
	By:	 	/s/ Zoltán Gábor
		 	Name:	 	Zoltán Gábor
		 	Title:	 	Finance Director

  
 [Signature Page to
Indenture] 

 
					
	VALEANT PHARMACEUTICALS IRELAND LIMITED
		
	By:	 	/s/ Michael Kennan
		 	Name:	 	Michael Kennan
		 	Title:	 	Director
	
	VALEANT HOLDINGS IRELAND
		
	By:	 	/s/ Michael Kennan
		 	Name:	 	Michael Kennan
		 	Title:	 	Director

  
 [Signature Page to
Indenture] 

 
					
	 OCEANA THERAPEUTICS, LIMITED

		
	By:	 	/s/ Linda LaGorga
		 	Name:	 	Linda LaGorga
		 	Title:	 	Director

  
 [Signature Page to
Indenture] 

 
					
	B.L.J. COMPANY, LTD.
		
	By:	 	/s/ Linda LaGorga
		 	Name:	 	Linda LaGorga
		 	Title:	 	Director

  
 [Signature Page to
Indenture] 

 
					
	AB SANITAS
		
	By:	 	/s/ Tomas Liesis
		 	Name:	 	Tomas Liesis
		 	Title:	 	General Manager

  
 [Signature Page to
Indenture] 

 
					
	UCYCLYD PHARMA, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer

  
 [Signature Page to
Indenture] 

 
					
	BAUSCH + LOMB OPS B.V.
		
	By:	 	/s/ Patrick Emanuel Petrus Jacobus Günther
		 	Name:	 	Patrick Emanuel Petrus Jacobus Günther
		 	Title:	 	Attorney-in-fact

  
 [Signature Page to
Indenture] 

 
					
	PRZEDSIĘBIORSTWO FARMACEUTYCZNE JELFA S.A.
		
	By:	 	/s/ Waldemar Stępień
		 	Name:	 	Waldemar Stępień
		 	Title:	 	President of the Management Board
		
	By:	 	/s/ Ryszard Bukowski
		 	Name:	 	Ryszard Bukowski
		 	Title:	 	Member of the Management Board
	
	VALEANT SP.Z O. O.
		
	By:	 	/s/ Tadeusz Pietrasz
		 	Name:	 	Tadeusz Pietrasz
		 	Title:	 	Member of the Management Board
	
	VP VALEANT SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ SP.J.
		
	By:	 	Valeant sp. z o.o., in its capacity as General Partner
		
	By:	 	/s/ Tadeusz Pietrasz
		 	Name:	 	Tadeusz Pietrasz
		 	Title:	 	Member of the Management Board
	
	VALEANT PHARMA POLAND SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
		
	By:	 	/s/ Tadeusz Pietrasz
		 	Name:	 	Tadeusz Pietrasz
		 	Title:	 	Member of the Management Board

  
 [Signature Page to
Indenture] 

 
					
	PHARMASWISS D.O.O.
		
	By:	 	/s/ Aljoša Tovornik
		 	Name:	 	Aljoša Tovornik
		 	Title:	 	Director

  
 [Signature Page to
Indenture] 

 
					
	PHARMASWISS SA
		
	By:	 	/s/ Matthias Courvoisier
		 	Name:	 	Matthias Courvoisier
		 	Title:	 	Director
	
	BAUSCH & LOMB SWISS AG
		
	By:	 	/s/ Matthias Courvoisier
		 	Name:	 	Matthias Courvoisier
		 	Title:	 	Member of the Board of Directors

  
 [Signature Page to
Indenture] 

 
	
	Executed by BAUSCH & LOMB U.K. LIMITED, acting by:
	
	/s/ Linda A. LaGorga
	Director
	
	Name of director: Linda A. LaGorga in the presence of:
	
	/s/ Kirsten O’Donnell
	Name of witness: Kirsten O’Donnell

  
 [Signature Page to
Indenture] 

 
					
	BAUSCH & LOMB IOM S.P.A.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Director

  
 [Signature Page to
Indenture] 

													
	 SIGNED for and on behalf
	  	 	)	 	 		  		 		  	
	of VALEANT PHARMACEUTICALS	  	 	)	 	 		 	
	NEW ZEALAND LIMITED 	  	 	)	 	 	/s/ Linda A. LaGorga	 	/s/ Christina Ackermann
	 	  	 	 	 	Name:	  	Linda A. LaGorga	 	Name:	  	Christina Ackermann
	 	  	 	 	 	Title:	  	Director	 	Title:	  	Director

  
 [Signature Page to
Indenture] 

 
					
	BAUSCH & LOMB NORDIC AB
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Director

  
 [Signature Page to
Indenture] 

 
					
	VALEANT LLC
		
	By:	 	/s/ John Connolly
		 	Name:	 	John Connolly
		 	Title:	 	General Director

  
 [Signature Page to
Indenture] 

 
					
	DR. GERHARD MANN CHEM.-PHARM. FABRIK GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Managing Director
	
	BAUSCH & LOMB GMBH
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Managing Director
	
	B L E P HOLDING GMBH
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Managing Director
	
	TECHNOLAS PERFECT VISION GMBH
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Managing Director

  
 [Signature Page to
Indenture] 

 
					
	BAUSCH & LOMB MEXICO, S.A. DE C.V.
		
	By:	 	/s/ Linda LaGorga
		 	Name:	 	Linda LaGorga
		 	Title:	 	Senior Vice President and Treasurer

  
 [Signature Page to
Indenture] 

 
					
	VALEANT PHARMA
		
	By:	 	/s/ Dmitry Khotko
		 	Name:	 	Dmitry Khotko
		 	Title:	 	General Director

  
 [Signature Page to
Indenture] 

 
					
	BAUSCH & LOMB PHARMA SA
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Director

  
 [Signature Page to
Indenture] 

 
					
	HUMAX PHARMACEUTICAL S.A.
		
	By:	 	/s/ Newar Andres Giraldo Alzate
		 	Name:	 	Newar Andres Giraldo Alzate
		 	Title:	 	Legal Representative

  
 [Signature Page to
Indenture] 

 
					
	PRECISION DERMATOLOGY, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	ECR PHARMACEUTICALS CO., INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer

  
 [Signature Page to
Indenture] 

 
					
	SPROUT PHARMACEUTICALS, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President, Chief Financial
		 		 	Officer and Treasurer
	
	SYNERGETICS USA, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President, Chief Financial
		 		 	Officer and Treasurer
	
	UNILENS VISION INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	COMMONWEALTH LABORATORIES, LLC
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Senior Vice President and Treasurer
	
	ALDEN OPTICAL LABORATORIES, INC.
		
	By:	 	/s/ Linda A. LaGorga
		 	Name:	 	Linda A. LaGorga
		 	Title:	 	Treasurer

  
 [Signature Page to
Indenture] 

 
					
	VALEANT DWC-LLC
		
	By:	 	/s/ Mohamed Ibrahim
		 	Name:	 	Mohamed Ibrahim
		 	Title:	 	Finance Director
		
	By:	 	/s/ Nicolas Esmieu
		 	Name:	 	Nicolas Esmieu
		 	Title:	 	General Manager

  
 [Signature Page to
Indenture] 

 
					
	THE BANK OF NEW YORK MELLON, AS TRUSTEE
		
	By:	 	/s/ Catherine F. Donohue
		 	Name:	 	Catherine F. Donohue
		 	Title:	 	Vice President

  
 [Signature Page to
Indenture] 

 EXHIBIT A 

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 

9.000% SENIOR NOTES DUE 2025 

[FORM OF FACE OF NOTE] 
 [UNLESS
THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO.
OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (AND ANY PAYMENT HEREON IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY
TRUST COMPANY), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE
INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS NOTE IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED
CIRCUMSTANCES DESCRIBED IN THE INDENTURE AND, UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE FORM, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE
OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY.]1 

[THIS NOTE HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY
NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT AS SET FORTH BELOW. BY ITS ACQUISITION HEREOF, THE HOLDER (1) REPRESENTS THAT (A) IT IS A “QUALIFIED INSTITUTIONAL
BUYER” (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT), (B) IT IS NOT A U.S. PERSON AND IS ACQUIRING THIS NOTE IN AN OFFSHORE TRANSACTION IN COMPLIANCE WITH RULE 904 UNDER THE SECURITIES ACT OR (C) IT IS AN ACCREDITED INVESTOR (AS
DEFINED IN RULE 501(a)(1), (2), (3), OR (7) UNDER THE SECURITIES ACT (AN “ACCREDITED INVESTOR”), (2) AGREES THAT IT WILL NOT PRIOR TO THE FIRST ANNIVERSARY OF THE ORIGINAL ISSUANCE OF THIS NOTE RESELL OR OTHERWISE TRANSFER THIS NOTE
EXCEPT (A) TO THE ISSUER OR ANY SUBSIDIARY THEREOF, (B) INSIDE THE UNITED STATES TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT, (C) INSIDE THE UNITED STATES TO AN ACCREDITED INVESTOR THAT,
PRIOR TO SUCH TRANSFER, FURNISHES (OR HAS FURNISHED ON ITS BEHALF BY A U.S. BROKER- DEALER) TO THE TRUSTEE A SIGNED LETTER CONTAINING CERTAIN REPRESENTATIONS AND AGREEMENTS RELATING TO THE RESTRICTIONS ON TRANSFER OF THIS NOTE (THE FORM OF WHICH
LETTER CAN BE OBTAINED FROM THE TRUSTEE FOR THIS NOTE), (D) OUTSIDE THE UNITED STATES IN AN OFFSHORE TRANSACTION IN COMPLIANCE WITH RULE 904 UNDER THE SECURITIES ACT (IF AVAILABLE), (E) PURSUANT TO THE EXEMPTION FROM REGISTRATION PROVIDED BY RULE
144 UNDER THE SECURITIES ACT (IF AVAILABLE), (F) IN ACCORDANCE WITH ANOTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT (AND BASED UPON AN OPINION OF COUNSEL IF THE ISSUER SO REQUESTS), OR (G) PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND (3) AGREES THAT IT WILL GIVE TO EACH PERSON TO WHOM THIS NOTE IS TRANSFERRED A NOTICE SUBSTANTIALLY 

 

	1 	 Include only if the Note is a Global Note. 

  
 A-1 

 
TO THE EFFECT OF THIS LEGEND. IN CONNECTION WITH ANY TRANSFER OF THIS NOTE WITHIN ONE YEAR AFTER THE ORIGINAL ISSUANCE OF THIS NOTE, IF THE PROPOSED TRANSFEREE IS AN ACCREDITED INVESTOR, THE
HOLDER MUST, PRIOR TO SUCH TRANSFER, FURNISH TO THE TRUSTEE AND THE ISSUER SUCH CERTIFICATIONS, LEGAL OPINIONS OR OTHER INFORMATION AS EITHER OF THEM MAY REASONABLY REQUIRE TO CONFIRM THAT SUCH TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION FROM,
OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. AS USED HEREIN, THE TERMS “OFFSHORE TRANSACTION,” “UNITED STATES” AND “U.S. PERSON” HAVE THE MEANING GIVEN TO THEM BY REGULATION S
UNDER THE SECURITIES ACT.]2 
 [THIS NOTE AND ANY RELATED DOCUMENTATION MAY BE AMENDED
OR SUPPLEMENTED FROM TIME TO TIME TO MODIFY THE RESTRICTIONS ON RESALES AND OTHER TRANSFERS OF THIS NOTE TO REFLECT ANY CHANGE IN APPLICABLE LAW OR REGULATION (OR THE INTERPRETATION THEREOF) OR IN PRACTICES RELATING TO THE RESALE OR TRANSFER OF
RESTRICTED SECURITIES GENERALLY. THE HOLDER OF THIS NOTE SHALL BE DEEMED BY THE ACCEPTANCE OF THIS NOTE TO HAVE AGREED TO ANY SUCH AMENDMENT OR SUPPLEMENT.]3 

[CANADIAN RESALE LEGEND 
 UNLESS
PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS NOTE OR A BENEFICIAL INTEREST HEREIN MUST NOT TRADE THIS NOTE OR THE BENEFICIAL INTEREST HEREIN BEFORE THE DATE THAT IS 4 MONTHS AND A DAY AFTER DECEMBER 18, 2017.]4 
  
  

 
  

	2 	Include only if the Note is a Restricted Note. 

	3 	Include only if the Note is a Restricted Note. 

	4 	Include until no longer necessary under Canadian securities laws. 

  
 A-2 

 VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 

 

			
	 CUSIP: 144A: 91911K AP7, Reg. S: C94143 AM3
	  	
	 ISIN: 144A: US91911KAP75, Reg. S: USC94143AM30
	  	No. [    ]

 9.000% SENIOR NOTES DUE 2025 

Valeant Pharmaceuticals International, Inc., a corporation continued under the British Columbia Business Corporations Act (the
“Company,” which term shall include any successor corporation under the Indenture referred to on the reverse hereof) promises to pay to ______________________________ or its registered assigns, the principal sum of
________________________ Dollars ($__________) on December 15, 2025 [or such greater or lesser amount as is indicated on the Schedule of Exchanges of Notes on the other side of this Note]5
and to pay interest thereon as provided on the other side of this Note. 
 Interest Payment Dates: June 15 and December 15,
beginning June 15, 2018. 
 Record Dates: June 1 and December 1. 

Additional provisions of this Note are set forth on the other side of this Note. 

 
  

	5 	Include only if the Note is a Global Note. 

  
 A-3 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 

 

					
	VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

 
					
		
	By:	 	 
		 	Name:	 	
		 	Title:	 	

  
 A-4 

			
	Trustee’s Certificate of Authentication:
	This is one of the Notes referred to in the within-mentioned Indenture for the 9.000% Senior Notes due 2025.
	
	THE BANK OF NEW YORK MELLON, as Trustee
		
	By:	 	 
		 	Authorized Signatory

 Dated: _________________________________ 

  
 A-5 

 [FORM OF REVERSE SIDE OF NOTE] 

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 

9.000% SENIOR NOTES DUE 2025 
  

	1.	INTEREST 

 The Company shall pay interest on this Note semiannually in arrears on June 15
and December 15, each an “interest payment date,” of each year, commencing on June 15, 2018, at the rate per annum specified in the title of this Note. Interest shall accrue from and including December 18, 2017 or
else the most recent interest payment date to which interest had been paid or duly provided for to but excluding the date on which such interest is paid. Interest on this Note will be computed on the basis of a
360-day year of twelve 30-day months. 
 The Company shall,
(in immediately available funds) to the fullest extent permitted by law, pay interest on overdue principal (including premium, if any) and overdue installments of interest from the original due date to the date paid, at the rate applicable to this
Note, which interest shall be payable on demand. 
 The interest so payable and punctually paid or duly provided for on any interest payment
date will be paid to the Person in whose name this Note is registered at the close of business on June 1 or December 1 preceding such interest payment date (the “Record Date”) except as provided in the Indenture. Payment
of the principal of (and premium, if any) and interest on this Note will be made in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts and as otherwise provided in
the Indenture. 
  

	2.	METHOD OF PAYMENT 

 [The Company will make payments in respect of this Note (including
principal, premium, if any, interest) by wire transfer of immediately available funds to the accounts specified by the Holder.]6 [The Company will make all payments of principal, interest and
premium, if any, with respect to this Note by wire transfer of immediately available funds to the accounts specified by the Holders, in the case of a Holder holding an aggregate principal amount of Notes of $1,000,000 or more, or, if no such account
is specified or in the case of a Holder holding an aggregate principal amount of Notes of less than $1,000,000, by mailing a check to each such Holder’s registered address.]7 All payments
shall be made in immediately available funds in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts. Payments to any Holder holding an aggregate principal amount of
Notes in excess of $1,000,000 shall be made by wire transfer in immediately available funds to an account maintained by such Holder in the United States, if such Holder has provided wire transfer instructions to the Company at least 10 Business Days
prior to the payment date. Any wire transfer instructions received by the Trustee will remain in effect until revoked by the Holder. Notwithstanding the foregoing, so long as this Note is registered in the name of a Depositary or its nominee, all
payments hereon shall be made by wire transfer of immediately available funds to the account of the Depositary or its nominee. 
  

	3.	PAYING AGENT AND REGISTRAR 

 Initially, The Bank of New York Mellon (the
“Trustee”) will act as Paying Agent and Registrar. The Company may change any Paying Agent or Registrar without notice to the Holder. The Company or any of their Subsidiaries may, subject to certain limitations set forth in the
Indenture, act as Paying Agent or Registrar. 
  
  

 

	6 	Include only if the Note is a Global Note. 

	7 	Include only if the Note is a Definitive Note. 

  
 A-6 

	4.	INDENTURE, LIMITATIONS 

 This Note is one of a duly authorized issue of Notes of the Company
designated as its 9.000% Senior Notes due 2025 (the “Notes”), issued under an Indenture dated as of December 18, 2017 (together with any supplemental indentures thereto, the “Indenture”), among the Company, the
Note Guarantors and the Trustee. The terms of this Note include those stated in the Indenture. This Note is subject to all such terms, and the Holder of this Note is referred to the Indenture and said Act for a statement of them. Capitalized terms
used and not defined herein have the meanings assigned to such terms in the Indenture. 
 The Company shall be entitled to issue Additional
Notes pursuant to Section 2.1(c) of the Indenture. 
  

	5.	OPTIONAL REDEMPTION; PURCHASE OF NOTES AT OPTION OF HOLDER. 

(a)    Optional Redemption. The Notes are redeemable at the option of the Company at the prices, and upon the terms
and conditions, set forth in Section 3.7 of the Indenture. 
 (b)    Repurchase at Option of Holder. If
there is a Change of Control, the Company shall be required to make an offer (a “Change of Control Offer”) to repurchase all or any part (equal to $2,000 or an integral multiple of $1,000 in excess thereof) of each Holder’s
Notes at a purchase price equal to 101% of the aggregate principal amount thereof plus accrued and unpaid interest thereon, if any, to, but excluding, the date of purchase. Within 30 days following any Change of Control, the Company shall transmit a
notice to each Holder setting forth the procedures governing the Change of Control Offer as required by the Indenture. 
 If after the
Company or a Restricted Subsidiary consummates any Asset Sale, the Company may be required to purchase Notes, as further specified in the Indenture. 

(d)     Notice of Redemption. Notice of redemption will be given at least 30 days but not more than 60 days before
the redemption date to each Holder whose Notes are to be redeemed at its registered address. Notes in denominations larger than $2,000 may be redeemed in part but only in whole multiples of $1,000, unless all of the Notes held by a Holder are to be
redeemed. On and after the redemption date, subject to satisfaction of any conditions precedent, interest ceases to accrue on Notes or portions thereof called for redemption. 
  

	6.	DENOMINATIONS, TRANSFER, EXCHANGE, CANCELLATION 

 The Notes are in registered form, without
coupons, in denominations of $2,000 and integral multiples of $1,000 in excess thereof. A Holder may register the transfer of or exchange Notes in accordance with the Indenture. The Registrar may require a Holder, among other things, to furnish
appropriate endorsements and transfer documents and to pay any taxes or other governmental charges that may be imposed in relation thereto by law or permitted by the Indenture. 

All Notes surrendered for payment, registration of transfer or exchange or conversion will, if surrendered to the Company or any of its other
Agents with respect to the Notes, be delivered to the Trustee. The Trustee will promptly cancel all Notes delivered to it. No Notes will be authenticated in exchange for any Notes cancelled, except as provided in the Indenture. 

 

	7.	PERSONS DEEMED OWNERS 

 The Holder of a Note may be treated as the owner of it for all
purposes. 
  

	8.	GUARANTEES 

 This Note is guaranteed as set forth in the Indenture. 

  
 A-7 

	9.	UNCLAIMED MONEY 

 If money for the payment of principal or interest remains unclaimed for two
years, the Trustee or Paying Agent will pay the money back to the Company at its written request, subject to applicable unclaimed property law. After that, Holders entitled to money must look to the Company for payment as general creditors unless an
applicable abandoned property law designates another person. 
  

	10.	AMENDMENT, SUPPLEMENT AND WAIVER 

 Subject to certain exceptions, the Indenture (with respect
to the Notes) or the Notes may be amended or supplemented with the consent of the Holders of at least a majority in aggregate principal amount of the Notes then outstanding, and an existing default or Event of Default and its consequence or
compliance with any provision of the Indenture or the Notes may be waived in a particular instance with the consent of the Holders of a majority in aggregate principal amount of the Notes then outstanding. Without the consent of or notice to any
Holder, the Company and the Trustee may amend or supplement the Indenture (with respect to the Notes) or the Notes to, among other things, cure any ambiguity, defect or inconsistency or make any other change that does not adversely affect the rights
of any Holder. 
 In addition, except as set forth under Article 10, without the consent of Holders of at least 66 2/3% in principal amount
of the Notes then outstanding (including, without limitation, consents obtained in connection with a purchase of, or tender offer or exchange offer for, Notes), no amendment or supplement may release the Note Guarantees. 

 

	11.	SUCCESSOR ENTITY 

 When a successor corporation assumes all the obligations of its predecessor
under the Notes and the Indenture in accordance with the terms and conditions of the Indenture, the predecessor corporation (except in certain circumstances specified in the Indenture) shall be released from those obligations. 

 

	12.	DEFAULTS AND REMEDIES 

 If an Event of Default, as defined in the Indenture, occurs and is
continuing, the Trustee or the Holders of at least 25% in principal amount of the Notes may declare all the Notes to be due and payable. If a bankruptcy or insolvency default with respect to the Company occurs and is continuing, the Notes
automatically become due and payable. Holders may not enforce the Indenture or the Notes except as provided in the Indenture. The Trustee may require indemnity satisfactory to it before it enforces the Indenture or the Notes. Subject to certain
limitations, Holders of a majority in principal amount of the Notes then outstanding may direct the Trustee in its exercise of remedies. 
  

	13.	TRUSTEE DEALINGS WITH THE COMPANY 

 The Bank of New York Mellon, the Trustee under the
Indenture, in its individual or any other capacity, may make loans to, accept deposits from and perform services for the Company or an Affiliate of the Company and may otherwise deal with the Company or an Affiliate of the Company as if it were not
the Trustee. 
  

	14.	NO RECOURSE AGAINST OTHERS 

 A director, officer, employee or shareowner, as such, of the
Company or any Note Guarantor shall not have any liability for any obligations of the Company or any Note Guarantor under the Notes or the Indenture nor for any claim based on, in respect of or by reason of such obligations or their creation. The
Holder of this Note by accepting this Note waives and releases all such liability. The waiver and release are part of the consideration for the issuance of this Note. 

  
 A-8 

	15.	AUTHENTICATION 

 This Note shall not be valid until the Trustee or an authenticating agent
manually signs the certificate of authentication on the other side of this Note. 
  

	16.	ABBREVIATIONS AND DEFINITIONS 

 Customary abbreviations may be used in the name of the Holder
or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants by the entireties), JT TEN (= joint tenants with right of survivorship and not as tenants in common), CUST (= Custodian) and UGMA (= Uniform
Gifts to Minors Act). 
  

	17.	INDENTURE TO CONTROL; GOVERNING LAW 

 In the case of any conflict between the provisions of
this Note and the Indenture, the provisions of the Indenture shall control. This Note shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to principles of conflicts of law. 

The Company will furnish to any Holder, upon written request and without charge, a copy of the Indenture. Requests may be made to: Valeant
Pharmaceuticals International, Inc., 400 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807, Telephone: (905) 286-3000, Attention: Investor Relations. 

  
 A-9 

 ASSIGNMENT FORM 

To assign this Note, fill in the form below: 

I or we assign and transfer this Note to 
  

      

 
 (Insert assignee’s soc. sec. or
tax I.D. no.) 
  
       

 

      

 

      

 
 (Print or type assignee’s name,
address and zip code) 
 and irrevocably appoint 

      

 
 agent to transfer this Note on the books of the
Company. The agent may substitute another to act for him or her. 
  

							
		 		 	 Your Signature:

				
	Date: ____________________________	 		 		 	 
		 		 		 	(Sign exactly as your name appears on the other side of this Note)

  

			
	*Signature guaranteed by:
		
	By:	 	 

  

	*	The signature must be guaranteed by an institution which is a member of one of the following recognized signature guaranty programs: (i) the Securities Transfer Agent Medallion Program (STAMP); (ii) the New York
Stock Exchange Medallion Program (MSP); (iii) the Stock Exchange Medallion Program (SEMP); or (iv) such other guaranty program acceptable to the Trustee. 

  
 A-10 

 OPTION TO ELECT PURCHASE 

If you want to elect to have this Note purchased by the Company pursuant to Section 3.8 or Section 4.14 of the Indenture, check the appropriate box
below: 
 ☐    Section
3.8                ☐    Section 4.14 
 If
you want to elect to have only part of the Note purchased by the Company pursuant to Section 3.8 or Section 4.14 of the Indenture, state the amount you elect to have purchased: 

$_________________ 
  

							
	 Date: ___________________
	 		 		 	
			
		 		 	 Your Signature:

			
		 		 	 
		 		 	(Sign exactly as your name appears on the face of this Note)
				
		 		 	 Tax Identification No.:
	 	 

 Signature Guarantee*: ___________________________ 

 

	*	Participant in a recognized Signature Guarantee Medallion Program (or other signature guarantor acceptable to the Trustee). 

  
 A-11 

 SCHEDULE OF EXCHANGES OF NOTES8 

The following exchanges, repurchases or conversions of a part of this global Note have been made: 

 

							
	 PRINCIPAL AMOUNT OF THIS
GLOBAL NOTE
FOLLOWING SUCH
DECREASE DATE OF EXCHANGE
(OR INCREASE)
	 	 AUTHORIZED SIGNATORY OF
NOTES
CUSTODIAN
	 	 AMOUNT OF DECREASE IN
PRINCIPAL AMOUNT OF
THIS
GLOBAL NOTE
	 	 AMOUNT OF INCREASE IN
PRINCIPAL AMOUNT OF
THIS
GLOBAL NOTE

		 		 		 	

  
  

	8 	This schedule should be included only if the Note is a Global Note. 

  
 A-12 

 CERTIFICATE TO BE DELIVERED UPON EXCHANGE OR REGISTRATION 

OF TRANSFER OF RESTRICTED SECURITIES9 

Re:    9.000% Senior Notes due 2025 (the “Notes”) of Valeant Pharmaceuticals International, Inc. (the
“Company”). 
 This certificate relates to $___________________ principal amount of Notes owned in (check applicable box)

 ☐  book-entry or ☐  definitive form by ____________________ (the “Transferor”). 

The Transferor has requested a Registrar or the Trustee to exchange or register the transfer of such Notes. 

In connection with such request and in respect of each such Note, the Transferor does hereby certify that the Transferor is familiar with
transfer restrictions relating to the Notes as provided in Section 2.12 of the Indenture dated as of December 18, 2017 among Valeant Pharmaceuticals International, Inc., the Note Guarantors party and thereto The Bank of New York Mellon, as
trustee (the “Indenture”), and the transfer of such Note is in accordance with any applicable securities laws of any state and is being made pursuant to an effective registration statement under the Securities Act of 1933, as
amended (the “Securities Act”) (check applicable box) or the transfer or exchange, as the case may be, of such Note does not require registration under the Securities Act because (check applicable box): 

 

	 	☐	Such Note is being transferred pursuant to an effective registration statement under the Securities Act. 

  

	 	☐	Such Note is being acquired for the Transferor’s own account, without transfer. 

  

	 	☐	Such Note is being transferred to the Company or a Subsidiary (as defined in the Indenture) of the Company. 

  

	 	☐	Such Note is being transferred to a person the Transferor reasonably believes is a “qualified institutional buyer” (as defined in Rule 144A or any successor provision thereto
(“Rule 144A”) under the Securities Act) that is purchasing for its own account or for the account of a “qualified institutional buyer,” in each case to whom notice has been given that the transfer is being made in
reliance on such Rule 144A, and in each case in reliance on Rule 144A. 

  

	 	☐	Such Note is being transferred pursuant to and in compliance with an exemption from the registration requirements under the Securities Act in accordance with Rule 144 (or any successor thereto)
(“Rule 144”) under the Securities Act. 

  

	 	☐	Such Note is being transferred to a Non-U.S. Person in an offshore transaction in compliance with Rule 904 of Regulation S under the Securities Act (or any successor
thereto). 

  

	 	☐	Such Note is being transferred to an institutional “accredited investor” (as defined in Rule 501(a)(1), (2), (3) or (7) of the Securities Act) that has provided a letter addressed to the Company, in the
form of Exhibit C attached to the Indenture, containing certain representations and agreements. 

  

							
				
	Date: ___________________________________	 		 		 	      

		 		 		 	 (Insert Name of Transferor)

  

	9 	This certificate should be included only if this Note is a Restricted Note. 

  
 A-13 

 EXHIBIT B 

FORM OF GUARANTEE 
 [Name of Note
Guarantor] and its successors under the Indenture, jointly and severally with any other Note Guarantors, hereby irrevocably and unconditionally (i) guarantee the due and punctual payment of the principal of, premium, if any, and interest on the
Notes, whether at maturity, by acceleration, redemption or otherwise, the due and punctual payment of interest on the overdue principal of and interest, if any, on the Notes, to the extent lawful, and the due and punctual performance of all other
obligations of Valeant Pharmaceuticals International, Inc. (the “Company”) to the Holders or the Trustee, all in accordance with the terms set forth in Article 10 of the Indenture and (ii) in case of any extension of time of
payment or renewal of any Notes or any of such other obligations, guarantee that the same will be promptly paid in full when due or performed in accordance with the terms of the extension or renewal, whether at stated maturity, by acceleration or
otherwise. Capitalized terms used herein have the meanings assigned to them in the Indenture unless otherwise indicated. 
 No stockholder,
officer, director or incorporator, as such, past, present or future, of [name of Note Guarantor] shall have any personal liability under this Note Guarantee by reason of his, her or its status as such stockholder, officer, director or incorporator.
This Note Guarantee shall be binding upon [name of Note Guarantor] and its successors and assigns and shall inure to the benefit of the successors and assigns of the Trustee and the Holders and, in the event of any transfer or assignment of rights
by any Holder or the Trustee, the rights and privileges herein conferred upon that party shall automatically extend to and be vested in such transferee or assignee, all subject to the terms and conditions hereof. 

This Note Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication on the Note upon which this Note
Guarantee is noted shall have been executed by the Trustee under the Indenture by the manual signature of one of its authorized officers. 

THE TERMS OF ARTICLE 10 OF THE INDENTURE ARE INCORPORATED HEREIN BY REFERENCE. 

This Note Guarantee shall be governed by and construed in accordance with the laws of the State of New York. 

 

					
	[NAME OF NOTE GUARANTOR]
		
	By:	 	 
		 	Name:	 	
		 	Title:	 	

  
 B-1 

 EXHIBIT C 

FORM OF CERTIFICATE FROM ACQUIRING 

INSTITUTIONAL ACCREDITED INVESTOR 
 Valeant
Pharmaceuticals International, Inc. 
 400 Somerset Corporate Boulevard 

Bridgewater, NJ 08807 
 Attention: General Counsel 

Facsimile No.: (949) 461-6609 
  

	 	Re:        ☐	9.000% SENIOR NOTES DUE 2025 

 CUSIP: 144A: 91911K AP7, Reg. S: C94143 AM3 

ISIN: 144A: US91911KAP75, Reg. S: USC94143AM30 

Dear Sirs: 
 Reference is hereby made to the
Indenture, dated as of December 18, 2017 (the “Indenture”), among Valeant Pharmaceuticals International, Inc., as issuer (the “Company”), the Note Guarantors party thereto and The Bank of New York Mellon, as
the Trustee. Capitalized terms used but not defined herein shall have the meanings given to them in the Indenture. 
 In connection with our
proposed purchase of $___________________ aggregate principal amount of 9.000% Senior Notes due 2025 (the “Notes”), we confirm that: 

1.    We understand that any subsequent transfer of the Notes or any interest therein is subject to certain restrictions
and conditions set forth in the Indenture and the undersigned agrees to be bound by, and not to resell, pledge or otherwise transfer the Notes or any interest therein except in compliance with, such restrictions and conditions and the United States
Securities Act of 1933, as amended (the “Securities Act”). 
 2.    We understand that the offer and
sale of the Notes have not been registered under the Securities Act, and that the Notes and any interest therein may not be offered or sold except as permitted in the following sentence. We agree, on our own behalf and on behalf of any accounts for
which we are acting as hereinafter stated, that if we should sell the Notes or any interest therein, we will do so only (A) to the Company or any of its subsidiaries, (B) in accordance with Rule 144A under the Securities Act to a
“qualified institutional buyer” (as defined therein), (C) inside the United States to an institutional “accredited investor” (as defined below) purchasing for its own account or for the account of another institutional accredited
investor that, prior to such transfer, furnishes (or has furnished on its behalf by a U.S. broker-dealer) to you and to the Company a signed letter substantially in the form of this letter, (D) pursuant to the provisions of Rule 144 under the
Securities Act (if available), (E) in accordance with another exemption from the registration requirements of the Securities Act (and based upon an opinion of counsel acceptable to the Company) or (F) pursuant to an effective registration
statement under the Securities Act, and we further agree to provide to any person purchasing the Notes from us in a transaction meeting the requirements of clauses (A) through (F) of this paragraph a notice advising such purchaser that resales
thereof are restricted as stated herein. 
 3.    We understand that, on any proposed resale of the Notes or beneficial
interest therein, we will be required to furnish to you and the Company such certifications, legal opinions and other information as you and the Company may reasonably require to confirm that the proposed sale complies with the foregoing
restrictions. We further understand that the Notes purchased by us will bear a legend to the foregoing effect. 

4.    We are an institutional “accredited investor” (as defined in Rule 501(a)(1), (2), (3) or (7) of
Regulation D under the Securities Act) and have such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of our investment in the Notes, and we and any accounts for which we are acting are
each able to bear the economic risk of our or its investment. 

  
 C-1 

 5.    We are acquiring the Notes or beneficial interest therein purchased by
us for our own account or for one or more accounts (each of which is an institutional “Accredited Investor”) as to each of which we exercise sole investment discretion. 

You and the Company are entitled to rely upon this letter and are irrevocably authorized to produce this letter or a copy hereof to any
interested party in any administrative or legal proceedings or official inquiry with respect to the matters covered hereby. 
 Dated: 

 

					
	[Insert Name of Accredited Investor]
		
	By:	 	 
		 	Name:	 	
		 	Title:	 	

  
 C-2 

 EXHIBIT D 

FORM OF CANADIAN NOTE GUARANTEE 
  

	 	Re:        ☐	9.000% SENIOR NOTES DUE 2025 

 CUSIP: 144A: 91911K AP7, Reg. S: C94143 AM3 

ISIN: 144A: US91911KAP75, Reg. S: USC94143AM30 

THIS CANADIAN NOTE GUARANTEE (as amended, restated, modified, renewed or extended from time to time, and including, for the avoidance of any
doubt, the preamble and recitals hereto, this “Canadian Note Guarantee”), is executed and delivered as of ☐ by ☐ (“Guarantor”) in favour of The Bank of New York Mellon, as the Trustee,
Registrar and Paying Agent, for the benefit of each Holder (together with the Trustee, collectively, the “Beneficiaries”). 
 RECITALS:

  

	A.	Reference is made to that Indenture dated as of December 18, 2017 among Valeant Pharmaceuticals International, Inc., a Canadian corporation (the “Company”) and the Trustee (as amended,
supplemented, restated, extended, renewed, or replaced from time to time, the “Indenture”). 

  

	B.	Guarantor is an Affiliate of the Company, and, as such, will benefit by virtue of the financial accommodations extended to the Company pursuant to the Indenture. 

THEREFORE, Guarantor agrees as follows: 

Section 1. 

Definitions and Principles of Interpretation 
  

	1.1.	Definitions. 

 All capitalized terms used and not defined elsewhere in this Canadian Note Guarantee, and
all capitalized terms used and not defined in the provisions incorporated by reference into this Canadian Note Guarantee, shall have the meanings ascribed to them in the Indenture (such meanings to be determined as if such terms were to be
interpreted in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable in the Province of Ontario) and shall be incorporated by reference into this Canadian Note Guarantee, and the following words and terms have
the meanings set out below: 
 “Guaranteed Obligations” has the meaning given to it in Section 2.1(a). 

“Indenture” has the meaning given to it in the recitals to this Canadian Note Guarantee. 

 

	1.2.	Certain Rules of Interpretation. 

 In this Canadian Note Guarantee: 

 

	(a)	Governing Law – This Canadian Note Guarantee (including terms incorporated by reference to the Indenture) is a contract made under and shall be governed by and construed in accordance with the laws of the
Province of Ontario and the federal laws of Canada applicable in the Province of Ontario. 

  

	(b)	Headings – Headings of Articles and Sections are inserted for convenience of reference only and shall not affect the construction or interpretation of this Canadian Note Guarantee. 

 

	(c)	Including – Where the word “including” or “includes” is used in this Canadian Note Guarantee, it means “including (or includes) without limitation.” 

  
 Schedule D-1 

	(d)	No Strict Construction – The language used in this Canadian Note Guarantee is the language chosen by the parties to express their mutual intent, and no rule of strict construction shall be applied against
any party. 

  

	(e)	Number and Gender – Unless the context otherwise requires, words importing the singular include the plural and vice versa and words importing gender include all genders. 

 

	(f)	Statutory references – A reference to a statute includes all regulations made pursuant to such statute and, unless otherwise specified, the provisions of any statute or regulation which amends, revises,
restates, supplements or supersedes any such statute or any such regulation. 

  

	(g)	Time – Time is of the essence in the performance of Guarantor’s obligations under this Canadian Note Guarantee. 

Section 2. 

GUARANTEE 
  

	2.1.	Guarantee of the Obligations. 

  

	(a)	Guarantor hereby unconditionally Guarantees to each Holder of a Note authenticated and delivered by the Trustee and to the Trustee and its successors and assigns, irrespective of the validity and enforceability of the
Indenture, the Notes or the obligations of the Company thereunder that: (i) the due and punctual payment of principal, premium and interest on the Notes shall be promptly paid in full when due, whether at maturity, by acceleration, redemption
or otherwise, (ii) the due and punctual payment of interest on the overdue principal of and interest on the Notes, if any, if lawful, and all other obligations of the Company to the Holders or the Trustee under the Indenture or any Note shall
be promptly paid in full or performed, all in accordance with the terms thereof, and (iii) in case of any extension of time of payment or renewal of any Notes or any of such other obligations, that same shall be promptly paid in full when due
or performed in accordance with the terms of the extension or renewal, whether at stated maturity, by acceleration pursuant to Section 6.2 of the Indenture or otherwise (collectively, the “Guaranteed Obligations”). Guarantor
agrees that this Canadian Note Guarantee is a guarantee of payment and not a guarantee of collection. Failing payment when due of any Guaranteed Obligations for whatever reason, Guarantor shall be obligated to pay the same immediately.

  

	(b)	 Guarantor hereby agrees that its obligations with regard to its Canadian Note Guarantee shall be unconditional,
irrespective of the validity or enforceability of the Notes or the obligations of the Company under the Indenture, the absence of any action to enforce the same, the recovery of any judgment against the Company or any other obligor with respect to
the Indenture, the Notes or the obligations of the Company under the Indenture or the Notes, any action to enforce the same or any other circumstances (other than complete performance) which might otherwise constitute a legal or equitable discharge
or defense of a guarantor. Guarantor further, to the extent permitted by applicable law, hereby waives and relinquishes all claims, rights and remedies accorded by applicable law to guarantors and shall agree not to assert or take advantage of any
such claims, rights or remedies, including but not limited to: (i) any right to require any Beneficiary, as a condition of payment or performance by Guarantor, to (A) proceed against the Company, any other guarantor (including any other
Note Guarantor) of the Guaranteed Obligations or any other person, (B) proceed against or exhaust any security held from the Company, any such other guarantor or any other person, (C) proceed against or have resort to any balance of any
deposit account or credit on the books of any Beneficiary in favour of the Company or any other person, or (D) pursue any other remedy in the power of any Beneficiary whatsoever; (ii) any defense arising by reason of the incapacity, lack
of authority or any disability or other defense of the Company including any defense based on or arising out of the lack of validity or the unenforceability of the Guaranteed Obligations or any agreement or instrument relating thereto or by reason
of the cessation of the liability of the Company from any cause other than payment in full of the Guaranteed Obligations; (iii) any defense based upon any statute or rule of law which provides that the obligation of a surety must be neither
larger in amount nor in other respects more burdensome than that of the principal; (iv) any defense based upon any Beneficiary’s errors or 

  
 Schedule D-2 

	 	
omissions in the administration of the Guaranteed Obligations, except behavior which amounts to bad faith; (v) (A) any principles or provisions of law, statutory or otherwise, which are or
might be in conflict with the terms of this Canadian Note Guarantee and any legal or equitable discharge of Guarantor’s obligations hereunder and under this Canadian Note Guarantee, (B) the benefit of any statute of limitations affecting
Guarantor’s liability hereunder or the enforcement hereof, (C) any rights to set-offs, recoupments and counterclaims and (D) promptness, diligence and any requirement that any Beneficiary
protect, secure, perfect or insure any security interest or lien or any property subject thereto; (vi) notices, demands, presentations, protests, notices of protest, notices of dishonor and notices of any action or inaction, including
acceptance of this Canadian Note Guarantee, notices of default under the Notes or any agreement or instrument related thereto, notices of any renewal, extension or modification of the Guaranteed Obligations or any agreement related thereto, and
notices of any extension of credit to the Company and any right to consent to any thereof; and (vii) any defenses or benefits that may be derived from or afforded by law which limit the liability of or exonerate guarantors or sureties, or which
may conflict with the terms of this Canadian Note Guarantee. 

  

	(c)	If any Holder or the Trustee is required by any court or otherwise to return to the Company, any Note Guarantor or any custodian, trustee, liquidator or other similar official acting in relation to either the Company or
any Note Guarantor, any amount paid to either the Trustee or such Holder, this Canadian Note Guarantee, to the extent theretofore discharged, shall be reinstated in full force and effect. 

 

	(d)	Guarantor agrees that it shall not be entitled to any right of subrogation in relation to the Holders in respect of any obligations guaranteed hereby until payment in full of all Guaranteed Obligations. Guarantor
further agrees that, as between Guarantor, on the one hand, and the Holders and the Trustee, on the other hand, (i) the maturity of the Guaranteed Obligations may be accelerated as provided in Section 6.2 of the Indenture for the purposes
of this Canadian Note Guarantee, notwithstanding any stay, injunction or other prohibition preventing such acceleration in respect of the Guaranteed Obligations and (ii) in the event of any declaration of acceleration of such obligations as
provided in Section 6.2 of the Indenture, such obligations (whether or not due and payable) shall forthwith become due and payable by Guarantor for the purpose of this Canadian Note Guarantee. Guarantor shall not exercise any right to seek
contribution from any non-paying Note Guarantor if the exercise of such right impairs the rights of the Holders under the Note Guarantees. 

 

	2.2.	Merger and Consolidation of Guarantors 

  

	(a)	In case of any sale or other disposition, consolidation, merger, amalgamation or conveyance and upon the assumption by the successor person on terms and conditions satisfactory to the Trustee of the obligations of
Guarantor under this Canadian Note Guarantee, and the due and punctual performance of all of the covenants and conditions of the Indenture to be performed by Guarantor, such successor person shall succeed to and be substituted for Guarantor under
this Canadian Note Guarantee with the same effect as if it had been named herein as Guarantor. 

  

	(b)	Except as set forth in Articles 4 and 5 of the Indenture, and notwithstanding clause (a) of this Section 2.2, nothing contained in the Indenture or in any of the Notes shall prevent any consolidation, merger
or amalgamation of a Note Guarantor with or into the Company or another Note Guarantor, or shall prevent any sale or conveyance of the property of a Note Guarantor as an entirety or substantially as an entirety to the Company or another Note
Guarantor. 

  

	2.3.	Release 

  

	(a)	 In the event (i) of a sale or other disposition of all or substantially all of the assets of any Guarantor,
by way of merger, amalgamation, consolidation or otherwise, or a sale or other disposition of all the Equity Interests of any Guarantor, then held by the Company and its Restricted Subsidiaries to a person that is not (either before or after giving
effect to such transactions) a Subsidiary of the Company, in each case so long as such sale or other disposition is permitted by the Indenture, including without limitation Section 4.14 thereof, (ii) of a designation by the Company of any
Restricted Subsidiary that is a Guarantor as an Unrestricted Subsidiary in accordance with the definition thereof or in the event that such Guarantor ceases 

  
 Schedule D-3 

	 	
to be a Restricted Subsidiary in accordance with the provisions of the Indenture, (iii) in the case of any Canadian Note Guarantee issued on the Issue Date, upon the release or discharge of
the Canadian Note Guarantee by such Guarantor in respect of the Credit Agreement, and in any other case upon the release or discharge of any Canadian Note Guarantee in respect of any Indebtedness that resulted in the issuance after the Issue Date of
the Canadian Note Guarantee by such Guarantor or (iv) the Company discharges the Notes and its Obligations under the Indenture under Section 8.1 thereof or exercises its legal or covenant defeasance options under Section 8.2 or 8.3
thereof, respectively, with respect of the Notes or, in the case of a sale or other disposition of all or substantially all of the assets of Guarantor, the Person acquiring such property, shall be released and relieved of any obligations under this
Canadian Note Guarantee without any further action being required by the Trustee or any Holder. 

  

	(b)	Upon delivery by the Company to the Trustee of an Officers’ Certificate and an Opinion of Counsel to the effect that such sale or other disposition was made by the Company in accordance with the provisions of the
Indenture, including without limitation Sections 4.8 and 4.14 thereof, the Trustee shall execute any documents reasonably required in order to evidence the release of Guarantor from its obligations under this Canadian Note Guarantee.

 Section 3. 

Miscellaneous 
  

	3.1.	Limitations Act, 2002 (Ontario) 

 Any and all limitation periods provided for in
the Limitations Act, 2002 (Ontario), as amended from time to time, or any other applicable law limiting the time for which an action may be commenced shall be excluded from application to the obligations of Guarantor hereunder to
fullest extent permitted by such Act or applicable law. 
  

	3.2.	Usury Savings Clause 

 If any provision of this Canadian Note Guarantee, the Indenture or any Note would
obligate any Canadian Note Guarantor to make any payment of or on account of interest or other amount in an amount or calculated at a rate which would result in a receipt by any Holder of interest at a criminal rate (as such term is construed under
the Criminal Code (Canada)), then notwithstanding such provisions, such amount or rate shall be deemed to have been adjusted with retroactive effect to the maximum amount or rate of interest, as the case may be, as would not so result in a
receipt by such Holder of interest at a criminal rate, such adjustment to be effected, to the extent necessary, as follows: (1) firstly, by reducing the amount or rate of interest required to be paid to such Holder, and (2) thereafter, by
reducing any fees, commissions, premiums and other amounts required to be paid to such Holder which would constitute “interest” for purposes of Section 347 of the Criminal Code (Canada). 

 

	3.3.	Interest Act (Canada) 

 For purposes of disclosure pursuant to the Interest Act (Canada), the
annual rates of interest or fees to which the rates of interest or fees provided for in this Canadian Note Guarantee, the Indenture or the Notes (and stated herein or therein, as applicable, to be computed on the basis of a 360 day year or any other
period of time less than a calendar year) are equivalent are the rates so provided for multiplied by the actual number of days in the applicable calendar year and divided by 360 or the actual number of days in such other period of time,
respectively. 
  

	3.4.	Counterparts; Execution 

 This Canadian Note Guarantee may be executed in any number of counterparts and
by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same agreement. Delivery of an executed counterpart
of this Canadian Note Guarantee facsimile or other similar method of electronic transmission (including by way of email attachment) shall be equally as effective as delivery of an original executed counterpart of this Canadian Note Guarantee. 

  
 Schedule D-4 

	3.5.	Severability 

 If, in any jurisdiction, any provision of this Canadian Note Guarantee or its application
to any party or circumstance is restricted, prohibited or unenforceable, such provision shall, as to that jurisdiction, be ineffective only to the extent of such restriction, prohibition or unenforceability without invalidating the remaining
provisions of this Canadian Note Guarantee and without affecting the validity or enforceability of such provision in any other jurisdiction or without affecting its application to other parties or circumstances. 

 

	3.6.	Notices 

 All notices and other communications hereunder shall be in writing and shall be mailed, sent,
or delivered in accordance with the terms of the Indenture. 
  

	3.7.	Successors 

 This Canadian Note Guarantee shall be binding upon Guarantor and its successors and shall
inure to the benefit of the successors of the Beneficiaries. 
  

	3.8.	Judgment Currency 

 Guarantor shall indemnify each Holder and each Person, if any, who controls any
Holder within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any loss incurred by such party as a result of any judgment or order being given or made against Guarantor for any U.S. dollar amount
due under this Canadian Note Guarantee and such judgment or order being expressed and paid in a currency (the “Judgment Currency”) other than U.S. dollars and as a result of any variation as between (i) the rate of exchange at
which the U.S. dollar amount is converted into the Judgment Currency for the purpose of such judgment or order and (ii) the spot rate of exchange in The City of New York at which such party on the date of payment of such judgment or order
is able to purchase U.S. dollars with the amount of the Judgment Currency actually received by such party if such party had utilized such amount of Judgment Currency to purchase U.S. dollars upon such party’s receipt thereof. Any amount due
from Guarantor under this Section 3.8 shall be due as a separate debt and shall not be affected by such judgment or order as aforesaid. The term “spot rate of exchange” shall include any premiums and costs of exchange payable in
connection with the purchase of, or conversion into, U.S. dollars. 
  

	3.9.	Payment of Additional Amounts 

  

	(a)	All payments made under or with respect to this Canadian Note Guarantee by Guarantor will be made free and clear of any withholding or deduction for or on account of any tax, duty, levy, impost, assessment or other
governmental charge of whatever nature (collectively, “Tax”) imposed or levied by or on behalf of Canada or any other jurisdiction in which Guarantor is organized, resident or doing business for tax purposes or from or through which
Guarantor makes any payment on the Canadian Note Guarantee or any department or political subdivision thereof (each, a “Relevant Taxing Jurisdiction”), unless Guarantor (or an applicable withholding agent) is required to withhold or
deduct Taxes by law. If Guarantor (or an applicable withholding agent) is required by law to withhold or deduct any amount for or on account of Taxes of a Relevant Taxing Jurisdiction from any payment made under or with respect to this Canadian Note
Guarantee, Guarantor, subject to the exceptions listed below, will pay additional amounts (“Additional Amounts”) as may be necessary to ensure that the net amount received by each Holder or beneficial owner of the Notes after such
withholding or deduction (including withholding or deduction attributable to Additional Amounts payable hereunder) will not be less than the amount the Holder or beneficial owner would have received if such Taxes had not been required to be so
withheld or deducted. 

  

	(b)	Guarantor will not, however, pay Additional Amounts to a Holder or beneficial owner of Notes: 

  

	 	(i)	 to the extent the Taxes giving rise to such Additional Amounts would not have been imposed but for the existence
of any present or former connection between the Holder or beneficial owner (or between a fiduciary, settler, beneficiary, member or shareholder of, or possessor of a power over, 

  
 Schedule D-5 

	 	
such Holder or beneficial owner, if such Holder or beneficial owner is an estate, trust, partnership or corporation) and the Relevant Taxing Jurisdiction (other than any connection resulting
solely from the acquisition, ownership, holding or disposition of Notes, the receipt of payments thereunder or under this Canadian Note Guarantee and/or the exercise or enforcement of rights under any Notes or this Canadian Note Guarantee);

  

	 	(ii)	to the extent the Taxes giving rise to such Additional Amounts would not have been imposed but for the failure of the Holder or beneficial owner of Notes, following Guarantor’s written request addressed to the
Holder, to the extent such Holder or beneficial owner is legally eligible to do so, to comply with any certification, identification, information or other reporting requirements, whether required by statute, treaty, regulation or administrative
practice of a Relevant Taxing Jurisdiction, as a precondition to exemption from, or reduction in the rate of deduction or withholding of, Taxes imposed by the Relevant Taxing Jurisdiction (including, without limitation, a certification that the
Holder or beneficial owner is not resident in the Relevant Taxing Jurisdiction); 

  

	 	(iii)	with respect to any estate, inheritance, gift, sales, transfer, capital gains, excise or personal property tax or any similar Taxes; 

 

	 	(iv)	to the extent the Taxes giving rise to such Additional Amounts would not have been imposed but for the presentation by the Holder or beneficial owner of any Note, where presentation is required, for payment on a date
more than 30 days after the date on which payment became due and payable or the date on which payment thereof is duly provided for, whichever occurs later; 

  

	 	(v)	to the extent the Taxes giving rise to such Additional Amounts would not have been imposed but for the Holder or beneficial owner not dealing at arm’s length, within the meaning of the Income Tax Act
(Canada), with the Company or Guarantor; 

  

	 	(vi)	to the extent the Taxes giving rise to such Additional Amounts would not have been imposed but for such Holder or beneficial owner being, or not dealing at arm’s length (within the meaning of the Income Tax Act
(Canada)) with, a “specified shareholder” of the Company as defined in subsection 18(5) of the Income Tax Act (Canada) for purposes of the thin capitalization rules in the Income Tax Act (Canada);

  

	 	(vii)	to the extent the Taxes giving rise to such Additional Amounts are United States federal withholding tax imposed pursuant to Sections 1471 through 1474 of the Internal Revenue Code of 1986, as amended (the
“Code”), as in effect on the date hereof (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations, official interpretations or administrative
authority promulgated thereunder and any agreements entered into pursuant to Section 1471(b)(1) of the Code as in effect on the date hereof (or any amended or successor version that is substantively comparable and not materially more onerous to
comply with), and, for the avoidance of doubt, any intergovernmental agreement (and related legislation, rules or practices) implementing the foregoing (taken together, “FATCA”), except to the extent that such Taxes result from a
failure of any Paying Agent to comply with FATCA; and 

  

	 	(viii)	any combination of items (i), (ii), (iii), (iv), (v), (vi) and (vii). 

 Additional Amounts also shall not be
paid with respect to any payment on a Note to a beneficial owner who is a fiduciary, a partnership (or entity treated as a partnership for tax purposes), or anyone other than the sole beneficial owner of that payment to the extent that payment would
be required by the laws of the Relevant Taxing Jurisdiction to be included in the income, for tax purposes, of a beneficiary or settlor with respect to the fiduciary, a member of that partnership, or a beneficial owner who would not have been
entitled to the Additional Amounts had that beneficiary, settlor, member or interest holder been the beneficial owner. 

  
 Schedule D-6 

	(c)	Guarantor or applicable withholding agent will (i) make any such withholding or deduction required by applicable law and (ii) timely remit the full amount deducted or withheld to the Relevant Taxing
Jurisdiction in accordance with applicable law. Guarantor will make reasonable efforts to obtain certified copies of tax receipts evidencing the payment of any Taxes so deducted or withheld from each Relevant Taxing Jurisdiction imposing such Taxes.
Guarantor will provide to the Trustee, within a reasonable time after the date the payment of any Taxes so deducted or withheld are due pursuant to applicable law, either a certified copy or tax receipts evidencing such payment, or, if such tax
receipts are not reasonably available to Guarantor, such other documentation that provides reasonable evidence of such payment by Guarantor. 

  

	(d)	Where Tax is payable pursuant to Regulation 803 of the Income Tax Act (Canada) by a Holder or beneficial owner of the Notes in respect of any amount payable under the Canadian Note Guarantee to the Holder (other
than by reason of a transfer of the Notes to a person resident in Canada with whom the transferor does not deal at arm’s length for the purposes of such Act), but no Additional Amount is paid in respect of such Tax, Guarantor will pay as or on
account of interest to the Holder an amount equal to such Tax (a “Regulation 803 Reimbursement”) plus an amount equal to any Tax required to be paid by the Holder or a beneficial owner as a result of such Regulation 803
Reimbursement within 45 days after receiving from the Holder a notice containing reasonable particulars of the Tax so payable, provided such Holder or beneficial owner would have been entitled to receive Additional Amounts on account of such
Tax (and only to the extent of such Additional Amounts that such Holder or beneficial owner would have been entitled to receive) but for the fact that it is payable otherwise than by deduction or withholding from payments made under or with respect
to the Canadian Note Guarantee. 

  

	(e)	Prior to the date on which the payment of any Additional Amounts are due, Guarantor will deliver to the Trustee such Additional Amounts payable, together with an Officers’ Certificate setting forth the Additional
Amounts, stating that such Additional Amounts will be payable on the payment date and setting forth such other information necessary to enable the Trustee to pay such Additional Amounts to Holders on the payment date. Any such Officers’
Certificate will be delivered to the Trustee at least two Business Days in advance of when the payments in question are required to be made (unless a shorter period of time is acceptable to the Trustee in its reasonable discretion). Guarantor will
promptly publish a notice in accordance with Section 11.2 of the Indenture stating that such Additional Amounts will be payable and describing the obligation to pay such amounts. 

 

	(f)	Guarantor will reimburse the Holders of Notes or beneficial owners of Notes, upon written request of such Holder or beneficial owner of Notes and certified proof of payment for the amount of (i) any Taxes levied or
imposed by a Relevant Taxing Jurisdiction and payable by such Holder or beneficial owner in connection with payments made under or with respect to this Canadian Note Guarantee; and (ii) any Taxes levied or imposed with respect to any
reimbursement under the foregoing clause (i) or this clause (ii), so that the net amount received by such Holder or beneficial owner after such reimbursement will not be less than the net amount such Holder or beneficial owner would have
received if the Taxes giving rise to the reimbursement described in clauses (i) and/or (ii) had not been imposed, provided, however, that the indemnification obligation provided for in this Section 3.9(f) shall not
extend to Taxes imposed for which the Holder or beneficial owner of the Notes would not have been eligible to receive payment of Additional Amounts hereunder by virtue of clauses (i) through (viii) of Section 3.9(b) hereof, or to the
extent such Holder or beneficial owner received Additional Amounts with respect to such payments. 

  

	(g)	In addition, Guarantor will pay any stamp, issue, registration, court, documentary, excise or other similar taxes, charges and duties, including interest and penalties with respect thereto, imposed by any Relevant
Taxing Jurisdiction at any time in respect of the execution, issuance, registration or delivery of this Canadian Note Guarantee or any other document or instrument referred to thereunder and any such taxes, charges or duties imposed by any Relevant
Taxing Jurisdiction at any time as a result of, or in connection with, (i) any payments made pursuant to any Guarantee or any other such document or instrument referred to thereunder and/or (ii) the enforcement of this Canadian Note
Guarantee or any other such document or instrument referred to thereunder. 

  

	(h)	Obligations described under this Section 3.9 will survive any termination, defeasance or discharge of this Indenture and will apply mutatis mutandis to any successor Person to Guarantor and to any
jurisdiction in which such successor is organized, doing business or is otherwise resident for Tax purposes or any jurisdiction from or through which payment is made by such successor or its respective agents. 

  
 Schedule D-7 

	(i)	Whenever this Canadian Note Guarantee refers to, in any context, the payment of principal, premium, if any, interest or any other amount payable under or with respect to any Note or under this Canadian Note Guarantee,
such reference includes the payment of Additional Amounts or other payments that would be payable pursuant to this Section 3.9, if applicable. 

- remainder of page intentionally left blank - 

  
 Schedule D-8 

 IN WITNESS WHEREOF, Guarantor has executed and delivered this Guarantee as of the first
date written above. 
  

					
	☐, as Canadian Note Guarantor
		
	By:	 	 
		 	Name:	 	
		 	Title:	 	

  
 Schedule D-9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]